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Abstract  
Interferon lambdas (IFNλs), termed IFN-λ1, IFN-λ2 and IFN-λ3, or IL-29, IL-28A 
and IL-28B are a recently identified family of cytokines with antiviral activity. IL-
28A/B and IL-29 bind to a novel heterodimeric receptor complex formed 
between IL-28 receptor (IL-28R) and IL-10 receptor (IL-10R2). Type I IFNs are 
used therapeutically in the treatment of chronic hepatitis B and C; however only 
~30% of patients with hepatitis B virus will be successfully treated and only 
~60% of patients with chronic HCV. New interventions are therefore required to 
address this unmet medical need and this thesis aimed to evaluate the potential 
use of IFNλs in treating viral infection.  
A range of in vitro antiviral assays were developed to determine which viruses 
were inhibited by IFNλs. Results showed IL-28A and IL-29 have antiviral effects 
with HCV 1a and 1b replicons and HBV. No antiviral effect was demonstrated 
against dengue, RSV or HIV. Gene expression stimulated by IFNλ was 
compared with IFNα; and the effects of IFNλ against HCV were investigated. 
The types of genes induced, and the kinetics of gene induction were similar 
between the type I and type III IFNs in the HCV replicon cell line. With the 
parental cell line, the interferon signalling pathway was the most greatly affected 
by IFNα, IL-28A and IL-29, but IL-29 strongly regulated the antigen presenting 
pathway compared with IFNα. IL-28R distribution was determined to investigate 
the tissue and cellular distribution of IFNλ responsive cells. IL-28R was 
expressed in epithelial tissues, lymphoid tissue, spleen, liver, kidney and 
thymus, with majority of IL-28R expression on macrophages and dendritic cells. 
The differences between type I and type III IFNs need to be further investigated 
but these differences identified provide a rationale for exploring the use of type 
III IFNs as an alternative to IFNα in the treatment of viral diseases.  
 
Statement of Originality 
All work is my own unless acknowledged and all else is appropriately 
referenced.  
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Chapter 1 
1. General Introduction 
1.1 Introduction to interferons and the discovery of type III 
interferons 
Type I interferons (IFNs) have been considered the gold standard for antiviral 
protection since their discovery over 50 years ago1. Interferons (IFNs) are 
defined by their ability to induce resistance to viral infection. However the recent 
discovery of type III interferons may add a new dimension to conventional 
treatment regimes. 
Interferon lambdas (IFNλs) are newly identified cytokines jointly discovered in 
2002/32,3 termed IFN-λ1, IFN-λ2 and IFN-λ32 or interleukin (IL) IL-29, IL-28A, IL-
28B respectively3. These cytokines are the first novel IFN family (IFN type III) 
defined in more than 20 years4. Initial studies showed that interferon lambdas 
had antiviral properties in vitro with encephalomyocarditis virus (EMCV)3, 
stimulated interferon sensitive genes (ISGs)2,3 and both groups described that 
the activity of the interferon lambdas is achieved through a novel receptor 
interferon-lambda receptor 1 (IFN-λR1)2 also known as interleukin-28 receptor 
(IL-28R)3.  
Interferon lambdas share similar expression patterns with type I IFNs and 
trigger common signal transduction cascades and sets of stimulated genes. 
Both type I and type III IFNs share many biological activities, including the 
ability to induce an antiviral state in cells. IFNs protect cells from virus infection, 
directly by inducing ISGs such as 2’, 5’-oligoadenylate synthetase 1 (2’, 5’-OAS) 
and myxovirus resistance-A (MxA) and intracellular proteins5 and, indirectly, by 
inducing major histocompatibility complex (MHC) class I antigen expression on 
and activation of antigen-presenting cells, stimulating dendritic cell maturation 
and activating macrophages and natural killer cells6.  
There are three families of interferons: type I interferons, like interferon alpha 
family (IFNαs) and interferon beta (IFNβ), which show potent antiviral activity; 
type II interferon like interferon gamma (IFNγ), which shows weak antiviral 
activity but is a strong activator of cellular immune responses; and now type III 
Chapter 1 
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interferons with novel IFNλs. In humans, the type I IFN family comprises at least 
13 nonallelic IFNα genes, IFNβ, IFNω, IFNκ and the limitin gene7; type II is IFNγ 
and the novel type III interferons IL-28A, IL-28B and IL-29. IL-28A, IL-28B and 
IL-29 are weakly related to type I IFNs at the amino acid level but have a 
genetic structure more similar to IL-10. IL-28A and IL-28B share 96% amino 
acid identity and IL-29 shows 81% homology to IL-283. Genes for all three 
members of the IFNλ family are found on chromosome 19 (q13.13 region)3, 
whereas the genes for all type I IFNs are clustered on human chromosome 98,9. 
The gene for IFNγ is located on chromosome 1210. Type I IFN genes lack 
introns, but the coding regions of the IFNλ genes are interrupted by 4 introns, 
and the positions of the introns with respect to the protein reading frames are 
conserved for the IFNλ genes and for genes encoding IL-10-related cytokines11. 
Even though the amino acid identity of type III IFNs is lower than even the most 
distant members of the type I IFN family, and the fact that they are clustered on 
different chromosomes, the conserved cysteine pattern and amphipathic profile3 
of the IFNλs suggest they belong to the helical cytokine family and appear to be 
an evolutionary link between IL-10 and type I IFNs.  
 
Figure 1.1:  A phylogenetic alignment of the class II cytokine family genes 
Figure taken from Donnelly et al12 Alignment of the human interferon-λ (IFN-λ) genes 
with either (A) the human type I IFN genes or (B) the human interleukin-10 (IL-10)-
related cytokines was used to generate a phylogenetic tree for the class II cytokine 
genes.   
IFN-λ genes are clustered together on human chromosome 19 (19q13.13 
region) or murine chromosome 7 (7A3 region). There are three functional IFN-λ 
genes in the human genome IFN-λ1 (IL-29), IFN-λ2 (IL-28A) and IFN-λ3 (IL-
28B) and 1 pseudogene IFN-λ4ψ, whereas there are only 2 functional IFN-λ 
Chapter 1 
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coding genes in the murine genome: IFN-λ2 (IL-28A) and IFN-λ3 (IL-29), mIFN-
λ1Ψ and mIFN-λ4Ψ genes are pseudogenes. Studies have shown that the 
mutated mIFN-λ1 gene does not encode a functional IFN-λ1 protein13. The high 
degree of homology between the IFN-λ genes suggesting that the genes 
evolved from a common predecessor, IFN-λ3 (IL-28B) gene is almost identical 
to the IFN-λ2 (IL28A) gene not only in the coding region but also in the 
upstream and downstream flanking sequences. The promoters of the IFN-λ2 
and IFN-λ3 genes are very similar and share several common elements with the 
IFN-λ1 promoter, suggesting that all 3 genes are likely to be regulated in a 
similar manner14,15.  
Type I and type III IFN genes have similar expression patterns, this is likely to 
be due to common regulatory elements in the promoters of the type I and type 
III IFN genes. Promoters of IFN-λ genes have predicted binding sites for 
transcription factors: AP1 (dimeric factor containing members of the JUN, FOS, 
ATF and MAF protein families), nuclear factor κB (NF-κB) and interferon 
regulatory factors (IRFs), crucial for the induction of type I and type III IFN 
expression14,15. IFN-λ1 is controlled by either IRF3 or IRF7, but importantly IFN-
λ2/3 like IFNα genes are more dependent on IRF715. IRF3 is ubiquitously 
expressed in cells and upon direct viral activation upregulates IFN-λ1 and IFNβ 
representing early response genes. IFN-λ2/3 gene expression is mainly 
controlled by IRF7, thus resembling those of IFNα genes with delayed kinetics 
conforming to a positive feed-back mechanism. The regulation of type III IFNs 
may differ in mice, however, since there is no functional IFN-λ1 gene in the 
murine genome13. Co-expression of type I and type III IFNs in response to 
diverse viruses and various TLR agonists has been shown by multiple cell types 
but plasmacytoid dendritic cells (pDCs) constitutively express IRF7, enabling 
these cells to rapidly produce high levels of type I and type III IFNs upon 
stimulation16. Differences in type I and type III IFN expression have been 
reported, including IFN-λs were shown to be the main IFN type produced by 
both murine and human airway epithelial cells in response to various respiratory 
viruses17,18, a model is proposed for IFN-λ1 gene regulation, in which IRF and 
NF-κB activate gene expression independently via spatially separated promoter 
elements19 showing type III IFNs can be induced through IRFs or  NF-κB unlike 
IFNα which needs multiple transcription factors. Though IFN-λ is typically 
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activated by viral infections, showing that it is an important part of the innate 
immune response, activation of TLR-4 by bacterial LPS has been shown to 
induce IFN-λ in DCs16,19 highlighting a role of IFN-λ in the modulation of the 
immune response. Interferon lambdas also have a role in antiviral immunity 
through modulation of both the maturation and differentiation of immune cells. 
Differentiation of monocytes into dendritic cells leads to upregulation of IL- 
28R and an increased ability to express IFN-λ20,21,22,23. When DCs are then 
exposed to IFN-λ, increased maturation and migration capacity are induced22. 
Interferon lambda influences the effects of DCs on interactions with T cells. DCs 
treated with IFN-λ preferentially expand regulatory T cells, which negatively 
regulate the immune response, and promote self-tolerance20,22. IFN-λ appears 
to be primarily focused on biasing T cell differentiation against Th2 development 
and Th2 cytokine secretion but also modulating Th1 cells 24,25,26,27,28although 
this role is not fully clear. Interferon lambdas are an important part of the innate 
immune response and have a role in the modulation of the adaptive immune 
response. 
 
1.2 Antiviral properties of interferon lambdas 
Like IFNα, IL-28A and IL-29 have antiviral properties and potentially could be 
used as or incorporated into another therapeutic approach to treating viral 
disease. Initial studies by Sheppard et al in 2003 showed that IL-28A and IL-29 
induced antiviral effects in response to encephalomyocarditis virus (EMCV) and 
stimulated interferon sensitive genes in vitro (Figure 1.2)3. 
As IFNλs had been shown to have antiviral properties it was an aim of this 
thesis to investigate the antiviral properties of IFNλs in vitro against a panel of 
viruses including hepatitis C (HCV), hepatitis B (HBV), human 
immunodeficiency virus (HIV), dengue fever and respiratory syncytial virus 
(RSV), with a primary focus on HCV.  
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Figure 1.2:  Graphical representations of IFNα, IL-28A and IL-29  
EMCV assay A and interferon sensitive gene induction with ISG B  
A Antiviral activity of IL-28A and IL-29. IL-28A, IL-29 and IFNα2a (IFNα) were added at varying concentrations to HepG2 cells before EMCV 
infection and dye-uptake was measured. Mean s.d. A570 values, which were directly proportional to antiviral activity, are shown (n = 3). 
B IL-28A and IL-29 signal through the IFN-stimulated response element (ISRE). HepG2 cells were transfected with an ISRE reporter plasmid and 
luciferase activity was analysed after treatment with varying concentrations of IL-28A, IL-29 or IFNα2a. Fold activation was determined by dividing 
the relative light units (RLU) of each experimental sample by the RLU of media alone. Mean s.d. data are shown (n = 2). Figure taken from 
Sheppard3. 
 
A B 
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Hepatitis C (HCV) has a positive-sense single stranded RNA genome and is 
classified as a flavivirus. The hepatitis C virus particle consists of a core of 
genetic material (RNA), surrounded by an icosahedral protective shell of 
protein, and further encased in a lipid (fatty) envelope of cellular origin. Two 
viral envelope glycoproteins, E1 and E2, are embedded in the lipid envelope29. 
The HCV genome is 9600 nucleotides and comprises of two non-coding regions 
in 5' and 3' flanking a large reading frame which codes for a polyprotein of 3000 
amino acids; this polyprotein is further cleaved into structural (C, El, E2) and 
non- structural (NS1, NS2, NS3, NS4, NS5) proteins. The positive RNA acts as 
a cap-independent messenger; the transcription is mediated by the NS5 RNA 
polymerase. After the maturation step, the virion is liberated by budding through 
the cytoplasmic membrane.  
 
Figure 1.3:  Organization of Flaviviridae genome HCV 
Figure adapted30to show organization of Flaviviridae genome, HCV showing structural 
proteins made by the hepatitis C virus include Core protein, E1 and E2; nonstructural 
proteins include NS2, NS3, NS4, NS4A, NS4B, NS5, NS5A, and NS5B.  
 
The structurural proteins made by HCV are further described below. Core 
protein is a highly basic, RNA-binding protein, proteins of various sizes (17 to 
23 kDa) are described but the 21-kDa core protein (P21) appeared to be the 
predominant form31. The core protein contains three distinct predicted domains: 
an N-terminal hydrophilic domain of 120 aa (domain D1), principally involved in 
RNA binding and nuclear localization, a C-terminal hydrophobic domain of 
about 50 aa (domain D2), responsible for core protein association with 
endoplasmic reticulum (ER) membranes, and the last 20 or so aa that serve as 
a signal peptide for the downstream envelope protein E132. Envelope proteins 
E1 and E2 are highly glycosylated and have a key role in cell entry, the p7 
protein, a 63 amino acid membrane spanning protein which locates itself in the 
endoplasmic reticulum, is dispensable for viral genome replication but plays a 
critical role in virus morphogenesis33. NS2 protein is a 21-23 kDa 
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transmembrane protein with protease activity, NS2 is a short-lived protein that 
loses its protease activity after self-cleavage from NS3 and is degraded by the 
proteasome34. NS3 is 67 kDa protein whose N-terminal has serine protease 
activity and whose C-terminal has NTPase/helicase activity. NS4A is a cofactor 
of NS3 protease activity. NS3-4A also bears additional properties through its 
interaction with host cell pathways and proteins that may be important in the 
lifecycle and pathogenesis of infection, NS3-NS4A protease is a popular viral 
targets for anti-HCV therapeutics35. NS4B is a small (27 kDa) hydrophobic 
integral membrane protein with 4 transmembrane domains. It is located within 
the endoplasmic reticulum and plays an important role for recruitment of other 
viral proteins36. NS5A is a hydrophilic phosphoprotein which plays an important 
role in viral replication, modulation of cell signaling pathways and the interferon 
response. The NS5B protein (65 kDa) is the viral RNA dependent RNA 
polymerase. Until recently when the complete replication of hepatitis C virus in 
cell culture was demonstrated37, the lack of a robust tissue culture system for 
HCV meant that HCV was studied using a replicon system38, where the effects 
of IFNs on HCV replication in vitro can be studied39. Replication of HCV 
involves several steps. The virus replicates mainly in the hepatocytes of the 
liver, where each infected cell produces approximately 10 virions per day40 and 
NS5B produces mutations at rate 10-4 per nucleotide41, this key in using current 
direct acting antivirals (DAA) in the treatment of HCV, the risk of rapid 
development of resistance, without the use of cotreatment of IFN. Entry into 
host cells occur through interactions between virions and cell-surface molecules 
CD81, LDL receptor, SR-BI, DC-SIGN, Claudin-1, and Occludin42. HCV uses 
portions of the intracellular machinery to replicate43. The HCV genome is 
translated to produce a 3000aa protein, which is processed by viral and cellular 
proteases to produce three structural and seven nonstructural (NS) proteins. 
The NS proteins then recruit the viral genome into an RNA replication complex. 
RNA replication takes places via the viral RNA-dependent RNA polymerase 
NS5B, which produces a negative strand RNA intermediate. The negative 
strand RNA then serves as a template for the production of new positive strand 
viral genomes. Nascent genomes can then be translated, further replicated or 
packaged within new virus particles. New virus particles are thought to bud into 
the secretory pathway and are released at the cell surface. 
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Figure 1.4:  Hypothetical HCV replication cycle 
This figure is taken from Bartenschlager et al., 200430. HCV particles bind to the host 
cells via a specific interaction between the HCV envelope glycoproteins and a yet 
unknown cellular receptor. After the viral genome is liberated from the nucleocapsid 
and translated at the rough ER, NS4B induces the formation of membranous vesicles 
(referred to as the membranous web; EM in the lower right). These membranes are 
supposed to serve as scaffolds for the viral replication complex. After genome 
amplification and HCV protein expression, progeny virions are assembled. Newly 
produced virus particles may leave the host cell by the constitutive secretory pathway. 
The upper right panel of the figure shows a schematic representation of an HCV 
particle. The middle panel shows a model for the synthesis of negative-stranded (−) 
and positive stranded (+) progeny RNA via a double-stranded replicative form (RF) and 
a replicative intermediate (RI).  
HCV is sensitive to IFNα, IFNβ and IFNγ44 but at the time this project was 
initiated (August  2004) there was not any published data on the role of type III 
interferons in HCV. Pegylated IFNα in combination with ribavirin is the current 
standard of care for the treatment of patients chronically infected with HCV; it 
results in a sustained virological response (defined as clearance of circulating 
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HCV RNA at 6 months post-treatment) in ~50% of HCV patients45. However, 
combination therapy remains less effective against infections caused by HCV 
genotype 1 which constitute ~75% of all HCV infections in the developed world. 
IFNα therapy is administered intravenously and has side effects such as flu-like 
symptoms, anorexia, depression, haemolytic anaemia and myelosuppression 
that can be severe and sometimes dose limiting. Approximately 500 million 
people worldwide are living with either hepatitis B or hepatitis C46. This 
represents 1 in 12 people, and was the basis for the 2008 ‘World Hepatitis Day 
Am I Number 12?’ campaign. HCV affects ~ 170 million people worldwide, with 
a seroprevalence in the United States and Japan of ~2%, and in Western 
Europe of 1-1.9%47 (Figure 1.5). HCV infection can lead to liver fibrosis, 
cirrhosis and liver cancer14. 
 
 
 
Figure 1.5: Geographical representation of HCV prevalence  
Percentage of the population infected with HCV globally. Figure from Shepard 200548 
 
The HCV genome exhibits a high degree of variability, especially in the E2/NS1, 
El, NS3 and NS5b regions, resulting in at least 6 genotypes of HCV numbered 
from 1 to 6 in Simmonds' classification49 and over 100 subtypes. Genotype 1, 
1a and 1b accounts for 60% of all HCV cases in USA and Europe and in Japan 
73% is 1b. Geneotype 2 is 8% in Europe; Genotype 3 is 60% in India and 58% 
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in Iran. Genotype 4 has been associated with 20% of chronic infections 
worldwide and is the genotype in 7% of Northern Europe HCV cases and 24% 
of Southern Europe, Genotype 4a makes up 90% of HCV cases in Egypt, Egypt 
has 13% of its population diagnosed with HCV. Genotype 5 is in 40% of the 
HCV cases in South Africa and genotype 6 is a diverse genotype now including 
genotypes originally classes as 7,8, and 11, it is the genotype in 30% of HCV 
cases in Asia and 20% in China. Genotype is clinically important in determining 
potential response to therapy, for example genotypes 1 and 4 are less 
responsive to interferon-based treatment than are the other genotypes (2, 3, 5 
and 6)49. 
Hepatitis B, which is caused by the hepatitis B virus (HBV), affects 350 million 
people worldwide and is responsible for one million deaths each year. HBV 
infection, like HCV, can lead to liver fibrosis, cirrhosis and liver cancer. Hepatitis 
B is the primary cause of liver cancer (60-80%), (WHO 2006). HBV is part of the 
hepadnaviridae (hepatitis DNA viruses) family. Hepatitis B is typically treated 
with interferon alpha (IFNα) which results in ~30% seroconversion, or 
nucleoside reverse transcriptase inhibitors (NRTIs) such as adefovir, entecavir, 
lamivudine, telbivudine, and tenofovir. Lamivudine, a nucleoside analogue, 
results in ~40% seroconversion, compared with 5% seroconversion with no 
treatment. As with HCV, there is a need for new treatments with increased 
efficacy. The effect of HBV and IFNα has been studied in vivo50. IFNλs have 
been shown to reduce levels of HCV mRNA in the HCV replicon system and 
reduce expression of HBV DNA in murine cells51. 
Human immunodeficiency virus (HIV) is an RNA reverse transcribing virus, part 
of the retroviridae family of viruses. Approximately 40 million people worldwide 
are living with HIV (WHO statistics 2005). HIV infection leads to the loss of CD4 
cells, which can result in immunosuppression (Acquired immune deficiency 
syndrome (AIDS)). There are currently a variety of treatments for HIV: IFNα, cell 
fusion inhibitors, reverse transcriptase inhibitors and protease inhibitors. 
Treatment options are often limited due to cross resistance. Overall prevalence 
of HIV drug resistance is on the increase52, so alternative therapies are still 
being developed for the treatment of HIV.  
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Dengue fever is a major threat to public health in many tropical and subtropical 
countries. There are an estimated 50 million infections per year (WHO 2006). 
Dengue is a flavivirus which circulates as four major serotypes and is passed on 
from an infected mosquito bite. Dengue haemorrhagic fever and dengue shock 
syndrome are the more severe manifestations of dengue infection and primarily 
occur on re-infection with a virus of differing serotype to the initial infection. 
IFNα in the dengue replicon system has been shown to have no antiviral effect 
and that dengue virus specifically inhibits IFNα signalling by the down-regulation 
of signal transducers and activators of transcription protein (STAT) STAT2 
expression53, however the effects on dengue with IFNλs remain to be 
determined. 
Respiratory syncytial virus (RSV) is a single stranded RNA paramyxovirus, 
which is the same family as para-influenza, measles and rubella. RSV infection 
is recognised as the leading cause, of bronchiolitis and pneumonia in infants 
and young children54. RSV is highly contagious and in immunocompromised 
patients can lead to persistent infection. Treatment options are currently limited 
to monoclonal antibody based therapy and supportive care; ribavirin has been 
used historically.  
Type III interferons have also been implicated as having antiviral properties in a 
range of viruses: DNA viruses; poxvirus55, murine cytomegalovirus (CMV)56,56, 
hepatitis B virus57,51,58 and herpes simplex virus 1 and 259, the single stranded 
(ss) (+) RNA viruses EMCV60,3, West Nile virus57 and hepatitis C virus57,61,62,51, 
as well as the ss (−) RNA viruses influenza-A virus63 and vesicular stomatitis 
virus,62. IL-28A and IL-29 has also been shown to modulate anti-viral proteins 
like 2′5′-oligoadenylate synthetase2,3, MxA protein, and IFN-inducible double 
stranded (ds) RNA-activated protein kinase, and multiple interferon sensitive 
genes (ISGs)56,57,2,64,62,65. 
1.3 IL-28 receptor and signalling 
IFNα and IFNβ (type I IFNs) bind to a specific and distinct heterodimeric 
receptor composed of IFNARα and IFNARβ. Binding of IFNα or IFNβ to their 
receptor leads to the activation of two receptor-associated tyrosine kinases, 
Janus kinase (Jak)1 and tyrosine kinase (Tyk)2; this is followed by tyrosine 
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phosphorylation of the Signal Transducers and Activators of Transcription 
(STAT)1 and STAT2 proteins. Phosphorylated STAT1 and STAT2 combine with 
IFN-regulatory factor 9 (IRF-9) to form the trimeric IFN-stimulated gene factor-3 
(ISGF-3) complex, which, upon translocation to the nucleus, binds to the cis 
element IFN-stimulated response element (ISRE), upstream of IFN-inducible 
genes, and modulates their transcription66,67. 
Type I, II and III IFNs are class II cytokine receptor ligands (CRF2) which also 
include interleukin 10 (IL-10) and IL-10 related proteins11.The activity of the type 
III IFNs is achieved through a heterodimeric receptor complex which, is formed 
between IL-28A receptor (IL-28R) and IL-10 receptor (IL-10R2). The 
promiscuous IL-10R2 is also part of the IL-10 and IL-22 receptor complex and is 
involved in signal transduction for IL-10 and IL-22 (Figure 1.6). Other key 
ligands have now been shown to include IL-28A, IL-28B and IL-292,3. 
IFNλs were initially shown to activate both STAT1 and STAT2 and the 
downstream signalling pathways including interferon sensitive gene complex 
ISGF3 and ISRE, similar to those activated by IFNα and IFNβ2. IFNλs like IFNα 
and IFNβ have been shown to activate STAT3, 4 and 568. Some of IFNα and 
IFNβ immunomodulatory functions are mediated via STAT469.    
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Figure 1.6: IL-10Rβ is a promiscuous cytokine receptor  
Figure 1.6 adapted from Dumoutier, Sheppard, Kotenko and Xie
2,3,70,71
 shows that part of this heterodimeric receptor is the promiscuous interleukin 10 
receptor beta (IL-10Rβ) which has a role in cytokine binding with not only the IFNλs but IL-10 and IL-22.  However the downstream signalling cascade 
shows that IFNλs cause STAT1 and 2 activation. This signalling pathway shares similarities with the IFNAR receptor. 
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Despite signalling through distinct receptor complexes, type I and type III IFNs 
trigger similar signalling pathways (Figure 1.7), leading to the activation of a 
transcriptional complex designated ISGF3 which is a unique and crucial 
mediator of type I and type III IFN-induced biological activities. ISGF3 binds to 
the ISRE in the promoters of ISGs leading to gene transcription.  
 
 
 
Figure 1.7: Type III IFN receptor signalling compared to type I and II 
Type I, II and III IFN receptor binding leads to activation of STAT, the translocation of 
STAT into the nucleus activates either interferon-stimulated genes (ISG) with a 
promoter interferon-stimulated response element (ISRE) or γ-activated sequence 
(GAS). Adapted Vilcek, J. Nat Immunol4.  
 
As well as the Jak-STAT pathway type I and type III IFNs can also induce 
signalling through mitogen-activated protein kinase (MAPK) cascades: stress-
activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK); extracellular 
signal-regulated kinase (ERK)-1/2; and mitogen-activated protein kinase p38 
56,65.  
The heterodimeric receptor IFNAR1/2 for IFN-α and IFN-β is present on all 
nucleated cells72. IL-10R2 is ubiquitously expressed73, whereas initial RNA 
expression data showed IL-28R is limited to specific tissues and cell types2. IL-
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28R has been shown to be present in intestinal epithelial cells, MCA205, a 
fibrosarcoma cell line56 and type III IFN expression has been shown in 
monocyte–derived dendritic cells (MDDC)74,75,76, plasmacytoid dendritic cells 
(pDC)74,76 and human primary macrophages where induction of type III IFNs 
required pre-treatment with IFNα74,75,76. Other studies showed in vivo 
experiments highlighting primary targets of type III IFNs are epithelial cells of 
the respiratory, gastro-intestinal and reproductive tracts59,77,78. IL-28R is 
predominantly expressed in epithelial cells and specific subsets of immune 
cells77,79,78,80.  
1.4 Transcriptomic analysis gene activation profiles and 
signalling pathways of IL-28A and IL-29 
Transcriptional (mRNA) expression patterns have been shown for IFNα, β and 
γ81, and for IL-29 in a HCV replicon cell line61 and Raji cells65. Zhou65 
investigated gene expression at an early time point, 4 hours, with 200 IU of 
IFNα and 10ng/mL of IL-29 in triplicate on Affymetrix gene chips. 27 unique 
genes with greater than a two fold change were seen with IL-29 compared with 
313 IFNα induced genes. Significance Analysis of Microarrays analysis (SAM) 
(Stanford University) showed that only 10 genes were unique to IFNα, the 
majority of genes were also present in the IFNλ dataset but due to IFNλ signal 
being weaker they did not reach the 2 fold cut off. IFNλ was shown to induce 
ISGs, none of which were determined to be unique to IFNλ. Marcello61 also 
used Affymetrix microarray analysis, but used 5ng/mL IFNα and 10ng/mL of IL-
29 in an HCV replicon system at looked at 3, 12 and 24 hour time points. 
Marcello showed in a dataset of 66 genes (being induced at least 2 fold in either 
IFNα or IL-29 at one or more time points); that IFNα and IL-29 induce most of 
the same genes (with no unique genes being expressed with IFNλ) but that over 
time the majority of IFNλ genes continue to increase by 24 hours whereas 
expression of IFNα genes are mainly decreased by 24 hours. Doyle57 also 
reported that IL-29 stimulates nearly identical patterns of gene expression as 
IFNα as analysed by microarray. Microarray analysis as documented in this 
thesis was initiated prior to the publication of microarray studies described 
above57,61,65. There is still a need to fully identify the antiviral effects and modes 
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of action of type III interferons by pathway expression analysis. Microarray 
analysis described in this thesis additionally investigated IL-28A versus IFNα 
and work was carried out in a HCV HuH7 parent cell line.  
Induction of similar sets of ISGs enables Interferon lambdas and IFNα to induce 
similar biological activities and functions primarily inducing an antiviral state in 
cells. 
1.5 Alternative therapies for HCV and IFN lambda as a therapy 
Chronic infection with hepatitis C virus affects 1:12 or approximately 3% of the 
world’s population and causes approximately 350,000 deaths annually46. 
Pegylated interferonα (IFNα) in combination with the nucleoside analogue 
ribavirin is the current standard of care for the treatment of patients chronically 
infected with hepatitis C (HCV). Combination therapy results in a sustained 
virological response (defined as clearance of circulating HCV RNA at six 
months post-treatment) of only ~50% of patients with HCV genotype 1 
infection82. IFNα therapy is administered parenterally and has side effects such 
as flu-like symptoms, anorexia, depression83 and myelosuppression84 that can 
be severe and often dose limiting85. In recent years, a number of new drugs 
against HCV have emerged. Direct-acting antivirals (DAAs) are specifically 
designed to inhibit viral targets, and host-targeted antivirals block host factors 
that are important for the viral lifecyle. Alternative interferons could be effective 
antiviral agents, without the side effects of IFNα. 
Direct-acting antivirals, NS3/4A protease inhibitors inhibit viral protease NS3/4A 
is required for the cleavage of downstream, nonstructural proteins, including the 
NS5A protein and the NS5B RNA-dependent RNA polymerase (RdRp). In May 
2011, NS3/4A protease inhibitors, telaprevir and boceprevir, were approved by 
the US Food and Drug Administration for the treatment of patients with chronic 
genotype 1 HCV infection. With the current DAAs there is rapid resistance due 
to rapid mutations of HCV40,41,86,87. The current DAAs are administered with 
peginterferon-alfa-2a and ribavirin to prevent resistance to the DAAs. Both 
telaprevir and boceprevir highly improve rates of SVR of HCV infected patients 
but there are limitations, designed to target genotype 1 HCV they have 
differential efficiency across the genotypes88,89,90, they are also limited by side 
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effects, rash (Telaprevir) and anaemia and pharmcokinetic properties meaning 
that they have to be taken with fatty meals every 8 hours.  
RdRp inhibitors inhibit the active site of polymerase activity, Preliminary results 
from Phase II trials reported rates of EVR >80% among patients with HCV 
genotype 1 or 4 infection who received mericitabine in combination with SOC 
PEG-IFN and RBV47; no viral rebound or resistance mutations were observed 
by week 1291. These inhibitors could be used without IFN. miR-122 inhibitors 
inhibit miR-122 which is a host liver-specific microRNA required for HCV 
replication. Miravirsen is in Phase IIa trials; and significantly reduces viral load 
after 8 weeks of therapy without significant adverse effects92 but there are 
concerns with microRNAs with off target effects. Host factor cyclophilins are 
important for viral replication, Alisporivir is in advanced clinical trials, it inhibits 
viral replication by disrupting the interaction between cyclophilin A and 
NS5A93,94. Alisporivir combined with PEG-IFN and RBV, led to an SVR in 76% 
of HCV genotype 1 infection patients compared to 55% with SOC94. 
Zymogenetics licensed lambda interferons to Novo-Nordisk and now Bristol-
Myers Squibb for viral infections including HCV. A pegylated form of IFN-λ1 (IL-
29) is currently in clinical trials for the treatment of chronic HCV infection and 
initial reports shows less severe side effects than pegylated IFNα, phase 1b 
dose-escalation study, PEG−IFN-λ1 inhibited HCV without significant systemic 
toxicity and phase 2b data showed that the highest doses of PEG−IFN-λ1, 
when combined with RBV, produced a complete EVR in 30% of patients with 
HCV genotype 1 infection, compared with 28% of the patients who received the 
SOC95,96. Clinical development: A recent press release from Bristol-Myers 
Squibb (19 April 2012) showed that peginterferon lambda-1a (Lambda) plus 
ribavirin achieved sustained virologic response rates 24 weeks post-treatment 
(SVR24) that were comparable to peginterferon alpha-2a plus ribavirin in phase 
IIb EMERGE clinical trial in 118 treatment-naïve patients chronically infected 
with genotype 2 or (HCV). There may be a role for IL-28B treatment in the 
future, four Genome Wide Association studies have highlighted the significance 
of IL-28B within the innate immune response to HCV97,98,99,100. Two protective 
SNPs were shown to be associated with a SVR to IFNα/Ribavirin in patients 
with HCV genotype 1. These were the T allele of rs8099917 and the C allele 
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of rs12979860 located 8 kilo bases (kb) and 3 kb respectively upstream of the 
IL-28B gene. In a study of rapid viral response (RVR) (undetectable HCV 
RNA at 4 weeks) rates in patients with HCV Genotype 1 and 4, of the RVRs 
100% of carriers of the protective rs12979860 C allele, and 64% of non-RVR  
individuals expressed the non-protective genotype T allele of rs8099917101.  
The potential broad roles of IFN-λs in immune function may also mean they play 
a future role in autoimmunity and cancer therapy. Type III IFNs like type I IFNs, 
may potentially be used for the treatment of other inflammatory or autoimmune 
diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE)102, or multiple sclerosis (MS)103. IFN-λs have been shown to have potent 
antitumor activities in murine models of cancer104,105,106, highlighting potential as 
anti-cancer therapy. 
1.6 Introduction summary  
The biological significance of IFNλs remains to be fully determined. This thesis 
shows the investigation of antiviral activity of IFNλs, the similarities and 
differences between the type I and type III IFNs determined by microarray 
analysis, and the distribution of IL-28R and the significance of limited 
distribution in bone marrow assays.   
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1.7 Hypothesis 
“Current treatment of antiviral diseases with type I IFNs can be inadequate. As 
IFNλs have antiviral activity and use a different receptor and signalling 
transduction pathways to IFNα, IFNλ therapy could be useful in the 
management of viral infections.” 
1.8 Thesis Aims 
1. Investigation of the antiviral activity of IL-28A and IL-29 on a panel of 
viruses in vitro and their effects on IFN sensitive gene models. 
2. Transcriptomic analysis to determine gene activation profiles and 
signalling pathways of IL-28A and IL-29. 
3.  Investigation of IL-28R tissue expression in a panel of mouse and human 
tissues. 
4. Further investigations to support hypothesis that IFNλ therapy could be an 
alternative to IFNα. 
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Chapter 2 
2. Materials and methods 
2.1 Investigation of the antiviral activity of IL-28A and IL-29 
using antiviral and interferon sensitive gene model assays 
2.1.1 Hepatitis C comparison of antiviral activity of IFNα, IFNβ, IFNγ, IL-
28A and IL-29  
The antiviral effects of interferon lambdas were investigated in a HCV replicon 
model which comprises of a HuH7 hepatoma derived cell line stably transfected 
with an autonomously replicating subgenomic HCV RNA38. Established stable 
replicon assays for HCV genotypes 1a and 1b were used; constructs are shown 
(Figure 2.1). Later work used clones of HCV genotype 1b with an integral 
luciferase; the structure is shown (Figure 2.2) and method is described (Section 
2.1.2). 
 
 
Figure 2.1: HCV replicon structure  
HCV replicon RNA in HuH7 hepatoma cells, replicons of HCV genotypes 1a (top) and 
1b (bottom). Non structural viral (NS) proteins are expressed 5 prime (‘) and 3’ 
nontranslated regions (NTR), neo is the neomycin phosphotransferase gene used with 
G418 to select cells containing the replicon, NS2- envelope protein not present in the 
1a replicon, NS3 serine protease, NS4A and 4B cofactors of NS3, NS5A interaction 
with cellular proteins and NS5B RNA dependant RNA polymerase. 
 
HuH7 cells containing either genotype 1a107 or 1b38 replicons were cultured in: 
Dulbecco's Modified Eagle Medium (DMEM) without sodium pyruvate, 
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4500mg/L Glucose and Pyridoxine hydrochloride (HCl), supplemented with 10% 
foetal bovine serum, 1% penicillin, 100μg/mL streptomycin, 2mM L-glutamine 
(left), 1% non-essential amino acids and 500μg/mL G418 (Geneticin) (addition 
of G418 selects cells with replicon) (all reagents from Invitrogen). 96-well flat 
bottomed microtitre plate (Nunc) containing 3 x 104 cells per well were 
incubated with compounds as detailed below in a humidified incubator at 37°C 
and 5% CO2 for 72 hours. 
Serial dilutions of IFNα, IFNβ, IFNγ (PBL biomedical laboratories) IL-28A and 
IL-29 (R&Dsystems) were made up in culture medium as described above 
without the addition of G418. IFNα2a was used in all experiments and called 
IFNα. IFNα, IFNβ dilutions were optimised to 1000, 500, 250, 125, 63, 32, 16, 8, 
4, 2 international units (IU)/mL, IFNγ 2000 to 4 IU/mL, IL-28A 200ng/mL to 
4ng/mL and IL-29 1000ng/mL to 2ng/mL.  Controls were included on each plate, 
these were: no primary antibody controls, cell control wells without the addition 
of compound and in house proprietary assay controls were included as a 
negative control and positive controls respectively. IFNα, IFNβ, IFNγ, IL-28A 
and IL-29 were run in duplicate at each dilution on the plate and each plate was 
run in triplicate over 3 separate occasions to allow for variability of cell passage.  
An Enzyme-linked immunosorbent assay (ELISA) was performed on the plates 
to detect NS5A protein using murine anti-HCV NS5A primary antibody. Medium 
was aspirated followed by a PBS wash and aspirate; the cells were then fixed 
for 5 minutes in methanol (MeOH): acetone (1:1). The fixative was removed and 
further washed in PBS. This was followed by a blocking step with 2% skimmed 
milk in PBS plus 0.05% tween 20 at 37oC for 1 hour. Blocking buffer was 
removed and primary antibody, 50µL of murine anti-HCV NS5A (Virostat) was 
diluted to 0.5µg/mL in blocking buffer and added to the plate, with the exception 
of no primary antibody wells (blocking buffer only) then incubated at 37oC for 2 
hours. Primary antibody was removed and plates were washed three times with 
wash buffer, PBS plus 0.05% tween 20. 50µL of horseradish peroxidase-
conjugated secondary antibody, rabbit anti-mouse immunoglobulin G (IgG) 
(Dako) was diluted 1:1000 in blocking buffer and incubated for 1 hour at 37oC.  
Secondary antibody was then removed and plates were washed five times with 
wash buffer. The next step was to allow a colour to develop by incubating the 
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plates for 30 minutes with 50µL OPD/peroxidase substrate in urea buffer. The 
colour reaction was stopped with the addition of 25µL of 2 molar (M) sulphuric 
acid. Absorbance was then measured at 490 nanometers (nm). Cells were also 
stained with 5% carbol fuchsin to visually assess cytotoxicity. 
2.1.2 Determination of IC50 values for four luciferase HCV replicon clones 
Values for 10 x IC50 concentrations in the replicon cell lines were determined to 
normalise for the antiviral activities of proteins IFNα, IL-28A and IL-29. Four 
luciferase replicon cell lines were compared for sensitivity with IFNα, IL-28A and 
IL-29 these were: 1a1_19, 1a3II, 1b 2.2, 1b2.5, and the most sensitive selected 
to carry through into transcriptomics analysis (Section 2.2.1).  
HuH7 HCV luciferase replicon cells were routinely maintained in DMEM, 
4500mg/L Glucose and Pyridoxine HCl supplemented with 10% foetal bovine 
serum, 100IU/mL penicillin, 100µg/mL streptomycin, 2mM L-glutamine, 1% non-
essential amino acids and 500µg/mL Geneticin. (All reagents from Invitrogen). 
The assay media conditions were as above minus Geneticin. 1 x 106 cells per 
well of each of the HuH7 HCV luciferase replicon cells were cultured in 96-well 
plates at 37°C. Dilutions of IFNα, IL-28A and IL-29 were made up in triplicate. 
For each luciferase cell line, 5 x 104 confluent cells in a 50µL volume per well 
were added to compound made up to 50µL with medium. The plates were 
incubated for 18 hours at 37oC. Supernatent was removed and 25µL of Steady-
Glo (Promega) was added per well and the plate was left in the dark for 15 
minutes before reading chemiluminescence at 450nm. The half maximal 
inhibitory concentration (IC50) was defined as the concentration of each 
treatment which reduced luciferase signal by 50% compared with untreated 
cells. 
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Figure 2.2: HCV luciferase replicon clones structure  
Clones 1a1_19, 1a3II and 1b 2.2, 1b2.5 were provided by Thomas Zurcher GSK, all 
clones had a 5’ lucifease unit (luc-ubiq). Neo is the neomycin phosphotransferase gene 
used with G418 to select cells containing the replicon, NS2- envelope protein not 
present in the 1a replicon, NS3 serine protease, NS4A and 4B cofactors of NS3, NS5A 
interaction with cellular proteins and NS5B RNA dependant RNA polymerase. 
2.1.3 IL-28A, IL-29 and IFNα synergy  
1b replicon cell line assay as described (Section 2.1.1) was used as results 
showed (Section 3.1.1) that the 1b cell line was most sensitive to interferons 
tested. Serial dilutions of IL-28A 200ng/mL to 4ng/mL and IL-29 1000ng/mL to 2 
ng/mL were made up in culture medium alone and then in addition with 
0.09ng/mL of IFNα (IC50 concentration as determined in experiments performed 
(Section 2.1.1)). To determine antiviral activity in the HCV 1b replicon cell line of 
IFNα at 0.09ng/mL this was also run separately on its own as a control. Controls 
were included on each plate, these were: no primary antibody controls, cell 
control wells without the addition of compound and in house proprietary assay 
controls were included as a negative control and positive controls respectively. 
IL-28A and IL-29 were run in duplicate at each dilution on the plate and each 
plate was run in triplicate over at 2, 4, 6, 8, 16 and 24 hours. 
2.1.4 IFN sensitive gene models 6-16 and ISG56 
To investigate type III interferon modulation of interferon sensitive genes (ISGs), 
two ISG assays were used: interferon sensitive gene 56 (ISG56) and interferon 
inducible gene 6-16 (G1P3). 
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ISG56 alternatively named interferon-induced protein with tetratricopeptide 
repeats 1 (IFIT1), a 293 cell line (a continuous line of transformed human 
embryonic kidney cells) with ISG56 promoter construct was used. ISG56 is the 
most highly induced IFN sensitive gene (30-100 fold induction), the assay is 
robust over several logs of IFN concentration and response is dependent on 
intact receptor and signal transduction pathways. 293 cells were cultured in 
DMEM + 4500mg/mL glucose, 20mM L-Glutamine, Pyruvate (Sigma-Aldrich), 
10% foetal calf serum, 100 IU/mL penicillin, 100μg/mL streptomycin and 
500μg/mL G418. 5 x 104 cells were cultured for 18 hours with serial dilutions of 
IFNα, IFNβ and IFNγ, 1000, 500, 250, 125, 63, 32, 16, 8, 4, 2 IU/mL and serial 
dilutions for IL-28A ranging from 200ng/mL to 4ng/mL and IL-29 from 
1000ng/mL to 2ng/mL. Untreated cell and virus controls were also included. 
IFNs were run in duplicate and the experiment was performed in duplicate. 
Supernatants were removed and 25μL of Steady-Glo, (Promega) was added 
per well and the plate was left in the dark for 15 minutes at room temperature 
before optical density (OD) measurement at 405nm.  
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Figure 2.3: ISG56-luciferase reporter  
The ISG56-luciferase reporter assay is used to show binding to Toll-like receptor 3 
(TLR3), inducing antiviral response resulting in ISG56 induction and involving TANK-
binding kinase 1(TBK-1), interferon regulatory factor 3 (IRF3) leading to modulation of 
ISG56.   
 
Interferon, alpha-inducible protein 6 (6-16) alias IFI6; 6-16; FAM14C; G1P3; IFI-
6-16; IFI616  an interferon sensitive gene model was also used to investigate 
type III interferon activity, this cell line was maintained at GSK. Human 
glioblastoma T98G cells were transfected with a plasmid containing a gene 
coding for soluble alkaline phosphatase under control of an interferon-inducible 
promoter. The assay was set up as described above for ISG56.  
2.1.5 Hepatitis B (HBV) 
Antiviral effects of IL-28A and IL-29 compared with IFNα were investigated in 
human hepatocellular carcinoma HepG2 (2.2.15) cell line stably transfected with 
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HBV subtype ayr maintained at the Department of Medicine, Imperial College. 
HepG2 cells were cultured at 37°C in a humidified 5% CO2 atmosphere in 
Minimum Essential Medium Eagle media (MEME) supplemented with 10% 
foetal calf serum, and 50µg/mL kanamycin. Cells were subcultured once a week 
by detaching the cells with pancreatin (0.5mg/mL) followed by change of 
medium on the following day. 8 well plates containing 5 x 104 cells per well were 
incubated with IFNs in a humidified incubator at 37°C and 5% CO2 for 1 week. 
Concentrations of IFNs used were: 100, 1000 IU/mL for IFNα, 200, 2000ng/mL 
for IL-28A, 100, 1000ng/mL for IL-29 and untreated. Total DNA was extracted 
from each well using a Wizard® Genomic DNA Purification kit according to 
manufacturer’s instructions.  
(http://www.promega.com/~/media/Files/Resources/Protocols/Technical%20Ma
nuals/0/Wizard%20Genomic%20DNA%20Purification%20Kit%20Protocol.pdf.) 
Antiviral activity was detected using quantitative real-time polymerase chain 
reaction (PCR) (TaqMan®) primers (Proligo) and probes (Applied Biosystems). 
This was performed in the presence of the house-keeping gene glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and all amplifications were performed in 
quadruplicate. 
Table 2.1: Hepatitis B virus probe and primer sequences  
HBV1 Sequence 
Forward primer 5’GGACGGAAACTGCACTTGTATTC-3’ 
Reverse primer 5’GACTGAGGCCCACTCCCATAG-3’ 
Probe FAM/ TAMRA 5’ CCATCATCCTGGGCTTTCGCAAGATT-3’ 
TaqMan® probes consist of a fluorophore (e.g. 6-carboxyfluorescein, (FAM)) covalently 
attached to the 5’-end of the oligonucleotide probe and a quencher (e.g. 
tetramethylrhodamine, (TAMRA)) at the 3’-end.  
2.1.6 Real-Time PCR assay overview 
TaqMan® (Applied Biosystems) is the trademark name of the PCR-based, 
fluorogenic 5'-nuclease assay, which allows for the real-time quantitation of 
DNA/RNA, allelic discrimination and pathogen detection. This can include 
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SybrGreen and fluorogenic probes (TaqMan®). Most PCR included in the thesis 
is covered by these two assays and run on Applied Biosystems 7900 PCR 
machines, the other PCR assay described in this thesis also uses SybrGreen 
dye but run on a different proprietary PCR machine Corbett Life Science Rotor-
Gene real-time PCR machine (Corbett Life Science). 
2.1.6.1 Sybr Green 1 dye 
Sybr Green 1 dye: binds to the minor groove of DNA and is fluorescent when 
bound.  As the PCR progresses through the cycles and more PCR product is 
accumulated so more dye binds resulting in an increase in fluorescence. By 
plotting fluorescence against cycle number an amplification plot is produced 
which provides a more accurate picture of the PCR rather than measuring end 
product. To ensure the specificity of the primers, dissociation curve analysis is 
carried out on the PCR’d samples. This collects the fluorescence levels 
associated with the melting point of the PCR product already produced and it 
allows detection of non-specific priming and primers dimers in the template free 
sample.    
2.1.6.2 Fluorogenic 5’ nuclease assay (TaqMan®) 
The fluorogenic 5' nuclease assay uses a fluorogenic probe to enable the 
detection of a specific PCR product as it accumulates during PCR. The reporter 
dye is incorporated on the 5' end and the quencher on the 3' end of the probe. 
When the probe is intact, the proximity of the reporter dye to the quencher dye 
results in suppression of the reporter fluorescence. During PCR, if the target of 
interest is present, the probe specifically anneals between the forward and 
reverse primer sites. The 5´–3´ nucleolytic activity of the AmpliTaq Gold DNA 
Polymerase cleaves the probe between the reporter and the quencher only if 
the probe hybridises to the target. The probe fragments are then displaced from 
the target, and polymerisation of the strand continues. The increase in 
fluorescence signal is detected only if the target sequence is complementary to 
the probe and is amplified during PCR. Because of these requirements, any 
non-specific amplification is not detected.  
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Figure 2.4: TaqMan® Real-time PCR process  
Real time PCR process probe containing R-reporter and Q- quencher, anneals to 
target sequence, during the extension phase the reporter is detached and can be 
measure at every cycle of the PCR. Taken from http://ukgwrdweb1.ggr.co.uk/TaqMan 
2.1.6.3 Primer and probe design 
Primer sequence and where applicable probe sequences were designed using 
NCBI entrez nucleotide website:  
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide 
Primers and probe are designed to the gene of interest using Applied 
Biosystems Primer Express software.  This software has some of the necessary 
requirements for acceptable probes and primers built in. The exception to this 
was IL-28R assay was on demand assay predesigned (Applied Biosystems). 
2.1.6.4 PCR reagents 
DNA or Total RNA was prepared from the tissue or cells being investigated and 
normally added at 50ng concentration. Copy number relative changes or a 
genomic standard curve was prepared for the species being investigated. This 
allowed quantification of gene copy number. Primers were diluted to a working 
concentration of 10M, and probe to 5M. Universal PCR Master Mix (Applied 
Biosystems) was added at 2 x concentration, it contains the AmpliTaq Gold 
DNA polymerase, AmpErase® Uracil N-glycosylase (UNG), deoxynucleotide 
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triphosphates (dNTPs), Passive reference ROX, and optimised buffer 
components. AmpErase UNG is present in the mix as it can prevent the 
reamplification of carryover PCR products by removing any uracil incorporated 
into single or double stranded DNA. ROX is a passive reference dye present in 
the master mix and allows for the normalisation of amplification across wells 
due to master mix variability. 
Multiplexing allowed normalisation of the gene of interest to an endogenous 
control whose levels are assumed not to change with treatment, reducing the 
well to well template variability within the data, e.g. GAPDH, b-actin, 18S 
ribosomal RNA.   
2.1.6.5 PCR cycling parameters 
PCR cycling parameters unless stated were 40 cycles of: 
50oC for 2 minutes 
95oC for 10 minutes 
95oC for 15 seconds 
60oC for 1 minute 
 
For Sybr Green Dissociation Curve analysis one cycle is added at the end of 
run. 
95oC for 15 seconds 
60oC for 20 seconds 
95oC for 15 seconds 
2.1.6.6 Data Analysis 
Key parameter for data analysis is the Threshold cycle (Ct): this is the cycle at 
which the amplification of the gene is in the exponential phase. The baseline 
was set to ensure that signal is not discarded as noise. The standard curve was 
checked to ensure reproducibility and satisfactory linear regression. No 
Template Control (NTC) wells were viewed to assess cross contamination. The 
starting copy number of the gene in each sample was calculated from the 
standard curve by the software, and then exported into Excel (Microsoft), for 
further data analysis including normalisation to endogenous control if 
applicable. 
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Figure 2.5: TaqMan® Real-time PCR amplification plot  
Adapted from TaqMan® data plot 7900 Applied Biosystems. 
 
2.1.7 Human immunodeficiency virus (HIV)  
An established method was adapted at GSK to look at antiviral effects of IFNα, 
IFNβ, IFNγ, IL-28A and IL-29. The assay used MT4 T lymphocyte derived cells 
infected with HIV virus HXB2. MT4 cells were split 1:4 two days before required 
using phenol red indicator media (RPMI) plus 10% Hyclone foetal bovine serum 
and Penicillin/streptomycin/L-Glutamine (100units/mL,100µg/mL and 2mM 
respectively). Cells were used at a concentration of 8 x 105 per mL and 2.4 x 
106 cells were used per infection. Cells were harvested by spinning at 400g for 
5 minutes at room temperature and re-suspended in RPMI medium without 
phenol red indicator containing the supplements as above. 
MT4 cells were infected with HIV virus HXB2 at a concentration of 100 x 50% 
Tissue Culture Infectious Dose (TCID50) per million cells for one hour. IFNs 
were then added to the cells. Serial dilutions of IFNα were optimised to 400, 
200,100, 50, 25, 12, 6, 3, 1.5 IU/mL, IFNβ were optimised to 3200, 1600, 800, 
400, 200, 100, 50, 25, 12 IU/mL and serial dilutions were made for IFNγ ranging 
from 25600 to 2 IU/mL, for IL-28A from 7.68mg/mL to 4ng/mL and for IL-29 from 
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1mg/mL to 2ng/mL. IFNs were run in quadruplicate on the plate and each plate 
was run in triplicate over different days. Non infected cells were used as a cell 
control and virally infected cells with media in place of drug were run as a virus 
control. The cells were incubated for 120 hours and then treated with Dimethyl 
thiazolyl diphenyl tetrazolium salt (MTT). Plates were read between 540-590nm 
and the IC50 for IFNs calculated. 
Category 3 lab training was required in order to work with HIV virus in the GSK 
Stevenage labs; and was completed before work using HIV was initiated. 
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Figure 2.6: MT-4 cells uninfected and infected with HXB2  
An example of MT-4 cells uninfected and infected with HXB2;  
A shows normal MT-4 cells in suspension, single cells and common clumping,  
B shows HXB2 infected cells, the cells circled show one cell full of HXB2 virus and the outline of a burst cell. 
 
  Chapter 2 
Page 48 of 183 
 
2.1.8 Dengue fever virus  
A cell line stably expressing dengue virus replicon established in Professor 
Graham Foster’s laboratory at Queen Mary's School of Medicine and Dentistry 
was used to test the antiviral properties of type III interferons. K562 (human 
chronic myeloid leukaemia) cell line stably expressing the dengue virus replicon 
ΔCprME-PAC2A was used. 
 
Figure 2.7: Schematic showing plasmid pDENΔCprME-PAC2A  
Dengue virus type 2 infectious clone cDNA (in plasmid pDVWS601)108 containing a 
single open reading frame carrying three structural genes (C, core; prM, premembrane; 
E, envelope), seven nonstructural (NS) genes, and flanking 5' and 3' untranslated 
regions (UTR). 
2.1.8.1 Cell Culture 
Cells stably expressing dengue virus replicon RNA were generated by 
transfection with ΔCprME-PAC2A RNA and then propagation in RPMI 
containing 10% foetal bovine serum (FBS) and 3μg of puromycin (Sigma-
Aldrich) per mL. Cells were removed from puromycin selection and checked for 
replicon expression before use by indirect immunofluorescence of the dengue 
virus NS1 protein with a specific monoclonal antibody (5H5.4)109. K562 cells 
without replicon were continuously maintained in the same medium without 
puromycin53. K562.ΔCprME-PAC2A cells were grown in the presence of 0, 100, 
1,000 IU/mL for IFNα, IFNβ and IFNγ, 0, 200, 2000ng/mL, 0, 100, 1000ng/mL 
for IL-28A and IL-29 respectively for 24 hours.  
2.1.8.2 Total RNA extraction 
Total RNA extraction from suspension cell cultures was carried out using the SV 
Total RNA Isolation System (Promega). Samples were centrifuged for 5 minutes 
and culture media was removed. Cell pellets were washed with 1mL of sterile 
PBS and centrifuged for a further 5 minutes. The PBS was removed and 150µL 
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SV Lysis Buffer added to each tube. The lysates were transferred into 
RNase/DNase free 1.5mL Eppendorf tubes. Genomic DNA was sheared by 
passing the lysates through a 19-gauge blunt-ended needle four times and 
placed on ice. Lysates were stored at -80ºC until required for total RNA 
extraction. 
2.1.8.3 Total RNA extraction using the SV Columns 
Lysates were thawed and 350µL transferred to a fresh RNase/DNase free 
1.5mL Eppendorf. 700 µL of SV Dilution Buffer was added, mixed by inversion, 
and the mixture incubated at 70oC for 3 minutes. Following centrifugation at 
12,000 x g for 10 minutes, the supernatant was transferred to a sterile 1.5mL 
Eppendorf containing 400µL of 95% v/v ethanol (Sigma-Aldrich). This mixture 
was loaded onto two SV RNA Isolation Tube Assemblies which were 
centrifuged at 14,000 x g for 1 minute. Liquid in the collection tubes was 
discarded, 600µL of SV RNA Wash Solution applied to each column and the SV 
RNA Isolation Tube Assemblies centrifuged at 14,000 x g for 1 minute. The 
collection tubes were emptied and 50µL of SV DNase Incubation Mix (prepared 
from 50µL of SV Yellow Core Buffer, 5µL of SV 0.09M MgCl2 and 5µL of SV 
DNase I enzyme) applied to the surface of each column membrane. SV RNA 
Isolation Tube Assemblies were incubated at room temperature for 15 minutes 
to allow DNA digestion to proceed, after which 200µL of SV DNase Stop 
Solution was added to each column. SV RNA Isolation Tube Assemblies were 
centrifuged at 14,000 x g for 1 minute, 600µL of SV RNA Wash Solution applied 
to each column and then centrifuged again at 14,000 x g for 1 minute. Liquid in 
the collection tubes was discarded and a final wash carried out by applying 
300µL of SV RNA Wash Solution to each column and centrifuging the SV RNA 
Isolation Tube Assemblies at 14,000 x g for 2 minutes (to eliminate ethanol 
carry-over). 
The column within each SV RNA Isolation Tube Assembly was transferred to a 
fresh 1.5mL RNase/DNase free Eppendorf tube and 100µL of SV Nuclease 
Free Water applied to the membrane. Columns were incubated at room 
temperature for 1 minute and the total RNA eluted by centrifuging the 
column/tube assemblies at 14,000 x g for 1 minute. The columns were 
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discarded and eluted total RNA from replicate columns pooled prior to storage 
at -80oC until required. 
2.1.8.4 Total RNA Quantification and Quality Control 
The concentration, yield and purity of each total RNA sample was determined 
using ultraviolet (UV) spectrophotometry. The integrity of each total RNA 
sample was determined by agarose gel electrophoresis. 
2.1.8.5 Quantification Using UV Spectrophotometry 
Spectramax 190 UV Microtitre Plate Reader (Molecular Devices) was used for 
measuring UV absorbance of total RNA samples. The absorbance of each total 
RNA sample (at an appropriate dilution in Molecular Grade Water) at 260nm 
(peak nucleic acid absorbance) and 280nm (peak protein absorbance) was 
measured and the A260/A280 ratio determined to indicate the level of protein 
contamination. Total RNA samples with an A260/A280 ratio of 1.8 to 2.1 were 
considered of acceptable quality. The total RNA concentration was derived 
using the following formula: 
RNA concentration in µg/µL = ((A260 x 40*) x dilution factor)/1000 
*Where 40 = the RNA extinction coefficient 
2.1.8.6 Quality determination using agarose gel electrophoresis 
A 1% weight/volume agarose gel was prepared by melting 1g of Molecular 
Biology Grade Agarose (Sigma-Aldrich) in 100mL of 1 x Tris-borate 
Ethylenediaminetetraacetic acid (EDTA) (TBE) buffer (45mM tris-borate, 2mM 
EDTA) (Sigma-Aldrich). The melted gel was allowed to cool to approximately 
60ºC before adding 5µL of 10mg/mL ethidium bromide solution (Sigma-Aldrich) 
(final concentration of 0.5µg/mL). The gel was mixed gently by swirling, poured 
onto a gel tray (containing two gel combs) and allowed to set for 30 minutes at 
room temperature. The set gel was transferred to an electrophoresis tank (Life 
Technologies) and submerged in 1 x TBE buffer. 
Total RNA samples were prepared by mixing 5µL of each total RNA sample 
with 1µL of 6 x Gel Loading Buffer (Sigma-Aldrich) and placed on wet ice until 
required. Samples were loaded into wells within the gel and electrophoresis 
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carried out for 30-45 minutes at 100 volts. To visualise total RNA staining, the 
gel was visualised using the GeneGenius Bioimager gel documentation system 
(Syngene) and the presence of intact discrete 18S and 28S ribosomal RNA 
(rRNA) bands indicated that the total RNA was of acceptable quality. If the 
rRNA bands were not present, or appeared degraded, the total RNA was 
discarded and a fresh isolation carried out. 
2.1.8.7 QPCR 
Extracted RNAs were treated with RQ1 RNase-free DNase (Promega) to 
degrade both double stranded and single-stranded DNA, and reverse 
transcribed with Moloney murine leukemia virus (M-MLV) reverse transcriptase 
(RT) (Promega) using random decamer primers. PCR reactions were performed 
and analysed on a Rotorgene instrument (Corbett Life Science) by the use of 
custom primers and a fluorescent probe specific for dengue virus NS1 and 
housekeeping gene GAPDH was analysed in the same samples by the use of 
specific primers and QuantiTect SYBR green (QIAGEN).  
Table 2.2: Dengue virus probe and primer sequences 
 Sequences 
Gene 
Forward primer  
(5’-3’) 
Reverse primer  
(5’-3’) 
Probe /equivalent 
(5’-3’) 
Dengue virus NS1 
CTGAAGTGTGGCAGT
GGGATT 
CTTCAAAGCTAGCTTCA
GCTATCCA 
CACAGACAACGTGCAC
ACATGGACAGA 
GAPDH 
ACAGTCCATGCCATCA
CTGCC 
GCCTGCTTCACCACCTT
CTTG 
QuantiTect SYBR green 
 
Table 2.2 shows probe and primer sequences used for RT-PCR analysis to detect 
dengue virus NS1 and housekeeping gene GAPDH.  
2.1.9 Respiratory Syncytial Virus (RSV) 
A tissue culture model of chronic viral infection using an RSV virus infected 
transformed human B cell line established in Professor Graham Foster’s 
laboratory at Queen Mary's School of Medicine and Dentistry, was used to test 
the antiviral properties of type III interferons.  
  Chapter 2 
      
Page 52 of 183 
 
2.1.9.1 RSV cell culture 
Transformed B cells (106 in 10 mL RPMI medium) were incubated with 2 x 108 
viral particles for a total of 14 days leaving the cells undisturbed. Chronic 
infection was assessed by direct cell staining and by quantitative PCR. After 
incubation for 14 days, greater than 90% of the cells expressed RSV antigens. 
Viral RNA was detected in the supernatant. The cells were maintained in culture 
for 16 weeks and passaged every two weeks (cells split 1:3 and the media 
exchanged). Cells in six well plates at 0.5 x 106 cells per well were treated with 
IFNα, IFNβ and IFNγ at 1000 IU/mL, IL-28A at 2µg/mL, IL-29 at 1µg/mL and 
untreated to assess the effects of antiviral treatment. Plates were incubated at 
two time points: 48 hours and 96 hours.  
Total RNA was extracted and quantified as described (Section 2.1.8.2 – 6) and 
reversed transcribed using M-MLV RT (Promega). A quantitative PCR reaction 
was performed and analysed by Rotorgene (Corbett Life Science) using primers 
designed to the WSX1 RSV virus. The values obtained for RSV concentration 
were normalised against GAPDH. 
Table 2.3 Probe and primer sequences for RSV  
 Sequences 
Gene Forward primer 
(5’-3’) 
Reverse primer 
(5’-3’) 
RSV GATATGCCTATAACAAATGATCAG GATACTGATCCTGCATTGTCAC 
GAPDH ACAGTCCATGCCATCACTGCC GCCTGCTTCACCACCTTCTTG 
Table 2.3 shows probe and primer sequences used for RT-PCR analysis to detect RSV 
and housekeeping gene GAPDH.  
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2.2 Transcriptome analysis in HCV replicon cells treated with 
type I and type III IFNs 
2.2.1 Determination of IC50 values for 4 replicon clones 
Values for 10 x IC50 concentrations in the replicon cell lines were determined to 
normalise for the antiviral activities of proteins IFNα, IL-28A and IL-29. Four 
luciferase replicon cell lines were compared for sensitivity with IFNα, IL-28A and 
IL-29 these were: 1a1_19, 1a3II, 1b 2.2, 1b2.5, and the most sensitive selected 
to carry through into transcriptomics analysis. Dilutions of IFNα, IL-28A and IL-
29 were made up in triplicate. For each luciferase cell line, 5 x 104 confluent 
cells in a 50µL volume per well were added to compound made up to 50µL with 
medium. The plates were incubated for 18 hours at 37oC. Supernatent was 
removed and 25µL of Steady-Glo (Promega) was added per well and the plate 
was left in the dark for 15 minutes before reading chemiluminescence at 
450nm. The IC50 was defined as the concentration of each treatment which 
reduced luciferase signal by 50% compared with untreated cells.  
2.2.2 Cell culture and treatment 
Parental HuH7 and HuH7 HCV 1a3II luciferase replicon cells were routinely 
maintained in DMEM, 4500mg/L Glucose and Pyridoxine HCl supplemented 
with 10% foetal bovine serum, 100IU/mL penicillin, 100µg/mL streptomycin, 
2mM L-glutamine, 1% non-essential amino acids and 500µg/mL Geneticin. (All 
reagents from Invitrogen). The assay media conditions were as above minus 
Geneticin. 1 x 106 cells per well of parental HuH7 and HuH7 HCV 1a3II 
luciferase replicon cells were cultured in 6-well plates at 37°C. Four treatments 
were used: untreated, 10 x IC50 for IFNα, IL-28A and IL-29 at time points of 4, 8, 
16 and 24 hours. Each condition was performed in triplicate. Values for 10 x 
IC50 concentrations in the replicon cell lines were determined to normalise for 
the antiviral activities of proteins IFNα, IL-28A and IL-29.  
2.2.3 Isolation of RNA 
Culture media was removed and monolayers were washed with 1mL of sterile 
PBS. The PBS was removed and 1mL TRIzol® Reagent (Invitrogen) 4°C added 
to each well. Cells were scraped with a sterile tissue culture scraper, the lysates 
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were collected in RNAse/DNAse free 1.5mL Eppendorf tubes. Genomic DNA 
was sheared by passing the lysates through a 19-gauge blunt-ended needle 
four times and placed on ice. Lysates were stored at -80ºC until required for 
total RNA extraction. Total RNA was isolated the SV Total RNA Isolation 
System (Promega) and stored at -80°C until required (description of method 
section 2.1.8.2). 
All RNA samples were analysed by the Agilent Bioanalyzer 2100 Lab-On-A-
Chip Nano 6000 chip (Section 2.2.6.6) to determine the integrity and by UV 
spectrometer; OD A260 and A280 for accurate RNA concentration determination. 
2.2.4 Quantitative QPCR pre-screen 
Real-time PCR was performed on the RNAs isolated above and data analysed 
to assess the suitability of the time points and concentrations of the IFNs in the 
assay before running the samples of full genome Affymetrix chips. Applied 
Biosystems assay on demand were used for interferon sensitive genes: 
Interferon-induced GTP-binding protein (IFIT1), myxovirus (influenza virus) 
resistance 1 (MX1), 2'-5'-oligoadenylate synthetase 1 (OAS1) and an interferon 
inducible gene 6-16 (G1P3). Five micrograms of each RNA sample was reverse 
transcribed to cDNA using SuperScript II first strand cDNA synthesis (Life 
Technologies). The relative levels of target transcripts were measured using an 
ABI PRISM 7900 Sequence Detector System (Applied Biosystems). Serial 
dilutions of human genomic DNA (Novagen) were used to generate a standard 
curve for quantitation. GAPDH and b-actin were used as housekeeping genes 
to normalise the data. Real-time data was collected and analysed using 
Sequence Detection System (SDS) software Version 2.0 (Applied Biosystems).  
2.2.5 Affymetrix GeneChips® Expression analysis 
Affymetrix analysis was carried out using RNA from PBS, IL-28A, IL-29 and 
IFNα treated samples in both replicon and parental HuH7 cells at time points of 
8,16 and 24 hours with each in triplicate (72 chips in total). Analysis of 12 
additional chips was performed at the 4 hour time point in parental cells only 
due to lack of RNA in the 4 hour time point in the replicon cells, making a total 
of 84 chips in the experiment. 
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The samples were hybridised to the Human Genome HG-U133plus2 GeneChip 
(Affymetrix). This array enables the analysis of the expression levels of over 
47,000 transcripts and variants including 38,500 well characterised genes. 
Further information on the Human Genome HG-U133plus2 GeneChip is 
available at: (http://www.affymetrix.com/products/arrays/specific/hgu133.affx). 
Briefly the standard expression GeneChips® possess 22 different 25mer oligo 
probes (termed a ‘probe set’) for each gene represented, which are distributed 
at locations remote to each other. The probe sets are 3’-biased and designed to 
give the optimal balance between sensitivity and specificity for the target gene. 
To evaluate any potential for non-specific hybridisation, each ‘perfect match’ 
(PM) probe feature has an adjacent paired ‘mismatch’ (MM) probe feature. The 
MM probe differs in sequence from the PM probe by a single nucleotide, located 
in the centre of the 25mer. The MM features serve as controls that allow the 
subtraction of non-specific hybridisation signals (non-specific hybridisation for 
the PM and MM features should be roughly equivalent) from the PM signal to 
derive the true signal for a particular gene. 
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Figure 2.8: Standard eukaryotic gene expression assay  
Labelled cRNA targets derived from mRNA of an experimental sample are hybridised 
to nucleic acid probes attached to the quartz wafer chip. By monitoring the amount of 
label associated with each DNA location, it is possible to infer the relative abundance of 
each RNA species represented (Affymetrix image library - http://affymetrix.com). 
 
Reverse transcription, second-strand synthesis, and probe generation were 
accomplished by standard Affymetrix protocols full details can be found at: 
(http://www.affymetrix.com/support/technical/manual/expression_manual.affx) 
and are described briefly below. 
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2.2.6 Preparation and Quality Control of cRNA Targets for Hybridisation to 
GeneChips® 
2.2.6.1 Preparation Double-Stranded cDNA 
Double-stranded cDNA (ds cDNA) was prepared from total RNA using the One-
Cycle cDNA Synthesis Kit (900431, Affymetrix).  
The following was added to a 0.75mL RNase/DNase free Eppendorf tube:  
 2µL of T7-(dT)24 primer (100pmol/µL), 5µg of total RNA in 9µL of 
Nuclease Free Water.  
The tubes were then centrifuged briefly and incubated at 70C for 10 minutes to 
allow total RNA denaturation and primer hybridisation. The tubes were cooled to 
4C and the following added to each reaction: 
 4µL of 5 x First Strand cDNA Buffer, 2µL 0.1M DTT, 1µL 10mM dNTP 
mix and 2µL Superscript II RT (200U/µL)  
The tubes were centrifuged briefly and incubated at 42C for 1 hour (to allow 
first strand synthesis to proceed). The tubes were cooled to 4C and the 
following added to each reaction: 
 91µL of nuclease free water, 30µL of 5 x Second Strand cDNA Buffer, 
3µL 10mM dNTP mix, 1µL of E. coli DNA ligase (10U/µL), 4µL of E. coli 
DNA polymerase (10U/µL) and 1µL of E. coli RNase H (2U/µL)  
The tubes were centrifuged briefly and incubated at 16C for 2 hours (to allow 
second strand synthesis to proceed). Two microlitres of T4 DNA polymerase 
was added to each reaction, the tubes centrifuged briefly and incubated at 16C 
for 15 minutes. To stop the reaction, 10µL 0.5M EDTA (Fluka) was added to 
each tube and the contents mixed well.  
2.2.6.2 ds cDNA cleanup 
ds cDNA was cleaned-up using the ds cDNA Cleanup Kit (Affymetrix). 600μl of 
Binding Buffer was added to each ds cDNA sample, mixed thoroughly and 
applied to a ds cDNA Spin Column Assembly. The Assemblies were centrifuged 
at 14,000 x g for 1 minute and the flow through discarded. The columns were 
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transferred to a fresh 2mL collection tube, 750µL of cDNA Wash Buffer added 
and the tube assemblies centrifuged at 14,000 x g for 1 minute. The flow 
through was discarded and the tube assemblies centrifuged at 14,000 x g for 5 
minutes with the caps open (to completely dry the columns). The columns were 
transferred to a 1.5mL Collection Tube and 25µL of cDNA Elution Buffer applied 
to the membrane. The columns were centrifuged at 14,000 x g for 1 minute and 
the purified ds cDNA stored at -20C until required for the in vitro transcription 
(IVT) reaction. 
2.2.6.3 IVT reaction 
Biotinylated complementary RNA (cRNA) targets were generated from ds cDNA 
using the IVT Labelling Kit (Affymetrix). The following were added to a 0.75mL 
RNase/DNase free Eppendorf tube: 
 20µL of ds cDNA sample, 4µL of 10 x IVT Labelling Buffer, 12µL of IVT 
Labelling NTP Mix and 4µL of IVT Labelling Enzyme Mix.  
The tubes were centrifuged briefly and incubated at 37C for 16 hours to allow 
IVT to proceed. The cRNA was either stored at -20ºC until required, or 
subjected to cRNA Cleanup. 
2.2.6.4 cRNA Cleanup 
Biotinylated-cRNA was cleaned-up using the cRNA Cleanup Kit (Affymetrix). To 
each cRNA sample, 55µL of Nuclease Free Water and 5µL of 3M Sodium 
Acetate (Fluka) were added. 350L of cRNA Binding Buffer and 250µL 100% 
ethanol were added to each cRNA sample, mixed thoroughly and applied to a 
cRNA Spin Column Assembly. The assemblies were centrifuged at 14,000 x g 
for 15 seconds. The flow through was reapplied to the columns and assemblies 
centrifuged again at 14,000 x g for 15 seconds. The columns were transferred 
to a fresh 2mL collection tube, 500µL of cRNA Wash Buffer added and the tube 
assemblies centrifuged at 14,000 x g for 15 seconds and the flow through 
discarded. This step was repeated, followed by a final centrifugation at 14,000 x 
g for 1 minute. The columns were transferred to a 1.5mL Collection Tube and 
50µL of Nuclease Free Water applied to the membrane. The columns were 
incubated at room temperature for 1 minute and centrifuged at 14,000 x g for 1 
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minute to elute the cRNA. The purified cRNA was stored at -20C until required 
for the quantification and fragmentation. 
2.2.6.5 Quantification of IVT Products and Fragmentation 
UV spectrophotometry was used to determine the cRNA concentration and 
yield. For cRNA samples where sufficient yield and concentration had been 
achieved, fragmentation was carried out using the Fragmentation Buffer as 
supplied with the cRNA Cleanup Kit. An appropriate dilution of each cRNA 
sample in Nuclease Free Water was prepared. The absorbance at A260 and A280 
was measured and the adjusted cRNA yield calculated using the following 
formula: 
Adjusted cRNA yield (µg) = A – (B x C) 
Where: 
A = Total yield of cRNA according to A260 result (µg). 
B = Starting amount of total RNA used in cDNA reaction (µg). 
C = Fraction of cDNA used in IVT reaction. 
For example: Start with 5µg of total RNA, use 80% (or 4µg) in the IVT, 
and the cRNA yield is 45µg. The calculation would therefore be: 
45 - (5 x 0.8) = 41µg 
To determine the adjusted concentration, the adjusted yield (in µg) is divided by 
the total volume (µL). A volume of each cRNA sample containing 15µg (based 
on the adjusted concentration) was transferred to a 0.75mL RNase/DNase free 
Eppendorf tube. 0.25µL of Fragmentation Buffer was added for each 1µL of 
cRNA and the tube incubated at 94C for 35 minutes and then cooled to 4C for 
5 minutes using a DNA Engine Tetrad PCR machine (Bio-Rad). Fragmented 
cRNA samples were stored at -20C until required. To determine whether cRNA 
fragmentation was successful, the size of cRNA and fragmented cRNA samples 
were assessed using the RNA 6000 Nano Labchip Kit (Agilent).  
2.2.6.6 Gel preparation and RNA 6000 Nano Labchip Priming 
RNA 6000 Nano Gel Matrix was prepared by placing 550µL into a Spin Filter 
and centrifuging at 1,500 x g for 10 minutes at room temperature. On the day of 
use, a 65µL aliquot of filtered RNA 6000 Nano Gel Matrix was transferred to a 
RNase free Eppendorf tube and 1µL of RNA Nano 6000 Dye Concentrate 
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added (Gel-Dye Matrix). The Gel-Dye Matrix was mixed by vortexing and 
centrifuged at 13,000 x g for 10 minutes at room temperature. A RNA 6000 
Nano Labchip was placed on the Priming Station (Agilent) and 9µL of Gel-Dye 
Matrix carefully pipetted into the ‘priming well’. The plunger of the Priming 
Station was positioned at the 1mL graduation and the manifold closed firmly 
over the Labchip. The plunger was firmly depressed until it was held by the clip 
and priming allowed to proceed for 30 seconds, after which the clip was 
released. The plunger allowed to recoil for 5 seconds and then pulled back to 
the 1mL graduation. The Priming Station was opened, the Labchip removed 
and 9µL of Gel-Dye Matrix carefully pipetted into each of the three ‘gel’ wells. 
Labchip priming was completed by adding 5µL of RNA 6000 Nano Marker 
Buffer to wells 1-12 and the ‘ladder’ well. 
2.2.6.7 Sample Preparation, Loading and Running the Labchip 
Frozen cRNA and fragmented cRNA samples were thawed and diluted 1/10 
with Molecular Biology Grade Water. Two microlitres of RNA Nano 6000 Ladder 
and each diluted cRNA/fragmented cRNA sample was transferred to a 0.75mL 
RNase free Eppendorf tube and heat denatured at 70ºC for 2 minutes. The 
tubes were immediately chilled on ice and the contents centrifuged to the 
bottom at 14,000 x g. One microlitre of heat denatured sample was added to 
each sample well; the same volume of heat denatured RNA Nano 6000 Ladder 
was added to the ‘ladder’ well. The RNA Nano 6000 Labchip was placed on the 
Labchip Vortexer (IKA) and vortexed for 1 minute at 2,400 rpm. The loaded 
Labchip was placed into the 2100 Bioanalyzer (Agilent). The ‘Nano 6000 Assay’ 
protocol was selected within 2100 Expert Software version B.02.02 (Agilent) 
and electrophoresis commenced. Once the electrophoresis was complete the 
results file was saved and the size profiles of each cRNA and respective 
fragmented cRNA sample inspected visually. 
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Figure 2.9: Representative RNA 6000 Nano Labchip cRNA Quality 
Assessment Images 
A Gel View and B Electropherogram View L = RNA 6000 Nano Marker Ladder. 1-6 = 
cRNA samples. 7-12 = fragmented cRNA samples. 
 
2.2.6.8  Hybridisation of cRNA Targets to Affymetrix GeneChips® and 
Scanning 
Fragmented cRNA targets were hybridised to GeneChips® using the GeneChip® 
Hybridisation, Wash and Stain Kit (Affymetrix). All reagents were used as 
supplied. The required number of GeneChips® were allowed to equilibrate to 
room temperature for a minimum of 1 hour. The GeneChip® was filled with 
250µl Pre-Hybridisation Buffer. GeneChips® were placed in a rotisserie rack and 
incubated at 45C for a minimum of 10 minutes with rotation (~60rpm) in a 
GeneChip® Incubator (Affymetrix). 
While pre-hybridisation proceeded, hybridisation cocktails were prepared. 
Reagents (Table 2.4) were added to a 1.5mL RNase/DNase free Eppendorf 
tube. The hybridisation cocktails were incubated at 99ºC for 5 minutes followed 
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by 45ºC for 5 minutes using a DNA Engine Tetrad PCR machine (Bio-Rad). 
Tubes were centrifuged at 14,000 x g for 10 minutes to remove particulates and 
stored at room temperature just prior to hybridisation. 
Table 2.4: Reagents and Volumes for Hybridisation Cocktail Preparation 
Reagent Human Genome HG-
U133plus2 GeneChip
®
 
Final Concentration 
Fragmented cRNA 15µg 0.05µg/µL 
Control Oligo B2 5µL 50pM 
20 x Hyb Controls 15µL 1.5, 5, 25 and 100pM spikes 
DMSO 30µL  
2 x Hyb Mix 150µL 1 x 
Nuclease Free 
Water 
Up to 300µL  
 
GeneChips® were removed from the incubator and the Pre-Hybridisation Buffer 
removed. 200µL hybridisation cocktail was applied to the GeneChip®. 
GeneChips® were placed in a rotisserie rack and incubated at 45C for 16 hours 
with rotation (~60rpm) in a GeneChip® Incubator (Affymetrix). 
2.2.6.9 Washing and Staining of Affymetrix GeneChips® 
GeneChips® were removed from the incubator and the hybridisation cocktail 
removed. The GeneChip® was filled with 250µL Wash Buffer A.  For each 
GeneChip® to be stained, 600µL of Staining Cocktail 1, 600µL of Staining 
Cocktail 2 and 800µL of Array Holder Buffer were dispensed into 1.5mL 
Eppendorf tubes on the fluidic station. The Experimental details and barcode for 
each GeneChip® were entered in Experiment Manager within Affymetrix 
Microarray Suite (MAS). To commence staining and washing, GeneChips® were 
loaded into cassette holders on the appropriate Fluidics Station 450. When the 
wash protocol was completed, the GeneChip® was removed for scanning.  
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2.2.6.10  Scanning of Affymetrix GeneChips®, Primary Analysis and 
Quality Assessment 
To scan the GeneChips®, Scanner Control within MAS was opened and the 
‘autoloader’ function selected. Stained GeneChips were loaded onto the 
autoloader of a GeneChip® Scanner 3000 (Affymetrix) and scanning 
commenced by clicking ‘start scan’ within Scanner Control. The GeneChips® 
were automatically scanned, producing a .dat file. GeneChip® .dat files that 
were of acceptable visual quality were analysed using the ‘batch analysis 
function’ within GeneChipA® operating software (GCOS) to generate .chp, .cel 
and .rpt files. Hybridisation quality was assessed by reviewing the metrics 
generated within the .rpt file and the quality assessed according to the 
thresholds (Table 2.5). 
Table 2.5: GeneChip® hybridisation quality control metrics  
Quality Indicator Metric Description 
Background values Average Background Values range  20-100 intensity units 
Background values Raw Q value Overall indication electrical noise  
Hybridisation controls 
BioB (1.5pM final) 
BioC (5pM final) 
BioD (25pM final) 
Cre (100pM final) 
Prokaryotic gene spikes. BioB equates to 
1:100,000 copies and is at the limit of 
assay sensitivity. BioB should be called 
‘present’ in 50% of arrays. BioC, D and 
Cre should always be called present. 
Internal control genes 
Beta-actin 
GAPDH 
Used to assess input RNA quality. Ratio 
3’:5’ ratio should be <3 for at least one 
gene.  
Percent present %P 
The number of probe sets called ‘present’ 
expressed as a percentage of the total 
probe sets on the GeneChip
®
.  
Scaling and 
normalisation factors 
SF 
Indicates the factor used to normalise the 
array to the Target Intensity Signal.  
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2.2.6.11 Downstream Analysis of Transcriptomic Data 
To undertake comparison analyses of different treatment conditions, the 
normalised .chp file for GeneChips® of acceptable quality (as defined in Table 
2.5) were imported into Rosetta Resolver® Version 6.0 (Merck Sharpe Dohme). 
Rosetta Resolver® is an integrated microarray data repository system that 
enables the storage, annotation and statistical analysis of GeneChip® 
experiments110. Upon import of .chp files Rosetta Resolver® associates 
individual probe set intensities with gene annotations. To analyse the data, 
Rosetta Resolver® uses a proprietary error model that is specific to the 
GeneChip® type being analysed111. The concept of the error model is to account 
for experimental error without the need to perform large numbers of replicate 
experiments. The error model is an empirical intensity-based method for 
obtaining a conservative estimate of the signal variability within a small replicate 
data set. To determine the average signal, and whether a particular probe set is 
significantly expressed above background (absolute analysis), Rosetta 
Resolver® computes the average PM minus MM value for the each probe pair. 
As part of this analysis the error model is used to define the variability of each 
probe set intensity. Significance of expression is determined by comparing the 
average signal of each probe set to the average signal of negative controls 
within the GeneChip®. Probe sets where the error-normalised difference in 
signal is significantly different are called as present (or significantly expressed). 
To undertake comparative analysis between control (‘baseline’) and treatment 
(‘test’), replicate arrays are defined for any number of groups and the 
‘RatioBuild’ function used. The RatioBuild function automatically performs 
comparisons between all pairs of baseline and test groups and produces a 
consensus result for ratio of change (relative to baseline) and significance of 
change. During the course of this analysis, a global normalisation is applied to 
all replicate GeneChips® and ratio of change computed from the group mean 
intensity for each probe set. To determine the significance of change, the error 
of the ratio of change is computed by combining the modelled error of individual 
probe sets and the variability of the actual replicates signals. With increasing 
numbers of experimental replicates, the relative contribution that the modelled 
error makes to the analysis decreases. The analysed data can then be exported 
by using the ‘TrendSet’ function within Rosetta Resolver®. The user defines all 
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comparisons within the data set and selects thresholds for ratio of change and 
significance (P-value). An arbitrary threshold can also be set for the number of 
comparisons in which the ratio of change and significance thresholds must be 
met. This data can then be exported to Excel or as tab-delimited files for 
downstream data analysis. 
The complexity of the data generated by microarray experiments necessitates 
the use of bioinformatics tools to aid interpretation and help confer biological 
meaning. To this end, transcriptional data exported from Rosetta Resolver® was 
analysed using biological theme analysis tools. This provides a high level 
overview of the functional classes of genes and pathways significantly 
overrepresented within a data set.  
Two alternative methods, GeneGo MetaCore™ pathways analysis software 
(http://www.genego.com/metacore.php) and Ingenuity Pathway Analysis (IPA) 
(Ingenuity Inc.) (Version 2.1), were used.  
IPA segregates groups of genes within the query set into networks defined by 
known interactions amassed from the literature112. In addition, biological themes 
are conferred to the networks by again utilising a modified version of the Fisher 
exact. IPA uses proprietary ‘function terms’ to assign overrepresented gene 
categories within the gene list. IPA (and GeneGo) are able to identify canonical 
pathways that are significantly regulated within the data113. Ingenuity Pathway 
Analysis Base (IPKB) has a knowledge base of ~1.4 million findings. 
Expression data sets containing gene identifiers (Entrez Gene ID) and their 
corresponding expression values with a cut off p-value of 95% or higher and 
fold changes were uploaded into IPKB or GeneGo. The genes identified as 
differentially expressed were included in the analysis and utilised to search for 
biological networks.  
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2.3 Distribution of type III interferon receptor in a panel of 
mouse and human tissues –genomic analysis 
2.3.1 TaqMan® quantative PCR for IL-28R RNA detection in mouse 
Total cellular RNA was extracted using the SV RNA Isolation kit (Promega), 
(Section 2.1.8.2-6). Using the Bioanalyser RNA 6000 Nano Chip (Agilent), the 
integrity of the RNA samples was assessed. 1µg of total RNA was reverse 
transcribed (RT) using the Superscript™ First-Strand Synthesis System for 
Reverse Transcription RT-PCR (Invitrogen). Three tissue replicates of 10ng/µL 
cDNA per tissue were pooled and then used in triplicate for TaqMan® analysis.  
IL-28R specific RNA levels were quantified using an ABI Prism 7900 sequence 
detector (Applied Biosystems). RT-PCR was performed using mastermix (1x) 
and IL-28R assay on demand, Mm00558035_m1 (Applied Biosystems): 18S 
ribosomal RNA used as the endogenous control in a multiplex reaction, RT 
reactions were incubated for 30 minutes at 50oC followed by the activation of 
Taq polymerase at 95oC for five minutes. After cooling for two minutes, 40 
cycles of PCR were performed with cycling conditions of 15 seconds at 95oC, 
40 seconds at 50oC and 30 seconds at 72oC. A relative standard curve using 
known standards of genomic human DNA was run in parallel and real-time 
amplification signals were analysed using SDS software (version 1.71 Applied 
Biosystems).  
2.3.2 Gene Logic human tissue microarray screen 
The BioExpress Human Atlas Suite (Gene Logic Inc), comprising of 2695 
normal human samples belonging to 101 tissue types profiled114 using human 
U133A & B chips (Affymetrix)115,114,116 was used to look at gene expression of 
IL-28R, IL-10R and IFNAR1. 
2.3.3 Human inflammatory cell microarray screen 
A GSK proprietary panel of mRNA from human primary cells was used to 
investigate IL-28R expression using microarray technology, developed by GSK. 
The panel included peripheral blood mononuclear cells (PBMCs), plasmacytoid 
dendritic cells (pDC), myeloid dendritic cells (mDC), alveolar macrophages, 
macrophages, mast cells, B cells, CD4+ T cells and CD8+ T cells, (unstimulated 
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and stimulated). The Affymetrix human HG-U133-Plus 2 chips were used to 
profile expression data on mRNA extracted from these cells, IL-28R (TIG45563) 
data is shown from this screen.  
2.3.4 Isolation & treatment of cells for human inflammatory cell microarray 
screen 
pDC and mDCs (>95%), CD4+ T cells, CD8+ T cells and CD4+ CD25+ 
regulatory T cells were isolated from PBMCs (three donors); separated using 
Accuspin Histopaque-1077 columns (Sigma-Aldrich) and purified using 
magnetically labelled beads (Miltenyi Biotec). pDCs and mDCs were 
magnetically labelled with BDCA-4 and BDCA-1 microbeads respectively. 
Untouched CD4+ T cells were prepared by magnetic depletion of other cells 
within PBMC using antibodies to CD8, CD11b, CD16, CD19, CD36, CD56. In a 
second step naїve CD4+ T cells were isolated from CD4+ T cells by depletion of 
CD45RO+ T cells (>90% CD4+ CD45RA+ T cells). Isolated CD8+ T cells are 
depleted of CD8+CD56+cells. Non-CD8+ T cells are indirectly magnetically 
labelled by using a cocktail of biotin-conjugated antibodies (CD4, CD15, CD16, 
CD19, CD34, CD36, CD56, CD123, TCR γ/δ, and CD235a), and the CD8+ T 
Cell MicroBead cocktail. Isolation of highly pure CD8+ T cells was achieved by 
depletion of magnetically labelled cells. CD4+CD25+ regulatory T cells were 
isolated by indirectly magnetically labelling non-CD4+ cells (by using a cocktail 
of biotin-conjugated antibodies against CD8, CD14, CD16, CD19, CD36, CD56, 
CD123, TCR γ/δ, and CD235a (glycophorin A)). In a second step CD4+CD25+ 
regulatory T cells are directly labelled with CD25 MicroBeads and isolated by 
positive selection from CD4+ T cells. Primary tonsillar B cells from three donors 
(>98%) were isolated by negative selection, non-B cells were labelled (CD2, 
CD14, CD16, CD36, CD43, CD235a). Macrophages derived from monocytes 
were prepared from PBMCs (three donors), separated using Accuspin 
Histopaque-1077 columns and purified using positive selection CD14 beads. 
Cells were resuspended in RPMI, 10% foetal calf serum, penicillin/streptomycin 
+L-glutamine and 100ng/mL Macrophage colony-stimulating factor (M-CSF) and 
incubated for four days to differentiate into macrophages. Mast cells were 
derived from cord blood mononuclear cells (AllCells), cells were cultured in 
Iscove’s modified Dulbecco’s medium (Invitrogen), supplemented with 5% foetal 
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bovine serum, 1% penicillin/streptomycin, human stem cell factor (100ng/mL), 
human IL-6 (50ng/mL) and IL-10 (10ng/mL) for 14 weeks.  
Cells were treated with a wide range of inflammatory stimuli. pDCs and mDCs 
were untreated. B cells were unstimulated or stimulated with CD40 ligand or 
anti B cell receptor (anti-IgM) co-stimulation assay at four time points; 0, 24, 48 
and 72 hours. Macrophages were cultured with vehicle alone, TNF (10ng/mL), 
LPS (10ng/mL), immune complex (IgG coated beads) and cytomix (TNF 
(10ng/mL), LPS (10ng/mL) and IFNγ (10ng/mL)) for 2, 6 and 24 hours. T cells 
treatments were CD4+ and CD8+ cells resting; 1, 6 and 24 hours post anti-
CD3/CD28. Mast cells were primed for 6 days with human IL-4 (10ng/mL) and 
human myeloma IgE, lambda (1µg/mL) / human myeloma IgE, kappa (1µg/mL), 
cells were triggered for 1 hour with anti-IgE (1.5µg/mL), control with no 
triggering.  
2.3.5 Human tissues and whole blood 
Human tissue and whole blood samples were collected from anonymised 
donors. Ethics committee approval was provided and all patients gave informed 
consent.  
2.4 Distribution of type III interferon receptor in a panel of 
mouse and human tissues, protein expression analysis 
2.4.1 Immunohistochemistry overview 
Immunohistochemistry (IHC) is a powerful investigative tool used to detect 
presence and location of antigens (e.g. proteins) in cells of a tissue (histo) 
section using antibodies specific for the antigen of choice. Antigen : antibody 
interaction is visualised using chromogenic detection; where enzyme 
conjugated antibody cleaves substrate resulting in coloured product at location 
of target protein, or fluorescent detection using fluorophore conjugation to 
specific antibody. In optimising IHC protocols, several stages need 
consideration and optimisation; these include antigen retrieval, blocking, 
primary antibody choice and incubation temperature and time, direct labelling or 
indirect labelling, choice of secondary antibody and detection method enzyme, 
substrate. Dual staining where multiple primary antibodies are used needs 
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further consideration, care needs to be taken to ensure compatibility of methods 
so both primary antibodies can be visualised. 
 
 
 
Figure 2.10: Avidin-Biotin Complex (ABC) method  
Diagram representation of immunohistochemistry using ABC method - adapted from 
Dako IHC Staining methods Fifth Edition. 
2.4.2 Immunohistochemical staining - IL-28R single stain in mouse and 
human 
IL-28R protein expression in a selected panel of mouse and human tissues was 
determined by immunohistochemistry. Optimal staining parameters for IL-28R 
were initially worked up in mouse spleen using two IL-28R antibodies 
(Capralogics and Abcam). Frozen tissues were evaluated first and then adapted 
for use in paraffin fixed tissues (formalin fixed for human). Experiments were 
designed to determine the optimal dilutions that yielded specific positive 
immunohistochemical staining with minimal non-specific background staining.  
The following conditions were optimised: dilution range of 4µg/mL to 0.4µg/mL, 
+/- antigen retrieval, +/- additional avidin/biotin blocking steps, +/- copper 
sulphate to enhance staining. Preliminary experiments to optimise rat IL-28R 
antibody (Capralogics) in mouse spleen showed non-specific staining so only 
IL-28R antibody (Abcam) was evaluated further. Immunohistochemistry method 
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was developed using IL-28R goat anti-mouse polyclonal antibody (Abcam) 
(amino acid residues corresponding to 44-72 of N-terminus of mouse CRF-2-12 
(IL-28R) protein: LPGLGSPPNVT YFVTYQSYIK TGWRPVEH. Tissue sections 
were de-waxed in xylene (Sigma-Aldrich) for 5 minutes and rehydrated in 
industrial methylated sprit (IMS) (Sigma-Aldrich) to distilled water, 2 x 5 
minutes. Antigen retrieval was carried out using a low pH buffer; slides were 
microwaved (Antigen retrieval programme, Milestone Mega TT microwave 
(Analytix)) in 1500mL of diluted antigen unmasking solution (Vector 
Laboratories). Slides were washed in water and mounted into sequenza 
cassettes and slide racks (Thermo Shandon), then rinsed in TBS* buffer for 5 
minutes. Peroxidases were blocked with peroxidase blocking solution (Dako) to 
block endogenous peroxidises for 10 minutes. Non-specific binding of protein 
was blocked using normal rabbit serum (Dako) (diluted 1:5 TBS) for 10 minutes, 
followed by a rinse in TBS for 5 minutes and then avidin and biotin blocks 
(Vector) (4 drops per mL of TBS) for 15 minutes with a TBS wash in between. 
Slides were incubated with IL-28R antibody at 0.8µg/mL diluted in TBS for 1 
hour at room temperature followed by a 5 minute TBS wash. Slides were 
incubated for 30 minutes with biotinylated rabbit anti-goat secondary antibody 
(Dako) at 13µg/mL TBS and then washed with TBS for 5 minutes. Slides were 
developed using streptavidin horseradish peroxidise (HRP) and 3, 3‐
diaminobenzidine tetrahydrochloride (DAB) (Dako). Staining was enhanced 
using 4% Copper Sulphate (Sigma-Aldrich) (diluted in distilled water) for 5 
minutes, washed in TBS for 5 minutes and then counterstained in Mayers 
haematoxylin (Sigma-Aldrich) for 5 minutes. Slides were ‘blued’ in running tap 
water and taken through IMS and xylene washed before being cover slipped 
using Entellen® mounting medium (Merck Sharpe and Dohme). A negative 
control goat IgG and a negative control (no antibody) for assessing the 
biological system were performed for every tissue. 
* TBS Tris Buffered Solution 50mM Tris, 0.15M NaCl, pH 7.4. (Dako). 
2.4.3 Immunohistochemical staining- IL-28R dual stain in mouse 
IL-28R dual staining in mouse tissues was additionally performed with mouse 
and rat monoclonal antibodies for macrophage identification; 1) Mac387 
(ab22506 Abcam) which recognises the L1 or Calprotectin molecule expressed 
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by granulocytes, monocytes and by tissue macrophages and 2) F4/80 (ab6640 
Abcam) which is expressed on a wide range of mature tissue macrophages 
including Kupffer cells, Langerhans and macrophages located in cords and 
marginal zone of the spleen. Macrophages are white blood cells derived from 
monocytes. Macrophages have a phagocytic role, secrete cytokines and are 
involved in antigen processing and presentation to other cells. OX-62a dendritic 
cell antibody (ab36444 Abcam) and CD79a b cell marker antibody (Dako 7050) 
were also used during the optimisation of dual staining protocol but not carried 
through as the methods for antigen retrieval for OX-62 and IL-28R antibodies 
were not compatible. All antibodies above were optimised as a single assay and 
then evaluated for compatibility as a dual assay with IL-28R. 
IL-28R dual staining in mouse tissues was performed with 5µg/mL Mac387 
(Abcam) and 10μg/mL F4/80 (Abcam), mouse and rat monoclonal antibodies for 
macrophage identification.  
Tissue sections were de-waxed in xylene for 5 minutes and rehydrated in 
industrial methylated spirit (IMS) to distilled water, 2 x 5 minutes. Antigen 
retrieval was carried out using a low pH buffer; slides were microwaved 
(Antigen retrieval programme, Milestone Mega TT microwave (Analytix,)) in 
1500mL of diluted (1:10 TBS) antigen unmasking solution (Vector). Slides were 
washed in water and mounted into sequenza cassettes and slide racks (Thermo 
Shandon), then rinsed in TBS buffer for 5 minutes. Peroxidases were blocked 
with peroxidase blocking solution (Dako) to block endogenous peroxidises for 
10 minutes. Non-specific binding of protein was blocked using normal rabbit 
serum (Dako) (diluted 1:5 TBS) for 10 minutes, followed by a rinse in TBS for 5 
minutes and then avidin and biotin blocks (Vector) (4 drops per mL of TBS) for 
15 minutes with a TBS wash in between.  Slides were incubated with IL-28R 
antibody at 0.8µg/mL diluted in TBS for 1 hour at room temperature followed by 
a 5 minute TBS wash. Slides were incubated for 30 minutes with biotinylated 
rabbit anti-goat secondary antibody (Dako) at 13µg/mL TBS and then washed 
with TBS for 5 minutes. Slides were developed using streptavidin horseradish 
peroxidase (HRP) and 3, 3‐diaminobenzidine tetrahydrochloride (DAB) (Dako). 
Staining was enhanced using 4% Copper Sulphate (Sigma-Aldrich) (diluted in 
distilled water) for 5 minutes.  
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Sections were incubated for 1 hour with the primary antibody MAC387 (5µg/µL 
Mouse tissue 1µg/µL Human tissue) or F4/80 10µg/mL at room temperature. 
Slides were incubated for 30 minutes with biotinylated rabbit anti-rat secondary 
antibody (Dako) at 13µg/mL. The sections were then developed using either 
VECTASTAIN® ABC-Alkaline Phosphatase (AP) reagent and Vector Red 
(Vector Laboratories) for MAC387 or HRP followed by VECTASTAIN® ABC-
Very Intense Purple® (VIP) (Vector Laboratories) F4/80, and counter-stained 
with either haematoxylin (Sigma-Aldrich) or methyl green (Vector Laboratories). 
Slides were taken through IMS and xylene washed before being cover slipped 
using mount with glycergel mounting medium (Dako).  A matched isotype 
control goat IgG for IL-28R comparison and rat IgG2b for MAC387/F4/80 
comparison and a negative control (no antibody) for assessing the biological 
system were performed for every tissue. 
2.4.4 Toluidine blue histochemical stain in mouse 
To identify mast cells toluidine blue was used on a section of mouse uterus and 
compared to serial sections stained with IL-28R antibody and a goat IgG isotype 
matched control. Mast cells are connective tissue cells with cytoplasm filled with 
granules comprising predominantly of histamine and heparin. Tissues 
containing glycosaminoglycans (GAGs) e.g. heparin GAGs, can be stained with 
basic (cationic) dye, toludine blue. This results in mast cells displaying a 
purple/violet ‘metachromatic’ colour and blue background staining. Toluidine 
blue dye structure is shown below. 
 
Figure 2.11: Structure of toluidine blue 
5µm paraffin sections were dewaxed using xylene and rehydrated in IMS and 
then distilled water. A toluidine blue working solution was made fresh (1g 
toluidine blue and 100ml 70% alcohol, mixed 1:10 with a 1% sodium chloride 
solution (0.5g sodium chloride and 50mL distilled water pH adjusted to 2-2.5 
using glacial acetic acid) (all reagents Sigma-Aldrich). Sections were stained in 
toluidine blue working solution for 3 minutes. Washed 3 times in distilled water 
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and then dehydrated quickly in 95% ethanol and then 100% ethanol. The 
sections were then cleared in xylene and cover slipped using Entellen® 
mounting medium (Merck, Sharp and Dohme). 
2.4.5 Flow Cytometric Analysis for tissue IL-28R determination 
Mouse tissues: spleen, liver, heart, brain, kidney were homogenised using 
Covaris focused acoustic system (Kbioscience). IL-28R antibody (Abcam) was 
biotinylated with an ImmunoProbe Biotinylation kit (Sigma-Aldrich) according to 
manufacturer’s instructions: 
http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Bulletin/bk101bul.Par.00
01.File.tmp/bk101bul.pdf 
Biotinylated IL-28R was then added to streptavadin phycoerythrin conjugate 
(R&D systems) and then incubated with tissue homogenate (~5 x 106/mL) for 15 
minutes at room temperature. Goat IgG antibody was used as a negative 
control. Cell pellets were suspended in CellWash (Becton Dickinson), 
centrifuged at 2100rpm for 3 minutes, supernatant decanted and this process 
was repeated until visibly clear of red blood cells. Labelled cells were analysed 
on a FACSCalibur flow cytometer (Becton Dickinson). A homogeneous 
population of cells was gated and analysed using FlowJo Version 4.5.4 software 
(Tree Star). 
2.5 Bone marrow assays 
2.5.1 Murine bone marrow in vitro assay 
This work was carried out in collaboration with David Brott, AstraZeneca, US all 
cell work was completed at AstraZeneca, US. Methods were adapted from 
those described by Brott & Pognan (2009)117, briefly: 
Cell lines & Cultures: M1 cell line (ATCC TIB-192) derived from Mus muscululs 
spontaneous myeloid leukemia with the cell type being myeloblast was used to 
evaluate myelotoxicity potential.  M1 cells were maintained by splitting cultures 
twice a week to 1-2 x 105 cells/mL in RPMI-1640 (Sigma Aldrich) and 10% 
foetal bovine serum (Sigma Aldrich).  
The HCD57 epo-dependent erythroleukemia cell line was kindly provided by Dr. 
Spiveck at Johns Hopkins University.  HCD57 cells were maintained by splitting 
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cultures twice a week to 2-5 x 105 cells/mL in Iscove’s Modified Dulbecco’s 
Medium containing 30% foetal bovine serum, L-glutamine (Sigma Aldrich), 
10pg/mL mouse recombinant erythropoietin (R&D Systems) and 20µM beta-
mercaptoethanol (Qiagen). 
Assay: M1 and HCD57 cells were seeded at 5,000 cell per well in 50µL 
media.  Compounds were dissolved and diluted in appropriate media with 50µL 
added to the appropriate wells.  Mouse IFNα (R&D systems (PBL)) and mouse 
IL-28A and IL-28B (R&D systems). IFNα, IL-28A and IL-28B were run in 
triplicate and over duplicate plates, serial dilutions were prepared 0.002, 0.004, 
0.008, 0.16, 0.031, 0.063, 0.125, 0.25, 0.5, 1 and 2µM. Assays were cultured at 
37oC and 5% CO2 for approximately 72 hours.  After adding 100µL of CellTiter 
Glo (Promega) to each well, relative luminescence was determined and IC50 
calculated. 
2.5.2 Human bone marrow  
2.5.2.1 Gene expression  
CD34+ hematopoietic cell samples were obtained from five human umbilical 
cords (purity >60%) and three bone marrow donors (Lonza, purity >95%) - 
CD3+ T-cells, CD19+ B-cells, CD11c+ DCs and CD14+ 
monocytes/macrophage cells were purified from peripheral blood from four 
normal donors using magnetic beads protocols for separation (Miltenyi Biotec, 
purity >80%). Cells were analysed for IFNAR1 (Hs01066118_m1 FAM labelled 
assay on demand (Applied biosystems)) and IL-28R (Hs00417120_m1 FAM 
labelled assay on demand (Applied biosystems)), IL-10RB (Hs00175123_m1 
FAM labelled assay on demand (Applied biosystems)) gene expression using 
TaqMan® using b-actin house keeper gene (Hs00417120_m1 VIC labelled 
assay on demand (Applied biosystems)). 
2.5.2.2 Human bone marrow CD34+ cell assays 
A colony forming cell (CFC) assay was used to determine the ability of 
hematopoietic progenitor bone marrow CD34+ cells to proliferate and 
differentiate into erythroid or myeloid colonies after two weeks in a 
methylcellulose-based semi-solid media (StemCell Technologies) in response 
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to cytokine stimulation. 0, 0.03125, 0.0625, 0.125µM of IFNα (Sigma-Aldrich), 
IL-28A (R&D), IL-28B (R&D) and IL-29 (R&D) were added in duplicate. Colony 
forming unit burst forming unit-erythroid (CFU-BFU), CFU-granulocyte, 
macrophage (CFU-GM) and CFU-granulocyte, erythrocyte, macrophage, 
megakaryocyte (GEMM) colonies formed were enumerated and characterised 
according to their unique morphology. 
 
For proliferation assays, 50,000 CD34+ cells (Lonza) were plated in 200 µL/well 
of culture medium: DMEM, 10% Hyclone foetal bovine serum and 
Penicillin/streptomycin, L-Glutamine (100units/mL, 100µg/mL and 2mM 
respectively). Cells were stimulated with TPO (100ng/mL, Preprotech), IL-3 
(60ng/mL, Preprotech), SCF (100ng/mL, Preprotech), Flt3 ligand (300ng/mL, 
Preprotech) and incubated with serial dilutions of 0.03125, 0.0625, 0.125µM of 
IFNα (Sigma-Aldrich), IL-28A (R&D), IL-28B (R&D) and IL-29 (R&D) in triplicate 
for 72 hours. After three days of culture 40µL of Cell Titer 96 aqueous solution 
(Promega) was added to each well to measure the number of viable cells after 
proliferation. After 2 hours of incubation at 37oC- the absorbance was 
measured at 490nm on a 680 microplate reader (BioRad). Stimulated samples 
exposed to IFN-α or IFN-
untreated controls. 
2.5.2.3 Human tissues and whole blood 
Human tissue and whole blood samples were collected from anonymised 
donors. Ethics committee approval was provided and all patients gave informed 
consent. San Raffaele Telethon Institute for Gene Therapy Biologic, specimens 
from umbilical cord blood and peripheral blood of healthy donors were collected 
for research purpose and used on informed consent in agreement with the rules 
defined by approved protocols TIGET01 and TIGET PERIBLOOD. 
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Chapter 3  
3.  Investigation of the antiviral activity of IL-28A 
and IL-29 using antiviral and interferon 
sensitive gene model assays 
3.1 Introduction 
At the time of this work being undertaken IL-29 and IL-28A had been shown to 
have antiviral properties in an EMCV model3 and sensitivity was shown with 
interferon sensitive gene assays2,3, but other antiviral activity against a virus or 
using a model/replicon had not been published. 
 The aim of this chapter was to evaluate the in vitro antiviral activity of IL-28A 
and IL-29 across a range of viruses spanning a cross section of viruses from all 
seven classes classified using Baltimore classification118 compararing their 
antiviral properties with each other and with IFNα primarily. IL-28B was not 
tested in these assays as at the time it was not commercially available and was 
deemed to be similar to IL-28A (96% amino acid identity). 
This Chapter looked aty the antiviral activity of IL-28A and IL-29 in the viruses 
below, class II and III were not covered: 
I: dsDNA viruses: Papillomaviridae – Human Papillomarvirus HPV-16 and 
HPV31 
II: ssDNA viruses (+)sense DNA (e.g. Parvoviruses) 
III: dsRNA viruses (e.g. Reoviruses) 
IV: (+)ssRNA viruses (+)sense RNA: Flaviviridae - Dengue and Hepatitis C, 
Togaviridae –Semliki Forest virus) 
V: (−)ssRNA viruses (−)sense RNA: Paramyxoviridae - Respiratory Syncytical 
virus. 
VI: ssRNA-RT viruses (+)sense RNA: Retroviridae - Human Immunodeficiency 
virus 
VII: dsDNA-RT viruses: Hepadnaviridae - Hepatitis B 
 
Effects of IL-28A and IL-29 were also investigated in IFN sensitive gene models 
IFIT6-16 and ISG-56. 
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IFNλs were tested in a wide range of viral cell assays and models in order to 
elicit interferon lambdas antiviral properties. IFNα was used as a comparison in 
all assays with IFNα and IFNγ being additional comparisons in the; 1a and 1b 
HCV replicon assays, HIV, dengue fever replicon assay, RSV assay and ISG 
assays. Positive sense RNA virus HCV (flavivirus) using replicon models were 
tested as a priority: as type I interferons have antiviral properties it was likely 
that interferon lambdas may also have been shown to reduce levels of HCV 
mRNA in the HCV replicon system. Human liver cells HuH7 containing either 
genotype 1a or 1b HCV replicons were tested in an ELISA assay, and later 
experiments were performed using two genotype 1a and two genotype 1b 
replicon luciferase clones in a common parent HuH7 cell (developed by Thomas 
Zurcher, GSK). HCV is responsive to IFNα, IFNβ and IFNγ119  but at the time 
this project was initiated (August 2004) there was no published work to show 
the role of type III interferons in HCV. 
Pegylated IFNα, in combination with ribavirin, is the current standard of care for 
the treatment of patients chronically infected with HCV; it results in a sustained 
virological response (defined as clearance of circulating HCV RNA at 6 months 
post-treatment) in ~50% of patients10. However, combination therapy remains 
less effective against infections caused by HCV genotype 1 which constitute 
~75% of all HCV infections in the developed world10. New interventions are 
therefore required to address this unmet medical need and the discovery of 
interferon lambdas presents the opportunity to explore their roles in antiviral 
therapy.  
Dengue was tested as a virus in the same family as HCV, flavivirus, this assay, 
like the hepatitis C assay, used a replicon model. A further range of viruses 
were investigated: DNA virus HBV (Hepadnaviridae), negative sense RNA virus 
Respiratory Synctial Virus (RSV) and the RNA transcribing virus Human 
Immunodeficiency Virus (HIV) (Retroviridae) to give a broad spectrum of 
different families of viruses. Other viruses: Influenza and Human papillomavirus 
HPV-16, HPV-31, Semliki Forest virus were considered and even work 
instigated but are not reported here.  
Additional work in this chapter: IFNα and IL-28A, IL-29 were evaluated together 
in a HCV 1a replicon assay over a time course of 2, 4 ,6, 8, 16 and 24 hours, in 
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order to determine any synergistic effects of the type I interferons with type III 
interferons. 
Effects of IL-28A and IL-29 were also investigated in IFN sensitive gene models 
IFIT6-16 and ISG-56 to see if interferon lambdas had a role in regulation of 
interferon sensitive genes. ISG56 is the most highly induced IFN sensitive gene 
(30-100 fold induction), and is stimulated by both IFNα and IFNβ, but not IFNγ, 
IFIT6-16 is also induced by type I IFNs but the role of IFNλ modulation was 
unknown.  
3.1.1 Hepatitis C comparison of antiviral activity of IFNα, IFNβ, IFNγ and 
interferon lambdas IL-28A and IL-29 in two replicon assays 
HuH7 cells containing either genotype 1a or 1b HCV replicons were stained 
with 5% carbol fuchsin to visually assess cytotoxicity. Cytotoxicity based on cell 
shape was not seen with any of the interferons tested at any concentration.  
The half maximal inhibitory concentration (IC50) values for all interferons were 
determined as the concentration of each treatment which showed 50% inhibition 
of the NS5A ELISA signal in HCV 1a and 1b replicon cell lines compared with 
untreated cells. IC50 values were determined for positive control, IFNα, IFNβ, 
IFNγ, IL-28A and IL-29. % inhibition values were determined according to the 
following formula: 
% Inhibition = 100 - [100x (mean concentration – mean cell control) / 
(mean cell control – mean no primary antibody control)] 
IC50 values for replicon assays of genotype 1b were determined; IFNα 18 
IU/mL, IFNβ 50 IU/mL, IFNγ 54 IU/mL, IL-28A 160ng/mL and IL-29 11ng/mL. 
IC50 values for genotype 1a replicon assays were as follows; IFNα 86 IU/mL, 
IFNβ 89 IU/mL, IFNγ 148 IU/mL, IL-28A 201ng/mL and IL-29 19ng/mL. 
For comparison purposes IU/mL values for IFNα, IFNβ and IFNγ were 
converted to pg/mL using the following formula: 
[1 x 109 ÷ (Lot specific activity)] x (Lot Concentration (IU/mL) = pg/mL) 
IC50 values for IFNα, IFNβ, IFNγ, IL-28A and IL-29 all in ng/mL units are shown 
below (Table 3.1) and determined from IC50 plots (Figure 3.1). 
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Table 3.1 IC50 values for IL-29, IL-28A, IFNα, IFNβ and IFNγ 
 IL-29  
Mean (SD) 
IL-28A 
 Mean (SD) 
IFNα  
Mean (SD) 
IFNβ  
Mean (SD) 
IFNγ 
Mean (SD) 
1a 20 (1.6) 202 (20.1) 0.4 (0.03) 7.3 (0.8) 7.2 (0.6) 
1b 11 (2.0) 161 (9.4) 0.09 (0.01) 5 (0.4) 6 (0.7) 
Table 3.1 shows IC50 values in ng/mL determined in two HCV replicon cell lines 1a and 
1b for: IL-29, IL-28A, IFNα, IFNβ and IFNγ. 
 
The results show that all IFNs had some potency against the HCV 1a and 1b 
replicons in vitro. IL-29 was shown to be ~10 x more potent than IL-28A against 
both replicons, IL-29 was shown to be in the same level of magnitude with 
potency in both cell lines comparable to IFNβ and IFNγ. IFNα was shown to 
approximately 100 times more potent than IL-29 and ~1000 times more potent 
than IL-28A. 
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Figure 3.1: IC50 plots for IFNα, IFNβ, IFNγ, IL-28A and IL-29  
Figure 3.1 shows IC50 plots for IFNα, IFNβ, IFNγ, IL-28A and IL-29 in HCV replicon cell assays 1a and 1b, values in ng/mL (Graffit V5). 
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3.1.2 Determination of IC50 values for luciferase HCV replicon clones 
Four luciferase HCV replicon clones 1a1_19, 1a3II and 1b 2.2, 1b2.5 were 
tested for their antiviral sensitivity to IL-28A and IL-29 compared to IFNα. These 
cells were all developed in the same parental HuH7 cell line. Log dose plots are 
shown (Figure 3.2) for clones 1a3II and 1b2.5 showing good curve fits for IL-29 
and IFNα and due to solubility issues the best fit for IL-28A is shown (Figure 
3.2).   
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Figure 3.2: IC50 plots for HCV replicon assays 1a3II and 1b2.5 
Figure 3.2: IC50 plots are shown for luciferase assays: A 1a3II and B 1b2.5 for IL-28A, 
IL-29 ng/mL and IFNα IU/mL (PRISM). 
All four HCV replicon clone assays 1a1_19, 1a3II and 1b 2.2, 1b2.5 were 
assessed and the IC50 values in ng/mL with IL-28A, IL-29 and IFNα shown 
(Table 3.2). 
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Table 3.2: IC50 values for IL-28A, IL-29 and IFNα in HCV replicon clones 
Clone 
IL-28A IC50 (ng/mL) 
Mean (SD) 
IL-29 IC50 (ng/mL) 
Mean (SD) 
IFNα IC50 (ng/mL) 
Mean (SD) 
1a 1_19 46.6 (2.9) 0.7 (0.08) 0.005 (0.0002) 
1a3II 21.8 (5.6) 0.55 (0.03) 0.003 (0.0001) 
1b 2.2 118 (16.5) 2.7 (0.17) 0.004 (0.0002) 
1b2.5 227 (19.9) 4.6 (0.31) 0.01 (0.003) 
Mean IC50 values for IL-28A, IL-29 and IFNα are shown for HCV replicon clones 
1a1_19, 1a3II and 1b 2.2, 1b2.5 in ng/mL. 
Replicon clone 1a3II was most sensitive to all tested interferons having the 
lowest IC50 value for IL-28A, IL-29 and IFNα. IC50 values for replicon clone 1a3II 
were used for later gene expression work (Section 4.2). 
3.1.3 IL-29 and IFNα synergy 
IFNα and IL-28A, IL-29 were evaluated together in a HCV 1b replicon assay 
over a time course of 2, 4 ,6, 8 16 and 24 hours, in order to determine any 
synergistic effects of the type I interferons with type III interferons. Serial 
dilutions of IL-28A 200ng/mL to 4ng/mL and IL-29 1000ng/mL to 2 ng/mL were 
tested with and without 0.09ng/mL of IFNα (IC50 concentration as determined in 
experiments performed (Section 2.1.1). To confirm baseline expression of IFNα 
at 0.09ng/ml this was also run separately. Results showed an additive effect 
only, not a synergistic effect. This was seen across all doses with IL-28A and IL-
29 at all tested time points. 
3.1.4 IFN sensitive gene models 6-16 and ISG56 
To investigate type III interferon modulation of interferon sensitive genes (ISGs), 
two ISG assays were used; interferon sensitive gene 56 (ISG56) and interferon 
inducible gene 6-16 (G1P3). 
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Half maximal effective concentration (EC50), representing the concentration of a 
compound where 50% of its maximal effect is observed, were determined for 
both ISG models.  
Table 3.3: EC50 values for IFNs in ISG models 
IFN  ISG56 EC50  
Mean (SD) 
6-16 EC50  
Mean (SD) 
IL-28A  439ng/mL (34.7) >2.0µg/mL  
IL-29  115ng/mL (18.4) >1.0µg/mL  
IFNα  50 IU/mL (3.2) 
(0.16ng/mL)  
48 IU/mL (4.6) 
(0.15ng/mL)  
IFNβ  121 IU/mL (14.3) 120 IU/mL (0.89) 
IFNγ  350 IU/mL (22.0) 500 IU/mL (35.7) 
 
In the Interferon sensitive assays, sensitivity was shown in the ISG56 assay to 
IL-28A and IL-29 but not in the 6-16 interferon sensitive gene model. These 
experiments suggested different modes of action for IL-28A and IL-29 
compared with IFNα, however Affymetrix gene expression data suggested that 
there was expression of the IFIT6-16, alias G1P3 with IFNα, IL-28A and IL-29 
treatment at 8, 16 and 24 hour time points.  
Data below is taken from replicon data (Section 4.5.2, Table 4.8). 
Table 3.4: Subsection of Table 4.7 to highlight G1P3 expression 
Symbol IFNα IL-29 IL-28A 
 8h 16h 24h 8h 16h 24h 8h 16h 24h 
G1P3 3.2 82.1 42.1 6.7 100 96.5 4.5 100 43 
 
This suggests that whilst the 6-16 cell model is not sensitive to type III IFNs, 
there is gene expression of 6-16 shown with Affymetrix and TaqMan® 
technology.  
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3.1.5 Hepatitis B (HBV) 
Antiviral effects of IL-28A and IL-29 compared with IFNα were investigated in 
human hepatocellular carcinoma HepG2.2.15 cell line stably transfected with 
HBV subtype ayr.  Concentrations of IFNs tested were: IFNα: 100, 1,000 ng/mL, 
IL-28A: 200, 2000 ng/mL and IL-29: 100, 1000 ng/mL, compared to untreated. 
Preliminary results shown (Figure 3.3) indicated that both IL-29 and IL-28A 
have antiviral properties in the HepG2 (2.2.15) cells stably transfected with HBV 
subtype ayr. These results show that IFNα has a greater antiviral effect of IL-29 
on HBV compared to IL-28A. Initial data shows IL-29 having a greater antiviral 
effect on HBV than IL-28A.  A publication by Robek51 superseded further work 
on HBV. 
 
 
Figure 3.3: Antiviral effects of IL-28A and IL-29 with HBV  
Antiviral effects of IL-28A and IL-29 compared with IFNα were investigated in human 
hepatocellular carcinoma HepG2.2.15 cell line stably transfected with HBV subtype ayr. 
IL-28A and IL-29 tested at low and high doses (200, 2000 and 100, 1000 ng/ml 
respectively) and compared with IFNα low and high dose dose (100, 1000 IU/ml). Copy 
number was determined from the mean of the 4 replicate samples using the following 
equation: 10-1(Ct-40)/3.5 where 10-1 is the inverse log, Ct is cycle threshold, 40 is 
number of total cycles and 3.5 is PCR efficiency.  
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3.1.6 Human immunodeficiency virus (HIV) 
IFNα, IFNβ, IFNγ have been shown to have antiviral properties against HIV120, 
and are used as positive controls and as comparisons to investigate the antiviral 
effects of IL-28A and IL-29 with HIV.  
Data (Figure 3.4) shows: a strong antiviral effect of IFNα and IFNβ on HIV, IFNγ 
has a weak antiviral effect and IL-28A and IL-29 have no antiviral effects even 
at very high concentrations. IC50 values were determined as: IFNα 2.8 IU/mL, 
IFNβ 43.2 IU/mL and IFNγ 140 IU/mL. There were no effects even at a high 
dose of 7.68mg/mL for IL-28A and 1mg/mL for IL-29; interestingly no toxicity 
was observed at these doses. In this cell system, type III lambdas do not seem 
to have an antiviral effect even at very high doses.  
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Figure 3.4: Antiviral effects of IL-28A and IL-29 against HIV virus HXB2  
The antiviral effects of IFNα, IFNβ, IFNγ, IL-28A and IL-29 in and MT4 cell line infected with HIV virus HXB2. The graph shows % viability of MT4 
cells against log dose concentration of IFNα, IFNβ, IFNγ, IL-28A and IL-29. (PRISM).  
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3.1.7 Dengue Fever Virus assay 
K562 myeloid/erythroid (human chronic myeloid leukaemia) cell line stably 
expressing the dengue virus replicon ΔCprME-PAC2A was used to test the 
antiviral properties of type III interferons, compared to IFNα, IFNβ and IFNγ. 
100, 1,000 IU/mL of IFNα, IFNβ and IFNγ, 200, 2000ng/mL of IL-28A and 100, 
1000ng/mL of IL-29 were tested against dengue virus replicon with an 
incubation of 24 hours. Results show for all IFNs at all concentrations that 
dengue virus RNA levels do not significantly vary from that of untreated cells, 
results shown (Figure 3.5). 
 
Figure 3.5: Dengue virus replicon  
Dengue RNA levels were measured by quantitative PCR and normalised to GAPDH 
mRNA levels; the data demonstrated no significant difference between untreated 
sample (negative control) and IFNα, IFNβ, IFNγ, IL-28A and IL-29 treatment, indicating 
that Interferon lambdas IL-29 and IL-28A do not have antiviral effects in a dengue 
replicon system. 
3.1.8 Respiratory Syncytial Virus (RSV) 
Transformed B cells infected with RSV WSX1 viral particles were treated with 
IFNα, IFNβ and IFNγ at 1000 IU/mL, IL-28A at 2µg/mL, IL-29 at 1µg/mL and 
untreated to assess the effects of antiviral treatment. Cells were incubated at 
two time points: 48 hours and 96 hours.  
No test samples differed significantly from control, suggesting that IFNs have no 
effect on the RSV WSX1 model. The negative results above may also be 
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explained by RSV RNA being very sensitive to manipulation and the cell model 
being quite difficult to maintain stable RSV levels.  
3.1.9 Discussion 
It has been shown that type I IFNs (IFNα, IFNβ, IFNЄ, IFNκ and IFNω in 
humans) are modulators of antiviral defence by many groups121,122,123, Type II 
IFN, IFNγ is also an important mediator of antiviral defence but not as its 
primary function which is stimulation of the immune responses124,125. The role of 
type III interferons, IL-28A, IL-28B and IL-29 in antiviral disease is still not fully 
known. 
HCV- in vitro assays show that IL-28A and IL-29 have a direct antiviral effect 
against HCV in the HCV genotype 1a and 1b replicon systems (ELISA).  
Despite having similar molecular weights (IFNα 19.5kDa, IL-29 21.9kDa and IL-
28A 20.8kDa) IFNα was shown to be ~100 fold more potent against HCV 
replicons 1a and 1b than IL-29 and 1000 fold more potent than IL-28A, 
suggesting that IFNα is more potent against HCV than type III IFNs. IFNβ and 
IFNγ showed similar potency to IL-29 in both 1a and 1b replicon assays and IL-
29 was shown to be ~10 times more potent in both assays than IL-28A. 
Replicon 1b assay was more sensitive to all IFNs tested; IFNα, IFNβ, IFNγ, IL-
29 and IL-28A.  
With an alternative luciferase replicon assay model for HCV 1a replicon clones, 
1a 1_19, 1a3II and 1b replicon clones 1b 2.2 and 1b2.5, similar results were 
shown with comparison of IFNα to IL-28A and IL-29 as with the HCV genotype 
1a and 1b replicon systems (ELISA). IFNα was shown to be ~100 fold more 
potent than IL-29 (1000 fold in 1b 2.2) and over 1000 fold more potent than IL-
28A. IFNα showed similar IC50 values in all the four replicon assays but IL-28A 
and IL-29 were ~10 times more potent against the 1a replicons than the 1b 
replicons which may show a difference in mode of antiviral action against the 
HCV sequence. Replicon clone 1a3II was shown to be most sensitive to IFNα, 
IL-28A and IL-29 and chosen for further investigation of pathway analysis (gene 
chip experiments). Robek51 demonstrated that IL-29 and IL-28A inhibits 
replication of subgenomic and full-length HCV replicons in HuH7 cells and this 
was also shown later by Doyle57 and Marcello61.  
  Chapter 3         
Page 90 of 183 
 
Due to IL-28A and IL-29 using a different receptor (IL-28R rather than IFNR1), 
IL-28A and IL-29 were tested in the HCV 1b replicon assay to determine any 
synergistic effects of the type I and type III interferons together. Results 
described only showed an additive effect not a synergistic effect, this was 
observed at all time points 2, 4, 6, 8, 16 and 24 hours. An additive effect though 
could show that IL-29 when used with IFNα could be good as a dual therapy as 
opposed to IFNα alone as the results demonstrate greater potency against HCV 
with both IFNa and IL-29 together. These results were confirmed by Marcello et 
al in 2006, his group also saw an additive effect not a synergistic effect of IL-
2961.  
Two interferon sensitive gene assays ISG56 and 6-16 were tested with IL-29 
and IL-28A and compared to IFNα, IFNβ and IFNγ. In the ISG56 assay (Human 
Embryonic Kidney 293 cells (HEK cells)) IL-28A and IL-29 were shown to be 
~1000 times less potent for activation of the ISG promoter in this model than 
IFNα and interestingly significantly less sensitive at modulation of ISG56 than 
IFNβ and IFNγ. In the HCV replicon assays IL-29 showed similar antiviral 
protective effects as IFNβ and IFNγ. IL-28A has been shown to have ~10 times 
less antiviral effect in the replicon assays than IL-29 but in the ISG56 assay, IL-
29 and IL-28A showed EC50 values in the same magnitude. In the interferon 
sensitive assays, sensitivity was shown in the ISG56 assay with IL-28A and IL-
29 but not in the 6-16 assay. It was initially thought the ISG experiments 
described above suggest different modes of action for IL-28A and IL-29 
compared with IFNα, but results later (Chapters 5 and 6) showed IL-28R had 
limited receptor distribution, and difference seen in reporter activity might be 
due to restricted receptor expression. Interferon lambdas have also been shown 
to induce expression of 2’5-OAS2 and MxA126 by other groups Kotenko et al and 
Brand et al. 
All cells described in Chapter 3 were tested by TaqMan® for presence of IL-28R 
gene, Human T98G cells (glioblastoma multiforma tumor cells) (6-16 assay 
cells) did not show signal for IL-28R.  
Initial data in a human HepG2 cell line stably transfected with HBV subtype ayr 
showed that both IL-29 and IL-28A had antiviral effects against HBV but 
significantly lower in antiviral activity than IFNα. The antiviral effect of IL-28A 
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compared to IL-29 was significantly lower. HBV data was consistent with data 
from Robek51, where IL-29 was shown to inhibit HBV replication in a murine 
model (HBV-Met cells). However, a later study suggested that the antiviral 
activity of type III IFNs against HBV may be limited in human cells; Kotenko et 
al found limited antiviral properties with IL-29 in human hepatoma cells stably 
transfected with HBV subtype adwR9127. 
No antiviral effects were observed with IL-28A or IL-29 in HIV, RSV assays or 
against the dengue replicon system. The presence of IL-28 receptor gene 
expression was confirmed by TaqMan® real-time PCR in these systems, 
implying that the specific type III receptor could be present, so an obvious lack 
of receptor is unlikely to be the reason for the lack antiviral response in these 
systems. There was no cytotoxicity observed with the type III IFNs in the HIV 
assays at concentrations of IL-28A and IL-29 up to 7.68mg/mL and 1mg/mL 
respectively. This initially was of great interest as IL-28A and IL-29 not having 
any antiviral activity against HIV in vitro could have indicated that the lambdas 
were functionally different to IFNα. To date limited studies have described the 
effects of IFN-λ on HIV-1 replication and disparate results were reported, the 
effect of interferon lambdas remains controversial. Hou et al demonstrated 
inhibition of HIV-1 replication in macrophages by IL-29 and IL-28A128, with Liu et 
al showing that IL-29 inhibition of HIV in macrophages is via the JAK-STAT 
pathway129. Another study showed pretreatment of uninfected PBMCs or CD4+ 
T-cell lines with IFN-λ improved the expression of HIV-1 receptor and co-
receptors that increase viral binding and replication130 and in July 2012 Tian et 
al demonstrated IL-28A and IL-29 treatment induced an antiviral state in 
cultured primary T-cells, suppressing HIV-1 integration whereas in vivo IL-29 
showed limited in vivo repression of viral production in CD4+ T cells131. 
It is possible to speculate that the IFN signal transduction pathway with type I, II 
and III IFNs is blocked in the dengue virus replicon system. Jones et al showed 
that IFNα in the same dengue replicon system had no antiviral effect and that 
dengue virus specifically inhibits IFNα signalling by the down-regulation of 
STAT2 expression53. Whilst HCV is very sensitive to the antiviral cascade 
induced by IFNα, in contrast, the related viruses West Nile virus (WNV) and 
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Japanese encephalitis virus are resistant to IFNα therapy. WNV has been 
shown to block the IFN signal transduction pathway132.  
Results from the RSV assay showed no differences between IFNα, IL-28A, IL-
29 compared with negative control, suggesting that IFNs have no effect on the 
RSV WSX1 model. The negative results above may also be explained by RSV 
RNA being very sensitive to manipulation and the cell model being quite difficult 
to maintain stable RSV levels. There are also reports to show that RSV inhibits 
IFNα signalling, IFNγ production and type III interferon expression133. 
The antiviral effects in other viral systems have been demonstrated for the 
IFNλs both in vitro and in vivo: IL-28A and IL-29 in an in vivo poxvirus infection 
model55, IL-29 reduced influenza A titre in vitro134, IL-28A and IL-29 in an in vitro 
murine CMV system56, IL-29 had antiviral effects against herpes simplex virus 
(HSV-1) in vitro comparable to that of IFNα135, IFNλs have antiviral effects in 
vivo and not in vitro with HSV-2136 highlighting the possibility that the majority of 
IFNλs antiviral effects against HSV may involve immune modulation. Taken 
together, these studies supported the value of studying IL-28A and IL-29 as a 
possible therapeutic approach to viral disease. Whilst there have been several 
studies looking at the antiviral properties of IFNλs in RNA viruses there is a gap 
in research on the effects of IFNλs with DNA viruses. 
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Chapter 4  
4. Transcriptome analysis in parent HuH7 cells 
and HCV replicon cells treated with type I and 
type III IFNs 
4.1 Introduction 
Type III interferons (IFNs) are a newly identified class of cytokines with antiviral 
activity(1,2). It is not yet clear how the function of these cytokines differs from the 
type I IFNs. This chapter therefore sets out to investigate how the pattern of 
gene induction by type III IFNs (IL-28A and IL-29) differs from that of type I and 
whether type III IFNs might have a superior therapeutic profile. IFNs protect 
cells from viral infection, directly by inducing interferon sensitive genes (ISGs) 
such as 2’, 5’-oligoadenylate synthetase 1 (2’, 5’-OAS) and myxovirus 
resistance-A (MxA) and intracellular genes and, indirectly, by inducing major 
histocompatibility complex (MHC) class I antigen expression on and activation 
of antigen-presenting cells, by stimulating dendritic cell maturation and 
activating macrophages and natural killer cells.  
IFNλs were initially shown to activate both STAT1 and STAT2 and the 
downstream signalling pathways including interferon sensitive gene complex 
ISGF3 and ISRE13 , similar to those activated by IFNα and IFNβ. However the 
mechanisms of IFNλs still need to be fully elucidated.  
The objectives of this chapter were to:  
1) identify which genes are regulated by type III IFNs  
2) to see how this profile differs from type I IFNs and  
3) to see the effect of IFNs on human hepatoma cell line HuH7 HCV replicon 
cells compared with parental HuH7 cells.  
By comparing the transcriptional levels of genes in tissues or cells from ‘control’ 
and ‘test’ states, it is possible to gain insight into the mechanisms and pathways 
underlying the comparative phenotypes observed. There are a multitude of 
techniques available to researchers to undertake these types of transcriptional 
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investigation, although they can be broadly defined as ‘open systems’ and 
‘closed systems’. Open transcriptional systems have the advantage of not 
requiring any prior sequence knowledge of the genes under investigation, 
examples are: ‘fragment display’ (FD)137, ‘tag sequencing’ and 
‘subtractive/competitive hybridisation’ techniques. In general, the main 
disadvantage associated with open transcriptional systems is their relatively low 
throughput, both in terms of numbers of gene modulations that can be positively 
identified and the number of transcriptional comparisons that can be made.  
Closed transcriptional systems include an equally diverse array of techniques, 
although the shared attribute is the requirement for prior sequence knowledge 
of the gene(s) under investigation. Closed systems include techniques that are 
only amenable to investigating the transcriptional levels of single (e.g. Northern 
blots and the ribonuclease protection assay) or small subsets of genes (e.g. 
real-time quantitative PCR (RT-QPCR)). At the other end of the spectrum, they 
include those capable of simultaneously measuring the expression levels of 
thousands of genes, i.e. Affymetrix GeneChips® microarrays, leading to the 
development of ‘transcriptomics’, broadly defined as the rapid and quantitative 
comparison of large-scale mRNA expression profiles in biological systems. 
Combined with the huge advances in genome sequencing and gene annotation 
made in recent years, they have led to the advantages of ‘open’ transcriptional 
systems becoming more or less obsolete. As genome sequencing of an 
increasing number of model species is completed, it is becoming practicable to 
use microarrays to measure transcription at a virtually genome-wide scale. This 
has enabled the generation of huge volumes of data, faster than ever before. 
Data (Section 3.1.2) showed that the HCV replicon system would be a suitable 
model for transcriptomic analysis of the IL-28A and IL-29 as the replicon cell 
line showed sensitivity to IL-28A and IL-29. To determine gene activation 
profiles and the signalling pathways of IL-28A and IL-29 transciptomic and 
pathway analysis were performed using Affymetrix GeneChips® analysis and 
pathway analysis.  
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4.2 Determination of 10 x IC50 for most IFN sensitive replicon 
cell line   
Results of the four replicon cell lines were compared and IC50 values 
determined (Section 3.1.2, Table 3.2),1a3II results highlighted below (Table 4.1) 
Table 4.1: IC50 values in ng/mL of IL-28A, IL-29 and IFNα in HCV replicons  
Clone IL-28A IC50 (ng/mL) IL-29 IC50 (ng/mL) IFNα IC50 (ng/mL) 
1a1_19 46.6 0.7 0.005 
1a3II 21.8 0.55 0.003 
1b2.2 118 2.7 0.004 
1b2.5 227 4.6 0.01 
HCV replicon clone 1a3II was most sensitive to interferons having the lowest 
IC50 value with IL-28A, IL-29 and IFNα. 10 x the IC50 level was calculated as: 
218ng/mL, 6ng/mL and 0.03ng/mL for IL-28A, IL-29 and IFNα respectively. 
These 10 x IC50 values were used to treat parent HuH7 cells and HuH7 HCV 
1a3II luciferase replicon cells for use in transcriptome analysis.  
4.3 TaqMan® analysis 
Real-time PCR was performed on the RNAs isolated from HuH7 cells and HuH7 
HCV 1a3II luciferase replicon cells treated with 10 x IC50 values of IL-29, IL-28A 
and IFNα at 4, 8, 16 and 24 hour time points The data was analysed to assess 
the suitability of the time points and concentrations of the IFNs in the assay 
before running the samples of full genome Affymetrix chips. 
TaqMan® analysis showed IFIT1 expression in all IL-29, IL-28A and IFNα 
samples showing that all RNAs were suitable for further Affymetrix genechip® 
analysis. 
TaqMan® analysis showed greatest gene expression change with IFIT1, MX1, 
OAS1 and G1P3 at the 8, 16 and 24 hour time points (Figure 4.1).  
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Figure 4.1: TaqMan® expression of IFITI, MX1, OAS1 and G1P3 
TaqMan® expression of IFITI, MX1, OAS1 and G1P3 compared with house keeping 
genes b-actin and GAPDH in parent HuH7 and HuH7 HCV replicon cells treated with 
10 x IC50 values of IFNα, IL-28A and IL-29 at 4, 8, 16 and 24 hour time points. 
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4.4 Parent HuH7  
Individual data and pathway analysis was undertaken for all treatments and 
time points. Data was analysed to a set criteria: in Rosetta Resolver (2.2.6.11), 
an ANOVA was generated for each compound versus PBS control, the genes 
were filtered to include genes with fold change >1.5 and >minus 1.5, and genes 
were included if their p-value was <0.05 (>95%). Lists were generated based on 
the above criteria of upregulated and downregulated genes for IL-28A, IL-29 
and IFNα at each time point. Lists were also generated of genes that were 
common and unique between IL-28A, IL-29 and IFNα in both HuH7 parent cells 
and HuH7 HCV replicon cells. Gene lists were then put into Ingenuity and 
GeneGo for pathway analysis.  
4.4.1 Parent HuH7 versus HCV replicon  
The Affymetrix dataset (P-value >95% Fold change -1.5< and >1.5) is 
represented numerically in a series of Venn diagrams (Figure 4.2), showing 
gene numbers common and unique to IFNα, IL-28A and IL-29 at all time points  
in both the parent HuH7 and HCV replicon datasets. 
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Figure 4.2: Venn diagrams 
The number of genes expressed by IL-28A, IL-29 and IFNα across the 8, 16 and 24 hour time points from both replicon and parental datasets 
are represented in Venn diagrams. (P-value >95%, fold change -1.5< and >1.5)   
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Results from the data presented as Venn diagrams (Figure 4.2) show at the 8 
hour time point show a 90, 92 and 56% reduction in gene expression for genes 
unique to IFNα IL-28A and IL-29 respectively in replicon compared to parent 
line. Similar reductions in gene expression are also seen at the 16 hour and 24 
hour time points. The Venn diagrams showed a trend between parent and 
replicon datasets of more genes being unique to an individual interferon than 
there were genes in common between the interferons.  
Principal component analysis (PCA) is a mathematical procedure that uses an 
orthogonal transformation to convert a set of observations of possibly correlated 
variables into a set of values of linearly uncorrelated variables called principal 
components. The first principal component (PCA1) shows the largest possible 
variance e.g. accounts for as much of the variability in the data as possible, this 
will be followed by PCA2 and so on. PCA1 is shown (Figure 4.3) and illustrates 
that time accounts for the biggest variable in the data, followed by cell type 
replicon versus parent in PCA2 plot (Figure 4.4). PCA1 plot shows 4 hour and 
16 hour clustering together and 8 hour data being separate for replicon and 
parent cell lines. PCA2 shows replicon cells separating from normal parent 
HuH7cells. 
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Figure 4.3: PCA plot –PC1 Vs 2 by time point 
The first principal component (PCA1) shows the largest possible variance time accounts for the biggest variable in the data, PCA1 
plot shows 4 hour and 16 hour clustering together and 8 hour data being separate for replicon and parent cell lines.  
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Figure 4.4: PCA plot –PC2 Vs 3 by cell type 
PCA2 shows replicon cells separating from normal parent HuH7cells. 
 
-10
-5
0
5
10
-20 -10 0 10 20
t[
3
]
t[2]
GP1546 intensity for PCA.M5 (PCA-X)
t[Comp. 2]/t[Comp. 3]
Colored according to classes in M5
R2X[2] = 0.18434             R2X[3] = 0.0725509           Ellipse: Hotelling T2 (0.95) 
Replicon
Normal cells
PBS16h-2R
IFNa2a16h-3R
IL28A16h-2R
IL28A -3
PBS8h-1R
IL28A8h-1R
IL2916h-1R
IFNa2a8h-1R
IL28A8h-2R
PBS8h-2R
IL 9
IL28A8h-3RIFNa2a8h-2R
IFNa2a8h-3R
IFNa2a16h-1R
IL2916h-2RIL2916h-3R
IL28A16h-1R
IFNa2a16h-2R
PBS16h-3
IL298h-2R PBS16h-1R
IL298h-3RPBS8h-3R
IL28A8h-3H
IL28A16h-2H
IFNa2a4h-1H
IL28A4h-3H
IL294h-3H
IL28A8h-1H
IL28A8h-2H
IL2916h-2H
IL28A16h-1H
IFNa2a16h-2HIL28A4h-1H
PBS4h-2H
IFNa2a4h-3H
PBS8h-1H PBS8h-2H
IL298h-2H
IFNa2a8h-3H
IL 8A16h-3H
PBS4h-3H
IL298h-1H
IFNa2a4h-2H
IFNa2a16h-1H
IL28A4h-2H
PBS16h-2H
PBS16h-1H
IL294h-1H
IFNa2a8h-2H IL2916h-1H
IL2916h-3H
PBS4h-1H
PBS16h-3H
IFNa2a8h-1H
IL294h-2H
IFNa2a16h-3H
PBS8h-3H
SIMCA-P+ 11 - 08/05/2006 13:02:37
Chapter 4 
Page 102 of 183 
 
4.4.2 Parent HuH7 signature genes 
The top 20 expressed genes in the parent cell line with IFNα, IL-28A and IL-29 
treatments at 4, 8, 16 and 24 hour time points in relation to IL-29 expression 8 
and 24 hour time points are shown below (Table 4.2). 
Table 4.2: Table to show top 20 expressed genes in parent HuH7 cells  
Symbol IFNα IL-29 IL-28A 
 4h 8h 16h 24h 4h 8h 16h 24h 4h 8h 16h 24h 
G1P3 100 79 74 74 100 100 100 100 84 52 69 48 
IFI6 - 79 - 74 - 100 - 100 - 52 - 48 
IFIT1 16 6.6 3.9 7.1 100 100 100 100 14 7.2 4.6 3.4 
MX1 8.8 2.9 2.9 2 66 51 53 46 7.7 5.2 2.7 1.9 
IFITM3 11 12 6.3 10 26 38 18 40 8.5 7.9 6 5.6 
IFIH1 - - - 5.2 34 - 30 30 3.9 5 - 3.4 
IFITM1 15 16 3.6 6.9 67 82 22 25 15 9.2 3.8 4.5 
ISG15 - 5 - 5.4 - 18 - 20 - 3.3 - 2.4 
OAS1 4.7 - 2.6 - 49 14 38 19 6.1 - 3.1 - 
ISGF3G 6.6 7.7 3.6 6.1 14 17 12 16 6.2 7.4 3.9 3.1 
SUPT16H - 49 - 
-
7.6 
- 29 12 - - 70 3.1 - 
STAT1 3.4 14 2 
-
2.2 
11 28 12 - 2.7 11 2.1 - 
IFI27 - - - - 12 - 14 9.7 - - - - 
IFITM2 4.5 2.8 2.6 3.9 9.3 8.1 7.2 9.4 3.5 2.3 2.9 2.6 
OAS3 2 1.7 - - 14 8.4 14 8.6 2.1 - - - 
PARP9 2.3 - 1.9 2.1 7.3 2.3 8.7 5.8 2.3 - 2 - 
PLSCR1 2.5 2.8 1.6 - 8.7 8.6 8.4 5.5 2.4 2.6 1.6 - 
DDX58 3.4 - - - 20 5.1 14 5 - - - - 
IFI35 2.6 - 2.8 2.1 5.7 2.7 9.3 5 2.4 - 2.8 1.8 
EPSTI1 2.4 - - - 11 5.6 7.2 4.7 2.5 - - - 
 
Table 4.2 shows the top 20 expressed genes in the parent cell line with IFNα, IL-28A 
and IL-29 treatments at 4, 8, 16 and 24 hour time points in relation to IL-29 expression 
at 8 and 24 hour time points. Genes are >1.5 fold up or down with one or more 
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treatments. Values represent fold activation compared with PBS treatment. Genes 
highlighted in yellow are also present in the replicon table (Table 4.8).  
(-) = <1.5 fold induction. 
 
There are highly expressed interferon stimulated genes (ISG) common to IFNα 
and IFNλs both in the replicon and the parent HuH7 cell lines, these include 
G1P3, IFI6, IFIT, IFITM1, MX1, IFITM3, STAT1, ISG15, ISGF3G and OAS1 as 
shown in Table 4.8. The only top 20 gene determined by IL-29 at the 24 hour 
time point to not be represented in the entire replicon dataset (genes expressed 
> or < 1.5 fold change) was SUPT16H which plays a role in general 
transcription, it has positive and negative effects on gene expression. Required 
for the appropriate synthesis during heat shock and continued expression of 
cyclin genes that determine the passage through start during cell cycle control it 
may act as an acidic activator.  
4.4.3 Parent HuH7 pathway analysis IPA 
To demonstrate the mechanisms of IFNλs, pathway analysis was performed 
using Ingenuity and GeneGo pathway analysis tools. The top 7 pathways 
determined by Ingenuity pathway analyses scoring for IFNα, IL-28A and IL-29 at 
the 4 hours and IFNα and IL-29 at 8 hours are shown in Figures 4.5 and 4.6 
respectively. For type I and type III IFNs at 4 hours, interferon signalling is the 
most strongly induced pathway determined by Ingenuity Pathway Analysis, 
complement coagulation pathway is the second most strongly induced pathway 
for IL-28A, and protein ubiquitination pathway is the second most strongly 
induced pathway for both IFNα and IL-29. After this, IL-29 induces immune 
modulation pathways such as antigen presentation pathway and complement 
and coagulation cascades predominantly, in contrast to IFNα that predominantly 
regulated cell signalling pathways. At 8 hours interferon signalling is the top 
pathway for IL-29 followed by antigen presentation and complement coagulation 
pathways, for IFNα there are gene expression changes in multiple signalling 
pathways: integrin, IGF-1, Jak/Stat, SAPK/JNK signalling pathways.
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Figure 4.5 A: Parent HuH7 cell line pathway analysis at 4 hours for IFNα  
Using IPA for the Parent HuH7 cell line at the 4 hour time point, showing the top seven pathways for: A  IFNα. Pathway analysis using IPA for the 
parent cell line at the 4 hour time point graphical representation of the top seven pathways for IFNα showing up and down regulated genes 
associated to the pathways IPA gives a score shown by the trend line and –log scale determined by expression level and number of genes 
expressed in pathway/total number of genes within pathway. Percentage is number of genes modulated in pathway; red represents up regulated 
genes and green represents down regulated genes. 
A 
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Figure 4.5 B: Parent HuH7 cell line pathway analysis at 4 hours for IL-28A  
Using IPA for the Parent HuH7 cell line at the 4 hour time point, showing the top seven pathways for: B IL-28A. Pathway analysis using IPA for 
the parent cell line at the 4 hour time point graphical representation of the top seven pathways for IL-28A showing up and down regulated genes 
associated to the pathways IPA gives a score shown by the trend line and –log scale determined by expression level and number of genes 
expressed in pathway/total number of genes within pathway. Percentage is number of genes modulated in pathway; red represents up regulated 
genes and green represents down regulated genes. 
B 
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Figure 4.5 C: Parent HuH7 cell line pathway analysis at 4 hours for IL-29 
Using IPA for the Parent HuH7 cell line at the 4 hour time point, showing the top seven pathways for: C IL-29. Pathway analysis using IPA for the 
parent cell line at the 4 hour time point graphical representation of the top seven pathways for IL-29 showing up and down regulated genes 
associated to the pathways IPA gives a score shown by the trend line and –log scale determined by expression level and number of genes 
expressed in pathway/total number of genes within pathway. Percentage is number of genes modulated in pathway; red represents up regulated 
genes and green represents down regulated genes. 
C 
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Figure 4.6 A: Parent HuH7 cell line pathway analysis at 8 hours for IFNα 
Using IPA for the Parent HuH7 cell line at the 8 hour time point, showing the top seven pathways for: A IFNα. Pathway analysis using IPA for the 
parent cell line at the 8 hour time point graphical representation of the top seven pathways for IFNα showing up and down regulated genes 
associated to the pathways IPA gives a score shown by the trend line and –log scale determined by expression level and number of genes 
expressed in pathway/total number of genes within pathway. Percentage is number of genes modulated in pathway; red represents up regulated 
genes and green represents down regulated genes. 
A 
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Figure 4.6 B: Parent HuH7 cell line pathway analysis at 8 hours for IL-29 
Using IPA for the Parent HuH7 cell line at the 8 hour time point, showing the top seven pathways for: B IL-29. Pathway analysis using IPA for the 
parent cell line at the 8 hour time point graphical representation of the top seven pathways for IL-29 showing up and down regulated genes 
associated to the pathways IPA gives a score shown by the trend line and –log scale determined by expression level and number of genes 
expressed in pathway/total number of genes within pathway. Percentage is number of genes modulated in pathway; red represents up regulated 
genes and green represents down regulated genes. 
B 
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4.4.4 Parent HuH7 unique IL-29 gene analysis  
Genes unique for IFNα belong to predominately signalling pathways; Jak/Stat, 
EGF, IGF-1, IL-2, GM-CSF, FGFF, IL-4 and IL-6. These unique genes for IFNα 
include: PIK3CB, PIK3R1, SOS2, SOCS2, MAP3K1. Genes unique to IL-28A 
belong to IGF-1, EGF, TGF, VEGF, IL-2, IL-6 and IL-4 signalling pathways. IL-
29 unique genes belong to interferon signalling as the top pathway but are 
followed by antigen presentation and complement and coagulation cascades; 
unique genes at the 8 hour time point include HLA-A, HLA-B, HLA-C, HLA-F, 
HLA-G, PLG, CFB and SERPINE1. Antigen presenting gene expression with 
IFNα and IL-29 treatments are shown (Table 4.3). Antigen presenting genes are 
shown to be expressed at earlier time points in cells treated with IL-29 
compared to cells treated with IFNα.(Table 4.3) 
Table 4.3: Antigen presenting genes IL-29 versus IFNα.  
 
 (-) = <1.5 fold induction
4.53.32.7-2.8---TAP1
--3.2-----PSMB8
-1.62.71.5----HLA-G
--1.6-----HLA-F
2.33.91.62.6----HLA-E
3.2-------HLA-DRB4
--3.6-----HLA-DRA
2.63.22.42.51.6---HLA-C
2.92.92.92.61.9---HLA-B
-1.61.51.5----HLA-A
24h16h8h4h24h16h8h4h
IL29IFNαSymbol
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Figure 4.7: A top pathway - antigen presentation pathway determined by Ingenuity for genes unique to IL-29 at 8 hours 
Antigen processing is a biological process that prepares antigens for presentation to T lymphocytes. This process involves two distinct pathways for 
processing of antigens from an organism's own (self) proteins or intracellular pathogens (e.g. viruses), or from phagocytosed pathogens (e.g. bacteria); 
subsequent presentation of these antigens on class I or class II MHC molecules is dependent on which pathway is used. Both MHC class I and II are 
required to bind antigen before they are stably expressed on a cell surface. Red correspondes to up regulation of gene.
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An Ingenuity pathway map for a top pathway antigen presentation pathway is 
shown (Figure 4.7) determined by genes unique to IL-29 at 8 hours. Other 
pathway analysis tools were used including GeneGo, data shown below 
(Section 4.4.5). 
4.4.5 Parent HuH7 pathway analysis GeneGo 
The top 10 pathways with genes uniquely regulated by IL-29 at 24 hours are 
shown in Table 4.4. Genes unique to IL-29 treatment at 24 hours induce IFNα, 
IFNβ and IFNγ pathways, so any gene changes with IL-29 at 24 hours may be 
due to secondary mechanisms, e.g. feedback from genes expressed at early 
time points. These pathways are also shown in a GeneGo pathway map (Figure 
4.8). 
Table 4.4: Pathway analysis for HuH7 cell line GeneGo  
 
Pathway analysis for genes unique to IL-29 at the 24 hours shows the top 10 pathways 
for IL-29 determined by GeneGo. 
3030.04662IFN alpha/beta signaling pathway
7250.04535Ascorbate metabolism
2930.04279Putative SUMO-1 pathway
2930.04279Gs-a Specific GPCRs (in brain)
6350.02765IFN gamma signaling pathway
4240.02636HETE and HPETE diosynthesis and metabolism
920.02321Mitochondrial ketone bodies biosynthesis and metabolism
2130.01824Propionate metabolism p.2
3350.001799IL9 signaling pathway
3460.000267RhoA regulation pathway (extension, GEFs/GAPs)
Genes ↑Genes ↓p-ValueGenego Map - Unique genes to IL-29 at 24 hours
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Figure 4.8: Top pathway interferon signalling determined by GeneGo for genes unique to IL-29 at 24 hours. 
This figure is a schematic produced in GeneGo, bars with one represent IL-29 upregulation, the higher the red in the bar –the higher the gene 
expression e.g. 2-5A synthetase is highly upregulated by IL-29 and not up-regulated significantly (≥ 1.5 fold) at this time point by IFNα.
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4.4.6 Additional unique gene changes –cytokine induction, TLR and MAPK 
signalling 
There are differences in cytokine induction between the types of interferons: IL-
24 is down regulated by type III IFNs, IL-27 is up regulated by type I IFN. IL-27R 
is up regulated by type I IFN and down regulated by IL-29.  
TLR7 signalling genes unique to IL-28A in the parent cell line at the 8 hour time 
point are: TLR7, TRAF4, TRAF5 and IRAK1BP1 (-2.9, 1.9, -1.9 and 1.7 fold 
change respectively) and at the 24 hour time point IRF7 and TRAF31P3 were 
expressed (-3.2 and -2.9).  
There are notable differences between the IFNs with MAPK signalling 
regulation in the parent cell line IFNα induces a far greater number of the MAPK 
genes than IL-29. For IFNα, 9 genes are expressed at the 8 hour time point and 
16 genes are expressed at the 24 hour time point, for IL-29 this is 3 and 2 
genes respectively. IL-28A has more similarities with IFNα with the regard to 
expression of MAPK genes with expression of 15 MAPK genes at the 8 hour 
time point but only 4 genes at the 24 hour time point. 
4.4.7 Parent HuH7 kinetics 
Table 4.5 shows the kinetics of expression in a selection of genes in the parent 
cell line 8, 16 and 24 hours after treatment with IFNα, IL-28A and IL-29 
treatments. The IFNs shown similar trends to each other over the time points 
e.g. IFI6 was shown to be expressed with IFNα, IL-29 and IL-28A at 8 hours 
and 24 hours but not at 4 and 16 hour time points. 
Table 4.5 Data subset: to illustrate kinetics in parent HuH7 cells  
Symbol IFNα IL-29 IL-28A 
4h 8h 16h 24h 4h 8h 16h 24h 4h 8h 16h 24h 
G1P3 100 79.3 74.2 74 100 100 100 100 84.3 51.7 68.7 48.2 
IFI6 - 79.3 - 74 - 100 - 100 - 51.7 - 48.2 
IFITM3 11.4 11.8 6.3 10.1 26.4 37.9 17.6 40.4 8.5 7.9 6 5.6 
ISG15 - 5 - 5.4 - 18.4 - 19.7 - 3.3 - 2.4 
OAS1 4.7 - 2.6 - 48.8 13.6 38.2 18.8 6.1 - 3.1 - 
STAT1 3.4 13.5 2 -2.2 11 28.2 11.8 - 2.7 10.9 2.1 - 
(-) = <1.5 fold induction. 
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4.5 HCV replicon 
4.5.1 Comparison of parental data with replicon data to investigate the 
effects of HCV on IL-28A, IL-29 and IFNα gene modulation 
 
RNA from time point 4 hours with the replicon cells was not of sufficient quality 
to use in Affymetrix genechip® analysis. 
HCV replicon inhibited gene induction by both type I and type III IFNs; this is 
seen at 8, 16 and 24 hour time points in the Venn diagrams (Figure 4.2), where 
there is a substantial decrease in the numbers of genes expressed in the 
replicon system from those expressed in the parent system. Parent HuH7 cells 
are more sensitive to interferons IFNα, IL-28A and IL-29 compared to the 
replicon cells. Gene expression is generally higher in the parent cells than the 
replicon cells, as shown for IF16 in Table 4.7. This is also highlighted in the 
Venn diagrams (Figure 4.2). Gene expression detail is shown below (Tables 4.6 
and 4.7). 
Table 4.6: Comparison of replicon versus parent HuH7 cells  
 
Replicon Parent Replicon Parent 
Symbol  IFNα  IFNα  IL-29  IL-29  
G1P3  3.2  79.3  6.7  100  
IFIT1  20  6.6  29.8  100  
IFI6  -  79.3  9.8  100  
MX1  2.3  2.9  3.4  53.1  
ISGF3G  15  7.7  18.3  12.1  
IFIH1  6  -  6.6  30  
IFITM3  -  11.8  4  17.6  
ISG15  2.6  5  3.1  -  
IFITM1  -  16.1  -  22.2  
Comparison of replicon cells versus parent HuH7 cells at 8 hours with IFNα and IL-29 
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Table 4.7: Sensitivity of parent HuH7 cell line versus replicon 
IF16 fold change 8hr IFNα 8hr IL-29 24hr IFNα 24hr IL-29 
 
Parent   79  >100  73  >100 
 
Replicon  0  9.7  52  41.9 
4.5.2 HCV replicon signature genes 
The top 20 expressed genes in the replicon cell line with IFNα, IL-28A and IL-29 
treatments at 8, 16 and 24 hour time points in relation to IL-29 expression at 24 
hour time point are shown below (Table 4.8). 
Table 4.8: A selection of top 20 expressed genes in the replicon cells  
Symbol IFNα IL-29 IL-28A 
 8h 16h 24h 8h 16h 24h 8h 16h 24h 
IFIT1 21 21 100 30 100 100 13 78 64 
G1P3 3.2 82 42 6.7 100 97 4.5 100 43 
IFI6 - - 52 9.8 100 42 - 54 20 
MX1 2.3 2.3 30 3.4 18 35 - 12 17 
ISGF3G 15 15 22 18 14 21 15 12 16 
IFIH1 6 6 23 6.6 23 15 4.4 13 9.5 
IFITM3 - - 7.6 4 4.9 12 3 3.5 4 
ISG15 2.6 2.6 11 3.1 14 9.9 - 7.4 5.4 
IFITM1 - - 7.1 - 9.9 8.7 - 5.6 4.3 
ADAMTS13 - - - - - 7.7 - - 6.7 
OAS1 3.2 3.2 5.3 6.2 10 7.4 3.8 5.4 4.1 
DDX58 3.4 3.4 7.9 3.7 11 6.5 - 4.8 3.6 
PRIC285 2.2 - 6.8 3.1 5.1 6.4 3.1 3.4 3 
OAS3 3.4 3.4 8 5.1 6.4 5.3 - - 2.8 
PARP9 - - 4.9 2.9 - 4.9 - - 3 
STAT1 3.2 3.2 5.4 3.5 5.2 4.8 - 3.2 3.3 
PLSCR1 - - 4.2 - 4.6 4.2 - - 2.9 
PML - - - - - 4 - - - 
IFI27 - - - - - 3.5 - - - 
IFITM2 - - - - - 3.3 - - - 
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Table 4.8 shows a selection of top 20 expressed genes in the replicon cell line with 
IFNα, IL-28A and IL-29 treatments at 8, 16 and 24 hour time points in relation to IL-29 
expression at the 24 hour time point. Genes are >1.5 fold activation with one or more 
treatments compared with PBS treatment. 100 represents 100 fold change or greater, 
Genes highlighted in yellow are also present in the parent table. (-) = <1.5 fold 
induction. 
The only top 20 gene determined by IL-29 at the 24 hour time point to not be 
represented in the entire replicon dataset (genes expressed > or < 1.5 fold 
change) was ADAMTS13 which prevents thrombosis through abnormal clotting.  
There are highly expressed interferon stimulated genes (ISG) common to IFNα 
and IFNλs both in the replicon and the parent HuH7 cell lines, these include 
G1P3, IFI6, IFIT, IFITM1, MX1, IFITM3, STAT1, ISG15, ISGF3G and OAS1.  
4.5.3 HCV replicon kinetics 
To compare gene expression trends in the replicon cells treated with IFNα, IL-
28A and IL-29 at 8, 16 and 24 hours, several types of data analysis was 
performed on the replicon data set. Cluster analysis was generated using 
Rosetta Resolver of all replicon fold change data greater than 2 fold up or down 
regulated and > 99% confidence; a total of 881 genes. The data clustered by 
groups of genes which share similar properties is shown in Figure 4.9. 
The up regulated data from the entire replicon data set where a gene is above 2 
fold change in relation to PBS control in a minimum of one time point, based on 
their fold regulation in response to IFNα at 8 hours. Data is represented visually 
in more detail as a Heat Map (Figure 4.10) and in further detail for MX1, IFIT1 
and ISGF3G genes in trend plots (Figure 4.11).  
   Chapter 4 
    
   
Page 117 of 183 
 
 
 
Figure 4.9: Cluster analysis plot  
Cluster analysis of 640 genes regulated significantly (p<0.01) regulated ±1.5-fold with either IFNα, IL-29 or IL-28A at 8, 16 and 24 hours. 
8 hours
IL-28   IL-29   IFNα
16 hours
IL-28   IL-29   IFNα
24 hours
IL-28   IL-29   IFNα
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 Figure 4.10: Heat map 
A visual summary of the replicon gene data. In the heat map, genes are sorted in decreasing order based on their fold regulation in response to 
IFNα at 8 hours. The heat map represents the entire up regulated data set for any one gene whose expression was above 2 fold compared with 
PBS treatment with one or more IFNs at one or more time points, p-value <0.5. To show low induction values, the maximum heat intensity (red) 
was set to a 20 fold induction value. 
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Figure 4.11: Trend plots 
Trend plots were used as an effective, efficient oversight screening tool to visualise 
control (PBS) versus treatments IL-28A, IL-29 and IFNα over 3 timepoints 8 hour (blue 
box), 16 hour (orange box) and 24 hour (green box). Trend plots for three genes Mx1, 
IFIT1 and ISGF3G are shown. 
Trend plots and trend analysis show that IFNα and IL-28A and IL-29 show the 
same trends, e.g. for Mx1 (MxA) there is low expression with IL-28A, IL-29 and 
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IFNα at 8 hours, this peaks at 16 hours and levels off at 24 hours for all IFNs 
tested (IL-28A, IL-29 and IFNα). 
4.6 Discussion 
There are many similarities in both gene modulation between type I and type III 
IFNs. When looking at the genes that are expressed most highly in both the 
parent HuH7 and the replicon systems IFNλs and IFNα show largely 
overlapping sets of interferon stimulated genes (ISGs). Although antiviral 
mechanisms of type I and III differ, they may actually involve similar ISG 
responses. The individual gene expression results from the replicon data set 
shown here showed good concordance with data published by Marcello et al 61, 
with 45/66 differentially regulated genes as a response to  IFNα and 49/66 as a 
response to  IL-29. Zhou et al, Doyle et al and Marcello et al have all shown 
similar sets of ISGs being expressed by type I and type III IFNs65,57,61.  
Genes common to both the replicon and parent gene expression were 
highlighted (in Tables 4.2 and 4.8). The majority of interferon stimulated genes 
(ISG) stimulated in the replicon cell line by IFNα, IL-28A and IL-29 are also 
stimulated in the parental cell line; these ISGs include: G1P3, IFIT1-5, ISG15 
and ISGF3G.  
Despite this there are more differences in the pattern of expressed genes 
between the IFNλs and IFNα than genes expressed in common as shown in the 
Venn diagrams (Figure 4.2). The Venn diagrams showed a trend between 
parent and replicon datasets of there being more genes being unique to an 
individual interferon than genes in common between the interferons. This is 
different to the findings of other groups 61,65. The unique genes shown in the 
Venn diagrams are generally expressed at low levels. 
For the majority of genes in both the replicon and the parent datasets, the 
kinetics of gene expression was the same for type I and type III IFNs, which is 
highlighted in subset of data (Table 4.5) GIP3, IF16, IFITM3, ISG15, OAS1, 
STAT1. The table shows that gene modulation with IFNα, IL-28A and IL-29 
shows similar patterns over the time courses even being expressed at some 
time points and not at all in other time points as shown with IFI6, and ISG15.  
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The Marcello study61 showed in the replicon system that the majority of type III 
stimulated genes continue to increase at 24 hours and with IFNα the same 
genes tend to decrease by the 24 hour time point. In contrast the data shown 
here demonstrates that the kinetics of the type I and III IFNs show similar 
patterns of gene expression. HCV replicon inhibited gene induction by both type 
I and type III IFNs; this is seen at 8, 16 and 24 hour time points, where there is 
a substantial decrease in the numbers of genes expressed in the replicon 
system from those expressed in the parent system. There are also multiple 
genes for which the expression levels are lower in the replicon data than that of 
the parent. The NS3/4A protease encoded by HCV has been shown to cleave 
the adaptor in the RIG-I-like receptor (RIG-I) pathway IPS1 thus disrupting the 
signalling to type I IFN138; this data indicates that signalling to type III IFN is also 
disrupted. Downstream genes from RIG-I are affected in the replicon system 
including MAPK genes which show lower abundance in number in the replicon 
system than in the parent system.  
Pathway analysis was carried out for the replicon dataset but due to limited 
gene numbers in the replicon dataset more focus was placed on the larger 
parental cell line dataset. At the earliest time point 4 hours, for type I and type III 
IFNs interferon signalling is the most strongly induced pathway determined by 
Ingenuity Pathway Analysis, complement coagulation pathway is the second 
most strongly induced pathway for IL-28A, and protein ubiquitination pathway is 
the second most strongly induced pathway for both IFNα and IL-29. At 8 hours 
after interferon signalling pathway, IL-29 induces immune modulation pathways 
such as antigen presentation pathway and complement and coagulation 
cascades predominantly, compared with IFNα mostly regulating cell signalling 
pathways. Interferon signalling was not represented in the top 7 pathways by 
IFNα at 8 hours potentially showing that IFNα is less specific in its signalling 
pathways than IL-29. 
The antigen presenting pathway regulated in the parent cell line showed gene 
expression of MHC class I antigens to be up regulated with IFNa and IL-29, but 
IL-29 up regulated MHC class expression at much earlier time points (4,8,16 
hours and 24 hours) than IFNα (24 hours). MHC class I antigen expression was 
shown to be up-regulated following type I or type III IFN addition2. Up regulation 
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of MHC class I expression may lead to increased recognition of virus-infected 
cells by the immune system. 
Genes unique for IFNα belong to predominately signalling pathways; Jak/Stat, 
EGF, IGF-1, IL-2, GM-CSF, FGFF, IL-4 and IL-6. These unique genes for IFNα 
include: PIK3CB, PIK3R1, SOS2, SOCS2, MAP3K1. Genes unique to IL-28A 
also belong to IGF-1, EGF, TGF, VEGF, IL-2, IL-6 and IL-4 signalling pathways. 
IL-29 unique genes belong to interferon signalling as the top pathway but 
interestingly are followed by antigen presentation and complement and 
coagulation cascades; unique genes at the 8 hour time point include HLA-A, 
HLA-B, HLA-C, HLA-F, HLA-G, PLG, CFB and SERPINE1.  
Genes unique to IL-29 treatment at 24 hours induce IFNα, IFNβ and IFNγ 
pathways, so any gene changes with IL-29 at 24 hours may be due to 
secondary mechanisms, e.g. feedback from genes expressed at early time 
points. 2-5A synthetase is of note being significantly (≥ 1.5 fold) expressed by 
IL-29 but not IFNα at 24 hours, this gene encodes a member of the 2-5A 
synthetase family, essential proteins involved in the innate immune response to 
viral infection.  
Gene expression analysis here suggests that IFNλs and IFNα have primarily 
complementary functions, signalling through common pathways enabling IFNλs 
and IFNα to induce similar biological activities in particular antiviral resistance 
mediated by very similar sets of interferon sensitive genes, this has also been 
shown by other groups65,57,61. The kinetics of IL-29 response has been shown to 
differ from IFNα by Marcello with gene expression data139 also demonstrating in 
Huh-7 hepatocellular carcinoma cells, that IFN-λ induces STAT-1 and STAT-2 
more rapidly than IFNα64,139 this is also seen in HaCaT keratinocytes63 these 
studies have also shown although the subsequent transcriptional response is 
slightly delayed, the increase in ISG expression induced by IFNλ is stronger and 
more prolonged than the response activated by IFNα64,139. There are several 
studies although Jak/STAT signaling mediates the primary functions of IFNλ, 
other pathways are also activated by the receptor including ERK-1/2, mitogen 
activated protein kinase (MAPK) and Akt in intestinal epithelial and colorectal 
cancer-derived cell lines126, activation of MAPKs was also observed in Raji cells 
following treatment with IFNλ65. These results indicate that IFNλ can induce 
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multiple signaling pathways that may contribute to its activity as an antiviral and 
immunomodulatory cytokine and complement the findings here. 
Where this research differs from that published is that IL-29 is more specific in 
its modulation and by modulating alternative pathways such as the antigen 
presentation and processing pathways at early time points may prove to be a 
useful therapeutic option for the management of chronic viral infection such as 
HCV. IL-28R is not as widely expressed as the type I IFN receptor which could 
mean a more specific target. IL-28R was shown to be found primarily on antigen 
presenting cells (Chapters 5 & 6). Coupled with IL-29 modulating the antigen 
presenting pathway at earlier time points than IFNα could prove to have a 
superior therapeutic profile to IFNα. 
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Chapters 5 & 6  
5. IL-28R distribution using genomic analysis  
5.1 Introduction 
The aim of this chapter was to study the expression of IL-28 receptor (IL-28R) in 
a panel of tissues and cells in order to identify type III IFN targeted tissues and 
cells. Tissues and cells containing IL-28R were identified using real-time PCR 
and gene expression data for IL-28R was analysed.  
IFNα and IFNβ (type I IFNs) bind to a heterodimeric receptor comprising an 
alpha component (IFNAR1) and a beta component (IFNAR2). Although the 
activities of type III IFNs are similar to type I IFNs, IFNλ signalling is achieved 
through a specific and distinct heterodimeric receptor complex which is formed 
between IL-28A receptor (IL-28R / IFN-λR1) and IL-10 receptor (IL-10R2)2,3. 
Similarly to type I IFNs, binding of type III IFNs to their receptor leads to the 
activation of the Jak:STAT pathway. This is upstream of IFN-inducible genes 
and modulates their transcription.  
The heterodimeric receptor IFNAR1/2 for IFNα and IFNβ is present on all 
nucleated cells72. IL-10R2 is ubiquitously expressed73, whereas initial RNA 
expression data showed that IL-28R is limited to specific tissues and cell types3. 
It is the aim of this chapter to conduct a comprehensive exploration of IL-28R 
distribution using gene expression techniques in both human and murine 
tissues and immunohistochemical techniques in both human and murine tissues 
are described in chapter 6. 
5.2 IL-28R gene expression in mouse tissue 
IL-28R gene expression was studied in a panel of mouse tissues using real-time 
PCR (Figure 5.1). IL-28R was shown to be expressed predominantly in 
epithelial tissue, lymph nodes and spleen, as was seen with the protein 
expression of IL-28R. High expression; greater than 1,000,000 copies per 50ng 
of cDNA was seen in mandibular and messenteric lymph nodes and gut tissues 
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(stomach, duodenum, jejunum, ileum and colon). Expression was also detected 
in epididymis, spleen, thyroids, kidney, lung, pancreas, prostate, oesophagus, 
ovaries, peripheral nerve and pituitary gland. Tissues with minimal expression 
were: liver, bone marrow, adrenals, heart, seminal vesicles and cerebellum. 
Tissues (not recorded in Figure 5.1) with no detectable expression were: aorta, 
bladder, eyes, harderian gland, skeletal muscle, skin and spinal cord. 
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Figure 5.1: TaqMan® IL-28R 
Quantative RT-PCR analysis of IL-28R expression in a range of mouse tissues, shown as magnitude of fluorescence signal ΔRn and measured 
in copy numbers, 3 samples for each tissue were pooled prior to PCR analysis. 
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5.3 Gene Logic human tissue microarray screen 
Using data from the Gene Logic human tissue microarray database, gene 
expression of IL-28R (TIG45563), IL-10RB (TIG1871) and IFNAR1 (TIG1823) 
were compared across a panel of human tissues (Figure 5.2 A-C). This data 
showed that while IL-10R and IFNAR mRNAs were ubiquitously expressed 
across tissues (with the exception of brain IL-10RB and skeletal muscle IFNAR1 
shown in red), several tissues were negative for IL-28R (left and right ventricles, 
blood, cervix, exo/endo cervix, brain, thymus, bone, ovary, testis, placenta, 
uterus, bladder, adipose, aorta and vein shown in red). Gene Logic data for IL-
28R in human tissues showed gene expression primarily in epithelial tissue, 
lymph nodes and spleen,). Tissues expressing IL-28R (shown in blue): small 
intestine, ileum, jejunum, pancreas, thyroid, lymph node, gallbladder, colon, 
rectum, liver, prostate, seminal vesicle, cecum, lung, skin, kidney, spleen, 
stomach, skeletal muscle, bronchus, breast, heart, oesophagus, adrenal gland, 
fallopian tube. 
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Figure 5.2 A: Gene Logic graph showing IFNAR1 expression in a range of human cell types and tissues 
Affymetrix data retrieved from a database of human gene expression data across a range of human cell types and tissues using the bioinformatics 
tool Gene Logic. Tissues highlighted in blue show significant expression and tissue highlighted in red insignificant expression.  
 
A – Gene Logic Normal Pathology: 225669_at(HG-U133_Plus_2): TIG1823(IFNAR1)   
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Figure 5.2 B: Gene Logic graph showing IL-28R expression in a range of human cell types and tissues 
Affymetrix data retrieved from a database of human gene expression data across a range of human cell types and tissues using the bioinformatics 
tool Gene Logic. Tissues highlighted in blue show significant expression and tissue highlighted in red insignificant expression.  
 
B – Gene Logic Normal Pathology: 244261_at(HG-U133_Plus_2): TIG45563(IL-28R)   
 
Chapter 5 
Page 130 of 183 
 
 
Figure 5.2 C: Gene Logic graph showing IL-10RB expression in a range of human cell types and tissues 
Affymetrix data retrieved from a database of human gene expression data across a range of human cell types and tissues using the bioinformatics 
tool Gene Logic. Tissues highlighted in blue show significant expression and tissue highlighted in red insignificant expression.  
C – Gene Logic Normal Pathology: 209575_at(HG-U133_Plus_2): TIG1871(IL-10RB)   
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5.4 Inflammatory cell microarray screen 
In order to investigate the expression of IL-28R in immune and inflammatory 
cells in more detail we looked at mRNA extracted from a panel of human cells 
(Figure 5.3). The graph demonstrates the distribution of IL-28R on a panel of 
cells both with and without a variety of inflammatory stimuli. The data reveal that 
IL-28R is highly expressed on stimulated and untreated B cells and alveolar 
macrophages. In non-alveolar macrophages only those stimulated for 24 hours 
with immune complex (IgG coated beads) showed significant IL-28R 
expression. Unstimulated pDCs have a higher level of IL-28R expression than 
unstimulated mDCs. Stimulated and resting CD8+ T cells show low levels of IL-
28R expression. Similarly resting PBMCs express IL-28R at low levels while 
CD4+ T cells and mast cells do not significantly express IL-28R. 
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Figure 5.3: GSK Inflammatory cell screen showing IL-28R gene expression 
Inflammatory cell screen: B cells were unstimulated or stimulated with CD40 ligand or anti B cell receptor (anti-IgM) co-stimulation assay at four 
time points; 0, 24, 48 and 72 hours. Macrophages were cultured with vehicle alone, TNF (10ng/mL), LPS (10ng/mL), immune complex (IgG coated 
beads) and cytomix (TNF (10ng/mL), LPS (10ng/mL) and IFNγ (10ng/mL) for 2, 6 and 24 hours. T cells treatments were CD4+ and CD8+ cells 
resting; 1, 6 and 24 hours post anti-CD3/CD28. Mast cells were cultured with human stem cell factor (100ng/mL), human IL-6 (50ng/mL) and IL-10 
(10ng/mL), then primed for 6 days with human IL-4 (10ng/mL), human myeloma IgE, lambda (1µg/mL) and human myeloma IgE, kappa (1µg/mL). 
Cells were triggered for 1 hour with anti-IgE (1.5µg/mL), control with no triggering. pDCs and mDCs; no treatment. Numbers in brackets indicate 
number of replicates. 
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5.5 Discussion 
IL-28R gene expression was shown in a panel of mouse tissues using real-time 
PCR (Figure 5.1). High levels of IL-28R gene expression were seen in 
mandibular and messenteric lymph nodes and gut tissues (stomach, 
duodenum, jejunum, ileum and colon). Expression was also detected in 
epididymis, spleen, thyroid, kidney, lung, pancreas, prostate, oesophagus, 
ovaries, peripheral nerve and pituitary gland. Tissues with minimal expression 
were: liver, bone marrow, adrenals, heart, seminal vesicles and cerebellum. 
Tissues with no detectable expression were: aorta, bladder, eyes, harderian 
gland, skeletal muscle, skin and spinal cord.  
The distribution of IL-28R, IFNAR1 and IL-10RB expression in human tissues 
was shown by mRNA expression profiles in the Affymetrix datasets.  
Whilst type I IFN receptor and IL-10RB are expressed on virtually all cell types, 
type III IFN receptor expression exhibits more restricted cellular distribution. 
Type III IFN receptor is expressed primarily in epithelial tissue, lymph nodes 
and spleen, tissues expressing IL-28R in detail were: small intestine, ileum, 
jejunum, pancreas, thyroid, lymph node, gallbladder, colon, rectum, liver, 
prostate, seminal vesicle, cecum, lung, skin, kidney, spleen, stomach, skeletal 
muscle, bronchus, breast, heart, oesophagus, adrenal gland, fallopian tube.  
Patterns of IL-28R gene expression in mouse tissues (summarised in Figure 
5.1) were compared with those found in human tissues (illustrated in Figure 5.2 
B). In both human and mouse high levels of IL-28R was expressed in lymph 
nodes, spleen and gut epithelial tissues, low levels of IL-28R were seen in brain 
and bone marrow, a notable difference in IL-28R expression between human 
and mouse was in liver where the levels in human were a lot higher than in 
mouse (mouse expression levels of IL-28R were low). This was also shown in 
Chapter 6 where compared with human liver, mouse liver was found to have 
very restricted IL-28R staining (mainly in Kupffer-like cells). The tissues above 
are complex in nature and contain a wide variety of cell types –some of these 
were investigated further in an inflammatory cell microarray screen (Figure 5.3) 
and immunohistochemistry was carried out on various tissues (Chapter 6) to try 
and identify specific cell types which express the IL-28R. 
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An inflammatory cell microarray screen was used to investigate the expression 
of IL-28R in human immune and inflammatory cells. Data from this screen 
showed that IL-28R is highly expressed on stimulated and untreated B cells and 
alveolar macrophages. In non-alveolar macrophages only those stimulated for 
24 hours with immune complex (IgG coated beads) showed significant IL-28R 
expression. Unstimulated pDCs have a higher level of IL-28R expression than 
unstimulated mDCs. Stimulated and resting CD8+ T cells show low levels of IL-
28R expression. Similarly resting PBMCs express IL-28R at low levels while 
CD4+ T cells and mast cells do not significantly express IL-28R140. While type I 
IFN receptors are expressed on virtually all cell types, results described above 
show that type III IFN receptor expression exhibits a more restricted cellular 
distribution.  
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6. Distribution of IL-28R, protein expression  
6.1 Introduction 
The aim of this chapter was to study the expression of IL-28 receptor (IL-28R) in 
a panel of mouse/human tissues and cells in order to identify type III IFN 
targeted tissues and cells. Tissues and cells containing IL-28R were identified 
using immunohistochemistry (IHC), dual staining IHC methods and FLOW.  
The heterodimeric receptor IFNAR1/2 for IFNα and IFNβ is present on all 
nucleated cells72. IL-10R2 is ubiquitously expressed73, whereas initial RNA 
expression data showed IL-28R is limited to specific tissues and cell types3. IL-
28R has been shown to be present in intestinal epithelial cells56,6,141, MCA205, 
a fibrosarcoma cell line142 and type III IFN expression has been shown in 
monocyte–derived dendritic cells (MDDC)74,75,76, plasmacytoid dendritic cells 
(pDC)74,76 and human primary macrophages where induction of type III IFNs 
required pre-treatment with IFNα74,75,76.  
6.2 Immunohistochemistry for IL-28R protein expression in 
murine lymphoid and epithelial tissues 
Positive IL-28R expression in mouse tissues (summarised in Table 6.1 and 
illustrated in Figure 6.2 A-H). Tissue type was confirmed /scored by peer review 
from two pathologists Dr Rob Goldin and Dr Chris Clarke. IL-28R was found to 
be widely expressed in epithelial tissues such as stomach, small and large 
intestine where baso-lateral staining of the epithelial cells and strongly staining 
individual cells was found in the lamina propria. In lymphoid tissue and spleen 
approximately 30% of cells visibly expressed IL-28R. This was confirmed by 
flow cytometry analysis on mouse spleen showing that ~60% of spleen cells 
stained positively for the IL-28R (Figure 6.1).  
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Figure 6.1: Flow cytometry showing IL-28R expression in mouse spleen 
Analysis of a murine spleen sample using IL-28R antibody by flow cytometry. A shows 
normal scatter plot for treated cells, B shows normal scatter plot for control. SS = side 
scatter and FS = forward scatter. C shows positive cells beyond negative point as 
shown in D. D = negative. (F = negative cells, G = positive cells) FL2 log shows PE-IL-
28R. 
 
In the spleen IL-28R positive cells were distributed throughout the red and white 
pulp but predominately in the red pulp, where antigen-presenting and 
phagocytic cells such as dendritic cells and macrophages are concentrated. In 
lymph nodes IL-28R expression was shown throughout the cortex and medulla 
with notable presence in the sub-capsular sinus. The sub-capsular sinus area is 
the receiving area for afferent (incoming) lymph and is populated by 'activated' 
dendritic cells from stimulated regional tissues. In the mouse liver, scattered 
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non-parenchymal cells lining the hepatic sinusoids express IL-28R; these are 
likely to be Kupffer cells or stellate cells.  
The following mouse tissues showed no observable IL-28R protein expression: 
adrenal gland, bladder, brain, eyes, harderian gland, heart, lungs, peripheral 
nerve, pituitary, prostate, seminal vesicles, skeletal muscle, skin, salivary 
glands, pancreas, spinal cord, testis, tongue and trachea. 
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Table 6.1: Location of IL-28R protein expression in mouse tissues 
Tissue Positive staining* Likely Cell type Likely background stain** 
Stomach Occasional interstitial cell ‘endocrine’ granular cells in basal area macrophage Glandular epithelial cells 
Duodenum Occasional cell in lamina propria  macrophage - 
Thymus Scattered cells throughout cortex and medulla  dendritic cell/ macrophage  
Gall bladder Occasional cell in subepithelial lamina propria   - 
Liver Occasional small cells with oval nuclei, sinusoidal spaces  Kupffer cell  - 
Epididymis Occasional small interstitial cell macrophage epithelium 
Kidney Rare interstitial cell in cortex  macrophage - 
Uterus Occasional cell with positive cytoplasmic granules and small non-granlular 
cells – subepithelial and myometrium  
mast cells - 
Spleen Scattered cells throughout red pulp and white pulp/PALS  dendritic cell/ macrophage - 
Large & small intestine Occasional cell in lamina propria  - 
Peyer’s patches Occasional cell  dendritic cell/ macrophage  
Blood Occasional cell dendritic cell/ macrophage - 
* Typically represented by sharply-defined, intense cytoplasmic/membrane staining. ** Typically represented by pale ‘wash’ effect  
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Figure 6.2 A and B: IL-28R distribution in mouse spleen using Immunohistochemistry 
 IHC specific staining of IL-28R is represented by sharply-defined, intense cytoplasmic/membrane staining in a selection of mouse tissues.  
A Spleen goat IgG negative control. B Spleen showing scattered positive cells throughout the marginal zone. 
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Figure 6.2 C and D: IL-28R distribution in mouse thymus and mesenteric lymph node using Immunohistochemistry 
 IHC specific staining of IL-28R is represented by sharply-defined, intense cytoplasmic/membrane staining in a selection of mouse tissues.  
C Thymus: scattered cells throughout cortex D Mesenteric lymph node. 
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Figure 6.2 E and F: IL-28R distribution in mouse liver using Immunohistochemistry 
 IHC specific staining of IL-28R is represented by sharply-defined, intense cytoplasmic/membrane staining in a selection of mouse tissues.  
E Liver goat IgG negative control. F Liver: occasional small cells stained. 
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Figure 6.2 G and H: IL-28R distribution in mouse colon using Immunohistochemistry 
 IHC specific staining of IL-28R is represented by sharply-defined, intense cytoplasmic/membrane staining in a selection of mouse tissues.  
G Colon: goat IgG negative control. H Colon: cells stained at base of crypt and non-specific staining of the brush border. 
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6.3 Toluidine blue histochemical stain in mouse showed mast cells express IL-28R 
In the uterus, IL-28R staining was found in cells with granular cytoplasm which stained positively for the mast cell stain toluidine blue 
on serial sections.  
 
Figure 6.3: IL-28R distribution in mast cells 
Mouse uterus A IL-28R staining in granular cells these were confirmed to be mast cells with a serial section stained with toludine blue B. 
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6.4 Dual staining- IL-28R and macrophage markers 
The distribution of IL-28R staining in mouse tissues suggested expression of the IL-28R in macrophages and dendritic cells. Mouse 
monoclonal antibodies Mac 384 and F4/80 were used for macrophage identification. Dual staining (illustrated in Fig. 6.4) revealed that 
a sub-population of macrophages/DCs express IL-28R in normal mouse spleen but with a different pattern of staining in lymph node.  
 
Figure 6.4: Dual staining 
IL-28R and macrophage markers A mouse spleen stained with Mac 387 and IL-28R B mouse lymph node stained with F4/80 and IL-28R. Red 
stained, Mac 387+ macrophages are predominantly in the marginal zone and cords. Cells demonstrating IL-28R staining (brown cytoplasmic) were 
distributed throughout the red pulp. A subset of IL-28R positive cells stain with Mac 387 indicating IL-28R distribution on phagoctic cells; dendritic 
cells and macrophages. However, in lymph node B F4/80-positive macrophages, stained with Very Intense Purple appear to be a separate 
population of cells from those which stained (brown) for IL-28R. 
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6.5 IL-28R protein expression in normal and diseased human 
tissues 
Human IL-28R protein expression was determined in a selection of relevant 
normal tissues and diseased tissues (Figure 6.5 A-F). In normal liver 
parenchyma, cells expressing IL-28R are relatively sparse and presumed to be 
Kupffer cells and some macrophages. In contrast, the number of IL-28R 
expressing cells in hepatitis C infected liver are increased, particularly around 
inflammatory infiltrates and portal areas. In addition to the inflammatory cells 
there appears to be low level expression of IL-28R in some hepatocytes. In fatty 
liver IL-28R staining was seen mainly at the edge of the cell membranes and in 
sinusoidal cells presumed to be Kupffer cells and macrophages. In a section of 
well differentiated hepatocellular carcinoma, IL-28R expression was observed in 
large pleomorphic cells of uncertain origin which may be mega macrophages. In 
ileal sections most of the positive IL-28R staining was within the lamina propria, 
expressed by lymphocytes. There was some IL-28R expression in cells close to 
the bottom of the crypt near the paneth cells. Some staining also occurred in the 
enterocytes but goblet cells were not involved. In sections of synovial tissue 
taken from patients with rheumatoid arthritis there was increased cellularity due 
to an influx of inflammatory cells. IL-28R staining is taken up by some of the 
spindle shaped/fibroblast like synovial cells and some macrophages. 
Patterns of IL-28R expression in mouse tissues (summarised in Table 6.1 and 
illustrated in Figure 6.2 A-H) were compared with those found in human tissues 
(illustrated in Figure 6.5 A-F). Human tissues showed a similar pattern of 
staining for IL-28R in uterus, ileum and lymph nodes with predominantly 
macrophages/DCs staining. Compared with human liver, mouse liver was found 
to have very restricted IL-28R staining (mainly in Kupffer-like cells), while in 
human cells staining of the hepatocytes as well as macrophages/DCs was 
seen. This was further enhanced in diseased tissue where there was an 
increased expression of IL-28R in hepatitis, fatty liver and liver tumor tissues in 
comparison with normal liver. 
Chapter 6 
Page 146 of 183 
 
 
 
Figure 6.5 A and B: Human diseased liver and IL-28R expression using Immunohistochemistry 
IHC specific staining of IL-28R in a selection of human tissues, A Normal liver showing IL-28R expression on mixed population of cells including 
hepatocytes. B Hepatitis C infected liver. 
 
A B 
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Figure 6.5 C and D: Human diseased liver and IL-28R expression using Immunohistochemistry 
IHC specific staining of IL-28R in a selection of human tissues. C Fatty liver (macrovesicular steatosis). D Hepatocellular carcinoma.  
 
C D 
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Figure 6.5 E and F: Human ileum and synovium and IL-28R expression using Immunohistochemistry 
IHC specific staining of IL-28R in a selection of human tissues, E Normal ileum. F Synovium - rheumatoid arthritis. 
E F 
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6.6 Discussion  
While type I IFN receptors are expressed on virtually all cell types, results 
(Chapter 5 and 6) show that type III IFN receptor expression exhibits a more 
restricted cellular distribution. Gene array data confirms that the IL-10RB 
component of the receptor is ubiquitously expressed but the IL-28R component 
is not. As both components are required for IFNλ signalling the distribution of 
the IL-28R is likely to determine which cells or tissues respond to this class of 
interferon.  
In the panel of murine tissues, immunohistochemical analysis shows that IL-
28R is expressed at highest levels by cells in lymph nodes and spleen. There is 
moderate cellular staining in the epithelial tissue of the gastrointestinal tract and 
low numbers of cells expressing IL-28R in the epididymis, uterus, thymus and 
kidney. Flow cytometric analysis revealed that ~60% of splenic and lymph node 
cells expressed IL-28R. The pattern of staining in these tissues, particularly the 
staining of cells in the sub-capsular regions of lymph nodes suggested that 
antigen presenting cells express IL-28R at high density. Dual staining with Mac 
387 and F4/80 illustrate that some but not all tissue macrophages express IL-
28R at high density. Interestingly, mast cells also appear to express IL-28R at 
high density. The immunohistochemical findings are effectively replicated in the 
IL-28R gene expression data (Figure 5.1). The distribution of IL-28R expression 
in mouse tissues was confirmed by TaqMan® PCR. 
In human tissues we first analysed the distribution of IL-28R using microarray 
screens which showed a broadly similar tissue expression pattern to the mouse. 
One major exception was a much greater expression in the human liver than in 
the mouse. Hepatocytes were seen to express IL-28R in human tissue but not 
in murine tissue. A low level of IL-28R expression in mouse liver has also been 
reported by other investigators78.  
Although IL-28R is highly expressed by macrophages, DC and lymphocytes, 
neither human nor murine bone marrow was found to express the IFNλ 
receptor. This may have important consequences if IFNλ is used 
therapeutically. Up to 20% of patients treated for chronic HCV infection with 
IFNα have to reduce the dose due to the consequences of bone marrow 
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suppression. From our data it appears unlikely that IFNλ would have any 
significant impact on bone marrow cells and therefore neutropenia and 
thrombocytopaenia are less likely to occur.  
Analysis of IL-28R mRNA in resting and activated inflammatory cells suggests 
that the IL-28R is responsive to inflammatory stimuli in some cell types. To 
some extent this is also seen in the comparison of IL-28R expression in normal 
and diseased liver tissue where there is a significant increase in the number of 
IL-28R expressing cells in non-alcoholic hepatitis and chronic HCV infection. 
However, in these tissues it is difficult to determine whether increased IL-28R 
expression is due to IL-28R induction or recruitment of IL-28R-expressing 
inflammatory cells into the diseased tissue.  
In summary we have demonstrated that the distribution of the IL-28R is 
restricted in comparison to the IFNα receptor. Differences in receptor 
expression may result in a different profile of therapeutic effects and a reduction 
of adverse events if patients are treated with IFNλ.  
IL-28R was found to be expressed in many mouse tissues including epithelial 
tissues such as stomach, and small and large intestine where there is baso-
lateral staining of the epithelial cells and in addition, strongly staining individual 
cells were found in the lamina propria. In the liver, scattered non-hepatocyte 
cells lining the hepatic sinusoids appear to express IL-28R. These may be 
Kupffer cells or stellate cells. In lymphoid tissue and spleen approximately 5% 
of cells expressed the IL-28R strongly. In the spleen these were distributed 
throughout the red and white pulp. In lymph nodes these were scattered 
throughout the cortex and medulla. There was a notable presence of cells in 
subcapsular sinus, this is an area of a lymph node that is the receiving area for 
afferent (incoming) lymph and hence tends to be populated by 'activated' 
dendritic cells from stimulated regional tissues. The distribution of staining 
suggested expression of the IL-28R in macrophages and dendritic cells could 
be confirmed by staining for these cells on serial sections and/or by flow 
cytometry analysis of these cell types. In the uterus, staining was found in cells 
with granular cytoplasm which stained positively for the mast cell stain toluidine 
blue on serial sections. The distribution of IL-28R expression in human tissues 
was shown by TaqMan® PCR and correlated directly with mRNA expression 
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profiles in the Affymetrix datasets. Gene expression analysis showed additional 
tissues likely to be expressing IL-28R including lung, heart and thyroid.  
Whilst type I IFN receptors are expressed on virtually all cell types (IFNαR1 
Gene Logic data), type III IFN receptor expression exhibits more restricted 
cellular distribution. Type III IFN receptor is expressed in epithelial tissue, lymph 
nodes and spleen. Macrophages and/or dendritic cells appear to express the 
receptor at high levels. Preliminary evidence shows IL-28R is predominately 
expressed on antigen presenting cells. If confirmed this suggests that 
therapeutic manipulation of these cells may be achieved by use of IFNλ without 
affecting a wide range of cell types as seen with IFNα. However none of the 
tissues in these experiments were stimulated or infected: IL-28R might be 
inducible in other cell types and tissues that are stimulated or infected.  
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Chapter 7  
7. Bone marrow 
7.1 Introduction 
Although IFN-α is a potent antiviral agent, the broad expression of the type I IFN 
receptor results in responses in many organs apart from the target tissue, 
leading to serious complications include the development of neutropenia and 
lymphopenia resulting from IFNAR1 expression in hematopoietic cells84, 
depression resulting from CNS effects83, and constitutional symptoms (fevers, 
chills, myalgias). Lymphopenia, is the condition of having an abnormally low 
level of lymphocytes in the blood and neutropenia is characterised by an 
abnormally low number of neutrophils, neutrophils account for 50-70% of 
circulating white blood cells and act as the primary defence against infection, 
destroying bacteria. Patients with neutropenia are more susceptible to bacterial 
infections which can lead to sepsis without treatment and often results in 
discontinuation of IFNα treatment. 
Although IL-28R is highly expressed by macrophages, DC and lymphocytes, 
neither human nor murine bone marrow was found to express the IFNλ receptor 
(Data from Chapter 5 and 6). The limitation of type III IFN receptor expression 
suggests that some side effects may be avoided by type III IFN administration. 
This may have important consequences if IFNλ is used therapeutically. Up to 
20% of patients treated for chronic HCV infection with IFNα have to reduce the 
dose due to the consequences of bone marrow suppression. From data in 
Chapters 5 & 6 it appears unlikely that IFNλ would have any significant impact 
on bone marrow cells, this chapter set out to investigate this further.  
Initially Professor Myrtle Y Gordon’s group and Dr Hayley Cordingley's groups 
at Imperial College, London were contacted for a collaboration to look at 
interferon lambdas in human bone marrow assays, the groups at Imperial were 
no longer doing these assays and could not reinstate. Commercial options were 
also considered but could not be funded by GSK. Through various contacts 
within GSK it was found that Astra Zeneca were doing bone marrow assays 
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using mouse cell lines, this was a good starting point to investigate the 
properties of IL-28A and IL-28B. 
Work in collaboration with David Brott, Astra Zeneca was done to look at IFNs 
in murine myeloid and erythroleukemia cell lines. IL-28A and IL-28B were tested 
in myeloid M1 and HCD57 erythroleukemia murine cell lines and compared to 
IFNα. M1 mouse cells were used to look at differentiation into M1 macrophage-
like cells (promoting a Th1 response –innate immune system) and HCD57, an 
erythroleukemia cell line derived from a mouse infected at birth with Friend 
murine leukemia virus, the cells proliferate in response to Epo to erythrocytes 
(red blood cells). 
IL-29 is not expressed in mice so only IL-28A and IL-28B were tested in the 
mouse cell lines.  
The mouse bone marrow data was very limited but data showed that it was 
worth pursuing collaboration with a group that did bone marrow research in 
humans. Human bone marrow work was performed in collaboration with 
Alessandro Aiutis lab, University of Rome using a gene therapy connection.  
Initially IL-28R gene expression in comparison with IFNAR was evaluated in 
hematopoietic stem cells and lymphoid lineages (Bone marrow derived CD34+ 
and CD3+ T-cells, CD19+ B-cells, CD11c+ DCs and CD14+ 
monocytes/macrophage cells were purified from peripheral blood) to determine 
IL-28R distribution. To determine if in vitro there was a myelosuppressive effect 
of IFNα or interferon lambdas IL-29, IL-28A and IL-28B, human CD34+ cells 
were tested in colony forming cell (CFC) assays and using a CD34+ 
proliferation assay showed the viability of CD34+ cells in the presence of 
interferon lambdas and IFNα.  
IL-28B was evaluated in the experiments above as it is commercially available 
(not the case when work was undertaken in Chapter 3 and 4) and of key 
interest as 3 independent genome-wide association studies have identified 
single nucleotide polymorphisms in the IL-28B gene region to be associated 
with response of patients with chronic hepatitis C to pegylated IFN-α 
treatment143,100,144, showing a role for IL-28B unique to that of IL-29 or IL-28A.  
Chapter 8 
Page 154 of 183 
 
7.2 Mouse cells  
The myeloid M1 cell line did not respond appropriately so only data from the 
HCD57 epo-dependent erythroleukemia cell line assay is shown below.  
The concentration that decreased the cell number by 50% (IC50) was calculated 
for IFNα, IL-28A and IL-28B from the data shown in Figure 7.1 and used to 
determine whether a compound was a bone marrow toxicant.  A compound was 
deemed positive if it had an IC50 <1µM. 
 
 
 
 
Figure 7.1: Mouse bone marrow data 
The values in the graph are percent of control (100 means same relative luminescence 
[cell number] as in the control well; 50 means 50% less relative luminescence [cell 
number] compared to the control well). From these values (triplicate wells for each 
concentration) the IC50 was calculated, IFNα is 0.04µM and IL-28A and IL-28B >2µM. 
 
In the HCD57 epo-dependent erythroleukemia cell line assay the IC50 for IFNα 
is 0.04µM or 40nM. IL-28A and IL-28B have IC50 values of >2µM (highest 
concentration tested due to solubility). This data shows that IFNα has an IC50 
value of <1µM which shows that it is classed as a bone marrow toxicant in the 
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HCD57 erythroleukemia cell line assay. IL-28A and IL-28B was not associated 
with any toxicity at 2µM. IL-29 was not tested as it is not expressed in mouse. 
7.3 Human cells - IL-28R gene expression in comparison with 
IFNAR in hematopoietic stem cells and lymphoid lineages 
The expression of IFNAR1 and IL-28R were tested on purified CD34+, CD3+, 
CD19+, CD14+ and CD11c+ purified from healthy donors. The expression 
levels for the IFNAR1 were higher than the expression of IL-28R, with CD34+, 
CD3+, CD14+ and CD11c+ cells but not with CD19+ cells where receptor 
expression for IL-28R and IFNAR1 were shown to be similar. IL-28R expression 
was detected in very low levels in peripheral myeloid cells CD11c+ but not 
detected in CD14+ cells or bone marrow derived CD34+ cells, Figure 7.2. High 
levels of IL-10R2 expression were detected in all cell types (data not shown). 
 
 
Figure 7.2: Human IFNαR1 and IL-28R expression  
Quantitative RT-PCR analysis of IL-28R and IFNAR1 expression in human 
hematopoietic stem cells and peripheral lymphoid lineages. Umbilical cord (UCB) and 
bone marrow (BM) CD34+ cells, peripheral blood (PB) CD3+, CD19+, CD11c+  and 
CD14+ cells. Gene expression data calculated as ΔCt in comparison with b-actin 
housekeeping control, concentration in µM. 
7.4 Colony forming capacity and proliferation of human CD34+ 
cells in vitro 
To assess a possible myelosuppressive effect of IFNα or interferon lambdas, 
human CD34+ cells were tested in colony forming cell (CFC) assays. As shown 
in Figure 5B, IL-29, IL-28A and IL-28B did not inhibit the capacity of BM CD34+ 
 
 
0 
 
0
.0
5
 
 0
 0
G
e
 
 
 
 
 
UCB 
CD34+ 
 
 
B
M 
C
D
3
4
+ 
 
 
 
P
 
 
Chapter 8 
Page 156 of 183 
 
cells to form erythroid or myeloid colonies (BFU, GM and GEMM) with the 
concentrations tested. In comparison the capacity of the plated cells to 
proliferate and form colonies is significantly reduced by the presence of all three  
IFNα concentrations tested, Figure 7.3. 
 
Figure 7.3: Colony forming cell (CFC) assay  
1000 BM CD34+ cells/ well after 14 days in methylcellulose with 0.03125, 0.0625 and 
0.125µM IL-29, IL-28A, IL-28B and IFNα stimulation. (A) BFU colonies= burst-forming 
unit erythroid= erythroid progenitor cells. (B) GM colonies= granulocyte, monocyte = 
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precursor for monoblasts and myeloblasts. (C) GEMM colonies= granulocyte, 
erythrocyte, monocyte, megakaryocyte= multipotential progenitor cells. 
 
In addition the CD34+ proliferation assay showed the viability of CD34+ cells 
after cytokine stimulation is lower for IFNα compared to the interferon lambdas 
(Figure 7.4), this comparible to the results seen for the mouse bone marrow 
data, Figure 7.1. 
 
 
 
 
Figure 7.4: CD34+ cells’ viability after proliferation 
50,000 bone marrow CD34+ cells/ well after cytokine stimulation (with TPO, SCF, Flt3, 
IL-3) and proliferation for 3 days in the presence of 0.03125, 0.0625 and 0.125µM 
IFNα, IL-29, IL-28A and IL-28B.  
 
7.5 Bone marrow cell discussion 
In the murine HCD57 erythroleukemia cell line assay data showed that IFNα 
has an IC50 value of <1µM which shows that it is classed as a bone marrow 
toxicant in the HCD57 erythroleukemia cell line assay and IL-28A and IL-28B 
show no toxicity at 2µM. IL-29 is not expressed in the mouse so work to look at 
IL-29 was done in a human CD34+ assay.  
Results for the IFNαR1 and IL-28R gene expression on purified CD34+, CD3+, 
CD19+, CD14+ and CD11c+ cells show the expression levels for the IFNR1 is 
higher in most cell types than IL-28R, including CD34+. Most importantly, IL-
28R expression was not detected in peripheral myeloid cells.  
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In vivo exposure to IFNα acting through IFNαR1 is therefore likely to have a 
greater effect on immune cell development and function as compared to the 
three interferon lambdas IL-29, IL-28A and IL-28B. The IL-28R is not only 
expressed at lower levels as compared to IFNαR1, but its expression is 
completely absent in peripheral blood myeloid cells (CD14+, CD11c+). This 
differential expression could contribute to a greater myeloablative action of IFNα 
as compared to lambdas in vivo. 
Consistently, the capacity of BM CD34+ cells to proliferate and form colonies 
was severely not compromised by the presence of IFN lambdas IL-29, IL-28A 
and IL-28B. But in vitro exposure to IFNα lowered the viability of CD34+ cells 
after cytokine stimulation and completely abolished their colony forming 
capacity. These findings are consistent with the findings that both human and 
murine bone marrow only expressed IFNAR but not the IL-28 receptor, thereby 
indicating an increased sensitivity of bone marrow haematopoietic stem cells to 
IFNα. It can be hypothesised that IFN-α exerts an inflammatory effect also on 
hematopoietic stem cells, thereby altering their quiescence state. Changes in 
their cellular turnover and increased proliferation are likely to lead to an 
exhaustion of their differentiation capacity. This effect might well underlie their 
abolished colony formation capacity in vitro and cause a myeloablative effect 
after treatment with IFNα. The conserved viability and colony forming capacity 
in the presence of interferon lambdas on the other hand indicates that this 
unwanted side effect could be prevented by administration of the interferon 
lambdas. Although the IL-28R was found expressed by macrophages, DC and 
lymphocytes in the peripheral blood, its expression was lower than the IFNAR in 
all cell types and comparable in B cells. 
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Chapter 8  
General Discussion 
8.1 Antiviral properties of interferon lambdas 
Interferon lambdas show a clear role in antiviral response, with EMCV, vesicular 
stomatitis virus,  herpes simplex virus 1, influenza A virus, cytomegalovirus, 
HIV, HBV, and HCV are all sensitive to the antiviral effects of 
IFNλ136,145,57,127,2,58,51,3,146,65. Data here shows in vitro assays show that IL-28A 
and IL-29 have an antiviral effect against HCV in the HCV genotype 1a and 1b 
replicon systems. IFNα was shown to have ~100 times greater antiviral activity 
than IL-29, and IL-29 had ~10 times greater antiviral effect in the HCV 1a and 
1b replicon system than IL-28A. Robek demonstrated that IL-29 and IL-28A 
inhibit replication of subgenomic and full-length HCV replicons in HuH7 cells. 
IFNα and type III interferons were tested in the HCV 1b replicon assay to 
determine any synergistic effects of the type I and type III interferons together: 
results showed an additive effect not a synergistic effect, also seen with IL-29 
and IFNα by Marcello et al 61. An additive effect though could show that IL-29 
when used with IFNα could be good as a dual therapy as opposed to IFNα 
alone. In the interferon sensitive assay, sensitivity was shown in the ISG56 
assay with IL-28A and IL-29: interferon lambdas have also been shown to 
induce expression of 2’5-OAS2 and MxA126. Initial data in a human HepG2 cell 
line stably transfected with HBV subtype ayr showed that both IL-29 and IL-28A 
had antiviral effects against HBV but significantly lower in antiviral activity than 
IFNα. IL-29 was shown to inhibit HBV replication in a murine model Robek51. No 
antiviral effects were observed with IL-28A or IL-29 in the HIV, RSV assays or in 
the dengue replicon system, Therefore, the inability of IFNλ to inhibit these 
viruses may be due to the cell line having limited IL-28R distribution or their 
inherent insensitivity to the antiviral effects of IFNs in general, rather than a 
specific shortcoming of the IFNλ response. 
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8.2 Gene Expression 
There are many similarities in gene modulation by type I and type III IFNs. 
When looking at the genes that are expressed most highly in both the parent 
HuH7 and the replicon systems IFNλs and IFNα show largely overlapping sets 
of interferon stimulated genes (ISGs). Although antiviral mechanisms of type I 
and III differ, they may actually involve similar ISG responses. Other groups 
have shown similar sets of ISGs being expressed by type I and type III 
IFNs65,57,61. Our data was different to these groups in that IL-28A was also 
tested in HuH7 and the replicon systems, and that parent HuH7 cells were used 
in gene expression analysis. Marcello and Zhou used HCV replicon cells and 
Doyle used HepG2 cells for microarray analysis and all groups compared IL-29 
with IFNα. 
The majority of interferon stimulated genes (ISG) stimulated in the replicon cell 
line by IFNα, IL-28A and IL-29 are also stimulated in the parental cell line. For 
the majority of genes in both the replicon and the parent datasets, the kinetics 
of gene expression was the same for type I and type III IFNs. Marcello61 
showed in the replicon system that the majority of type III stimulated genes 
continue to increase at 24 hours and with IFNα the same genes tend to 
decrease by the 24 hour time point. In contrast the data shown here 
demonstrates that the kinetics of the type I and III IFNs show similar patterns of 
gene expression. HCV appears to influence IFNλ induced gene expression 
similar to IFNα induced gene expression. HCV replicon inhibited gene induction 
by both type I and type III IFNs; this may be due to the NS3/4A protease 
encoded by HCV cleaving the adaptor in the RIG-I-like receptor (RIG-I) pathway 
IPS1 thus disrupting the signalling to type I IFN138; this data indicates that 
signalling to type III IFN is also disrupted. Downstream genes from RIG-I are 
affected in the replicon system including MAPK genes which show lower 
abundance in number in the replicon system than in the parent system.  
Pathway analysis showed in the parent HuH7 cells at the earliest time point 
tested, 4 hours, for type I and type III IFNs interferon signalling is the most 
strongly induced pathway. At 8 hours after interferon signalling pathway, IL-29 
induces immune modulation pathways such as antigen presentation pathway 
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and complement and coagulation cascades predominantly, compared with IFNα 
mostly regulating cell signalling pathways. Interferon signalling was not 
represented in the top 7 pathways by IFNα at 8 hours potentially showing that 
IFNα is less specific in its signalling pathways than IL-29. This gene expression 
analysis suggests that IFNλs and IFNα have primarily complementary functions 
but where IL-29, by modulating alternative pathways such as the antigen 
presentation and processing pathways at an early time point, may prove to be a 
useful therapeutic option for the management of chronic viral infection such as 
HCV.   
8.3 IL-28R distribution 
While type I IFN receptors are expressed on virtually all cell types, results show 
that type III IFN receptor expression exhibits a more restricted cellular 
distribution. This is also reported by other groups showing not all cell types 
respond to interferon lambdas including fibroblasts and endothelial cells13. 
In the panel of murine tissues, immunohistochemical analysis shows that IL-
28R is expressed at highest levels by cells in lymph nodes and spleen and 
epithelial tissue of the gastrointestinal tract. Type III interferons have been 
shown to be the main interferon giving antiviral protection of intestinal epithelial 
cells against GI viruses identifying a critical role of IFN-λ in the epithelial 
antiviral host defense147 and possibly maintenance of GI tract homeostasis, 
linking this role to high level of IL-28R expression in gut tissue. A high level of 
IL-28R on intestinal epithelial cells has been shown to be of importance. 
Antiviral protection of intestinal epithelial cells against gastrointestinal viruses 
mainly relies on the type III antiviral system147. This study showed mice lacking 
functional IL-28R had impaired control of oral rotavirus infection, which infects 
intestinal epithelial cells. Additionally it was demonstrated that systemic 
administration of IL-29 not IFNα, induced an antiviral state in these cells 
resulting in suppression of rotavirus replication. The immunohistochemical 
findings were confirmed in the IL-28R gene expression data. The unique 
functional tissue-specificity of IFN-λs is due to the cell type-restricted pattern of 
IFN-λR1 expression it was shown here the unique of staining in these tissues, 
particularly the staining of cells in the sub-capsular regions of lymph nodes 
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suggested that antigen presenting cells express IL-28R at high density. Dual 
staining with Mac 387 and F4/80 illustrated that some but not all tissue 
macrophages express IL-28R at high density. Literature also shows that unlike 
IFNα IFN-λR1 is primarily expressed in epithelial cells and specific subsets of 
immune cells59,57,13,148,77,79,78,80,23. In human tissues the distribution of IL-28R 
using microarray screens showed a broadly similar tissue expression pattern to 
the mouse. One major exception was a much greater expression in the human 
liver than in the mouse. Hepatocytes were seen to express IL-28R in human 
tissue but not in murine tissue, this may account for the IFN-λ antiviral system 
appearing to play minimal if any role in the protection of mice against 
hepatotropic viruses148.  
IHC data didn’t not show IL-28R in lung but stimulated alveolar macrophages 
showed high gene expression of IL-28R, type III IFN system is shown to have 
an important role in asthma and respiratory viral infections149,140. 
Neither human nor murine bone marrow was found to express the IFNλ 
receptor in significant levels. This may have important consequences if IFNλ is 
used therapeutically. Up to 20% of patients treated for chronic HCV infection 
with IFNα have to reduce the dose due to the consequences of bone marrow 
suppression. It appears unlikely that IFNλ would have any significant impact on 
bone marrow cells and therefore bone marrow suppression is less likely.  
In summary the distribution of the IL-28R is restricted in comparison to the IFNα 
receptor. IFN-λs have a specialized role in diseases of epithelial tissue, and in 
the treatment of viral infections of these and other responsive tissues. Limited 
IL-28R may explain the findings that IFN-λ independently of IFNα cannot 
provide full protection against systemic virus infections; these viruses infect 
cells that are not responsive to type III IFNs. Restriction of IL-28R receptor 
expression may result in a different profile of therapeutic effects and fewer or 
milder adverse events if patients are treated with IFNλ rather than IFNα. 
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8.4 Bone marrow experiments 
In a murine HCD57 erythroleukemia cell line assay, IFNα was classed as a 
bone marrow toxicant while IL-28A and IL-28B were shown to not cause 
toxicity. In a murine HCD57 erythroleukemia cell line assay, IFNα was classed 
as a bone marrow toxicant while IL-28A and IL-28B were shown to not cause 
toxicity. Consistently, the capacity of BM CD34+ cells to proliferate and form 
colonies was not compromised by the presence of IFN lambdas IL-29, IL-28A 
and IL-28B. But in vitro exposure to IFNα lowered the viability of CD34+ cells 
after cytokine stimulation and completely abolished their colony forming 
capacity. These findings are consistent with the finding that both human and 
murine bone marrow only expressed IFNAR but not the IFN-λ receptor, thereby 
indicating an increased sensitivity of bone marrow haematopoietic stem cells to 
IFNα. The conserved viability and colony forming capacity in the presence of 
interferon lambdas, indicates that this unwanted side effect could be prevented 
by administration of the latter. Although the IL-28R was found expressed by 
macrophages, DC and lymphocytes in the peripheral blood, its expression was 
lower than the IFNAR in all cell types and comparable in B cells. These findings 
might therefore have important consequences if IFNλ is used therapeutically. 
Up to 20% of patients treated with IFN-α for chronic HCV infection have to 
reduce the dose due to the consequences of bone marrow suppression. From 
data in Chapter 7 it appears unlikely that IFNλ would have any significant 
impact on bone marrow cells and therefore neutropaenia and 
thrombocytopaenia are less likely to occur. In support of this hypothesis phase 
1b data from Zymogenetics showed that repeated dosing with PEG-IFN-λ was 
well tolerated with minimal constitutional symptoms and in contrast to the 
effects of type I interferons, there were no significant decreases from baseline 
values in neutrophil or platelet counts96,150,116. 
8.5 IFNλs as a therapy 
Type III interferons have been implicated as having antiviral properties in a 
range of viruses: DNA viruses; poxvirus55, murine cytomegalovirus (CMV)56,56, 
Chapter 8 
Page 164 of 183 
 
hepatitis B virus57,51,58 and herpes simplex virus 1 and 259, the single stranded 
(ss) (+) RNA viruses EMCV60,3, west nile virus57 and hepatitis C virus57,61,62,51, 
as well as the ss (−) RNA viruses influenza-A virus63 and vesicular stomatitis 
virus,62. Chronic infection with hepatitis C virus causes approximately 350,000 
deaths annually46. Pegylated interferonα (IFNα) in combination with the 
nucleoside analogue ribavirin is the current standard of care for the treatment of 
patients chronically infected with hepatitis C (HCV). There is a role for Interferon 
lambdas in the treatment of HCV, data described here showed IL-29 and IL-28A 
have an antiviral effect against HCV in the HCV genotype 1a and 1b replicon 
systems. An additive effect of IFNα and IL-29 or IL-28A treatment could show 
that IFN lambdas when used with IFNα could be good as a dual therapy as 
opposed to IFNα alone.  
The data presented shows that by modulating alternative pathways such as the 
antigen presentation and processing pathways at an early time point and having 
a limited receptor distribution it may prove to be a superior therapeutic option for 
the management of HCV chronic viral infection, causing fewer and/or milder 
adverse events. Up to 20% of patients treated for chronic HCV infection with 
IFNα have to reduce the dose due to the consequences of bone marrow 
suppression, this data shows IFNλ does not have a significant impact on bone 
marrow cells and therefore neutropaenia and thrombocytopaenia are less likely 
to occur. In support of this hypothesis, phase 1b data from Zymogenetics 
showed repeated dosing with PEG-IFNλ was well tolerated with minimal 
constitutional symptoms and in contrast to effects of type I interferons, there 
were no significant decreases from baseline values in neutrophil or platelet 
counts96,116. Latest data from Bristol Myers Squibb Co. showed peginterferon 
lambda achieved SVR24 rates comparable to peginterferon alpha with fewer 
flu-like and musculoskeletal symptoms in phase IIb study in treatment-naïve 
genotype 2 or 3 hepatitis C patients. 
There is a potential role for IL-29 instead of IFNα in the treatment regime with 
direct-acting antivirals (DAAs), NS3/4A protease inhibitors, telaprevir and 
boceprevir. With the current DAAs there is rapid resistance due to rapid 
mutations of HCV40,41,86,87. The current DAAs are administered with 
peginterferon-alfa-2a and ribavirin to prevent resistance to the DAAs. Both 
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telaprevir and boceprevir highly improve rates of SVR of HCV infected patients 
but there are limitations, designed to target genotype 1 HCV they have 
differential efficancy across the genotypes88,89,90, they are also limited by side 
effects, rash (Telaprevir) and anaemia, replacement of IFNα with IL-29 could 
reduce side effects caused by IFNα and may reduce side effects attributed to 
the DAA as this may be exasperated by IFNα. Other HCV therapies are 
currently being evaluated using co treatment of IFNα , these include RdRp 
inhibitors which inhibit the active site of polymerase activity, preliminary results 
from Phase II trials reported rates of EVR >80% among patients with HCV 
genotype 1 or 4 infection who received mericitabine in combination with SOC 
PEG-IFN and RBV47; may not need the co-administration of IFNs and host 
factor cyclophilins, Alisporivir is in advanced clinical trials, it inhibits viral 
replication by disrupting the interaction between cyclophilin A and NS5A93,94. 
Alisporivir combined with PEG-IFN and RBV, led to an SVR in 76% of HCV 
genotype 1 infection patients compared to 55% with SOC94. There may be a 
role for Interferon lambdas to replace IFNα as a co treatment but the aim with 
these therapies is to have an interferon free regime. 
A pegylated form of IFN-λ1 (IL-29) is currently in clinical trials for the treatment 
of chronic HCV infection and initial reports shows less severe side effects than 
pegylated IFNα and similar antiviral activity95,96. Caution would be needed if 
administrating interferon lambda with HCV/HIV co infection as the role of IFNλs 
is still unclear, whilst IL-29 and IL-28A are reported to inhibit HIV-1 replication in 
macrophages151 pretreatment of uninfected PBMCs or CD4+ T-cell lines with 
IFN-λ improved the expression of HIV-1 receptor and co-receptors that increase 
viral binding and replication130. 
There may be a role for IL-28B treatment in the future, four Genome Wide 
Association studies have highlighted the significance of IL-28B within the innate 
immune response to HCV97,98,99,100. Two protective SNPs were shown to be 
associated with a SVR to IFNα/Ribavirin in patients with HCV genotype 1. In a 
study of rapid viral response (RVR) rates in patients with HCV Genotype 1 and 
4, of the RVRs 100% of carriers of the protective rs12979860 C allele, and 64% 
of non-RVR individuals expressed the non-protective genotype T allele of 
rs8099917101.  
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The potential broad roles of IFN-λs in immune function may also mean they play 
a future role in autoimmunity and cancer therapy. Type III IFNs like type I IFNs, 
may potentially be used for the treatment of other inflammatory or autoimmune 
diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE)102, or multiple sclerosis (MS)103, IFN-λ therapy may represent a novel 
approach to prevention and/or treatment of respiratory virus-triggered asthma 
exacerbations149,140. IFN-λs have been shown to have potent antitumor activities 
in murine models of cancer104,105,106, highlighting potential as anti-cancer 
therapy. 
 
 
8.6 Future work 
Further experiments could be designed looking at the effects of interferon 
lambdas on antigen presenting cells, as experiments above have suggested 
that the interferon lambdas not only modulate alternative pathways such as the 
antigen presentation and processing pathways at an early time point compared 
with IFNα but their receptor IL-28R is also found primarily on antigen presenting 
cells. Maturation of dendritic cells (DCs) (generated from buffy coats) can be 
investigated by applying a fixed dose of antigen to DCs, treating the DCs with 
IFNλ, IFNα and no interferon and looking at T-cell responses. The current, 
immunomodulatory activities of IFNλs are still not defined and studies to date 
show opposing functions e.g. DC-mediated stimulation of either T-reg 
proliferation22 or towards Th1 differentiation140. There is value in continuing to 
look at the properties of IL-28A and IL-28B as well as IL-29 and look at their 
broader roles in immune function including autoimmunity and cancer therapy. 
8.7 Conclusions 
Interferon lambdas (IFNλs), termed IFN-λ1, IFN-λ2 and IFN-λ3, or IL-29, IL-28A 
and IL-28B are a recently identified family of cytokines with antiviral activity. 
Type I IFNs are used therapeutically in the treatment of chronic hepatitis B and 
C; however only ~30% of patients with hepatitis B virus will be successfully 
treated and only ~60% of patients with chronic HCV. New interventions are 
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therefore required to address this unmet medical need and this thesis aimed to 
evaluate the potential use of IFNλs in treating viral infection.  
A range of in vitro antiviral assays were developed to determine which viruses 
were inhibited by IFNλs. Results showed IL-28A and IL-29 have antiviral effects 
with HCV 1a and 1b replicons and HBV. No antiviral effect was demonstrated 
against dengue, RSV or HIV. Gene expression stimulated by IFNλ was 
compared with IFNα; and the effects of IFNλ against HCV were investigated. 
The types of genes induced, and the kinetics of gene induction were similar 
between the type I and type III IFNs in the HCV replicon cell line. With the 
parental cell line, the interferon signalling pathway was the most greatly affected 
by IFNα, IL-28A and IL-29, but IL-29 strongly regulated the antigen presenting 
pathway compared with IFNα. IL-28R distribution was determined to investigate 
the tissue and cellular distribution of IFNλ responsive cells. IL-28R was 
expressed in epithelial tissues, lymphoid tissue, spleen, liver, kidney and 
thymus, with majority of IL-28R expression on macrophages and dendritic cells. 
In mouse HCD57 erythroleukemia cell line assay, IFNα was classed as a bone 
marrow toxicant and IL-28A and IL-28B were shown to not cause toxicity. 
Human BM CD34+ cells ability to proliferate and form colonies was not 
compromised by the presence of IFN lambdas IL-29, IL-28A and IL-28B whilst 
IFNα completely abolished their colony forming capacity. Human and murine 
bone marrow only expressed IFNAR but not the IL-28 receptor, thereby 
indicating an increased sensitivity of bone marrow haematopoietic stem cells to 
IFNα. The conserved viability and colony forming capacity in the presence of 
interferon lambdas, indicates that this unwanted side effect could be prevented 
by administration of the latter.  
These findings might therefore have important consequences if IFNλ is used 
therapeutically. Up to 20% of patients treated with IFNα for chronic HCV 
infection have to reduce the dose due to the consequences of bone marrow 
suppression. From our data it appears unlikely that IFNλ would have any 
significant impact on bone marrow cells and therefore neutropenia and 
thrombocytopenia are less likely to occur. In support of this hypothesis phase 
1b data from Zymogenetics showed that repeated dosing with PEG-IFN-λ was 
well tolerated with minimal constitutional symptoms and in contrast to the 
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effects of type I interferons, there were no significant decreases from baseline 
values in neutrophil or platelet counts53, 63.  
 
In summary differences in receptor expression and gene expression compared 
to IFNα may result in a different profile of therapeutic effects and adverse 
events if patients are treated with IFN-λ.
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Appendix I 
A data CD containing  Affymetrix gene chip raw data is enclosed. 
 
Appendix II Suppliers 
Below are listed the names and contact details of most suppliers or materials 
and reagents used in this study. 
Abcam www.abcam.com 
Affymetrix www.affymetrix.com 
Agilent www.agilent.com 
AllCells www.allcells.com 
Analytix www.analytix.co.uk 
Applied Biosystems www.appliedbiosystems.com 
Becton Dickinson www.bdbiosciences.com 
Bio-Rad www.bio-rad.com 
Capralogics www.capralogics.net 
Corbett Life Science www.corbettlifescience.com 
Dako www.dako.com 
Eppendorf www.eppendorf.co.uk 
Fluka www.sigmaaldrich.com/Fluka 
Gene Logic Inc. www.genelogic.com 
Gibco www.invitrogen.com 
IKA www.ika.com 
Ingenuity Inc. www.ingenuity-inc.org 
Invitrogen www.invitrogen.com 
Kbioscience www.kbioscience.co.uk 
Life Technologies www.lifetechnologies.com 
Lonza www.lonza.com/research 
Merck, Sharpe and Dohme www.msd-uk.com 
Miltenyi Biotec www.miltenyibiotec.com 
Molecular devices www.moleculardevices.com 
Novagen www.merckmillipore.com/novagen 
Nunc www.nuncbrand.com 
PBL  www.interferonsource.com 
Proligo www.sigmaaldrich.com  
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Promega www.promega.com 
Qiagen www.qiagen.com 
R&D systems www.rndsystems.com 
Sigma-Aldrich www.Sigma-Aldrich.com 
Syngene www.syngene.com 
Thermo Shandon www.thermoscientific.com 
Tree Star www.treestar.com 
Vector Labratories www.vectorlabs.com 
Virostat www.virostat-inc.com 
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Appendix III Publications 
 
TALKS: 
 
Rhiannon Lowe Talk entitled ‘Use of IHC to show distribution of IL-28R’. 9th European 
Histopathology Forum (19-21st April 2010) - Stratford on Avon. Awarded best new 
speaker award. 
 
 
PUBLICATIONS: 
 
Jaimini Mistry, Rhiannon Lowe, Christian Weise, Mikala Skydsgaard  and Zuhal 
Dincer.Morphometric assessment of minipig skin thickness in relation to age, sex and 
anatomical location using a computerised system. 8th European Histopathology Forum 
(20th - 22nd April 2009) - Stratford on Avon 
 
Coelho A-M, Lowe R.M. (May 2008) Analysing the phenotype and function of 
regulatory T cells (EuroSciCon meeting) meeting report. Immunology News, 2008 15.2, 
pp. 33-36. 
 
Lowe R Toll-like receptors - Investigating innate immunity & infection meeting report. 
Nov 2007 Immunology News. 
 
Lowe R; Morley P; Simecek N; Scott L; Thursz M. (Aug 2007). Microarray comparison 
of type I and type III interferons: Superior therapeutic profile for IL-29? J INTERF 
CYTOK RES. 27:733-733.  
 
Lowe R; Morley P; Scott L; Simecek N; Thursz M. (Aug 2007). HCV replicon inhibits 
gene induction by type III interferons. J INTERF CYTOK RES. 27:732-733.  
 
Lowe RM; Fung SSL; Clarke CJ; Thursz MR. (Aug 2007). Distribution of the type III 
interferon receptor. J INTERF CYTOK RES. 27:732-732. 
 
Claire J. Weekes, Gino Brunori, Tracy M. Walker, Rhiannon M. Lowe, Angela T. 
White, Joel D. Parry. Mitochondrial toxcitiy of nucleoside analogoues and the 
application of real-time PCR. Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract 
No. P185 
 
W Wu*, S E Wildsmith, A J Winkley, R Yallop, F J Elcock, P J Bugelski. 
Chemometric strategies for normalisation of gene expression data. Analytica 
Chimica Acta Mar 2001.  
 
SE Wildsmith, R Yallop, P Bugelski, G Morgan. EP1101114B-Method of Protein 
Analysis. Patent filed July 1999, Granted in Europe July 2005. 
 
M Thursz, R Yallop, R Goldin, C Trepo, HC Thomas. Influence of MHC class II 
genotype on outcome of infection with hepatitis C virus. Lancet. 354(9196): 2119-24, 
1999 Dec 18-25.
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